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Abstract 
Micturition requires the precise reciprocal function of the urinary bladder and 
urethral outlet.  Perhaps due to this degree of precision, micturition is prone to 
dysfunction with injury or disease.  One such disease, interstitial cystitis (IC)/painful 
bladder syndrome (PBS), is characterized by urinary urgency, frequency and pelvic pain.  
Inflammation has been implicated as a factor in IC/PBS.  The overall hypothesis of this 
project is that urinary bladder inflammation induces expression of inflammatory 
mediators and changes neurotrophin receptor expression that contribute to functional 
changes in the urinary bladder.  Using a well-characterized rat model of 
cyclophosphamide (CYP)-induced urinary bladder inflammation, the expression and 
function of cyclooxygenase-2 (COX-2), a known inflammatory enzyme, and the p75 
neurotrophin receptor (p75NTR), involved in neurotrophin signaling, were examined in 
micturition reflex pathways using neuroanatomical, biochemical, molecular and 
physiological techniques.   
 Although COX-2 expression is increased in urinary bladder and involved in 
bladder hyperreflexia after CYP-induced cystitis, the localization and time course of 
upregulation was not known.  We hypothesized increased COX-2 expression in specific 
tissue compartments (urothelium or smooth muscle) of the urinary bladder with CYP-
induced inflammation. Western blotting for COX-2 showed a significant increase in 
COX-2 expression in both detrusor and urothelium/suburothelium, with the greatest 
increase in the urothelium/suburothelium.  Immunostaining showed increased COX-2 
staining in suburothelium with cystitis, co-localized with CD86, a marker for dendritic 
cells and macrophages.  
 Nerve growth factor (NGF) has been implicated in inflammation, increased 
voiding frequency and altered sensation in urinary bladder.  The specific NGF tyrosine 
kinase receptor, TrkA, is increased in bladder afferent cells with CYP.  NGF also binds 
p75NTR.  The second goals were to examine the expression and functional role of p75NTR 
in urinary bladder pathways in control and CYP-treated rats.  We hypothesized that 
p75NTR is constitutively expressed in micturition pathways and upregulated with cystitis.  
With cystitis, p75NTR expression was increased in lumbosacral spinal cord and in bladder 
afferent cells in dorsal root ganglia.  Western blotting for p75NTR showed increased 
expression in whole urinary bladder with cystitis.  Based on bladder function effects of 
TrkA blockade with cystitis, we hypothesized that p75NTR blockade in the urinary bladder 
would also decrease bladder hyperreflexia with cystitis.  The functional role of p75NTR 
was studied by intravesical blockade by immunoneutralization with a monoclonal 
antibody to p75NTR and by PD90780, known to block NGF-p75NTR binding.  Both forms 
of p75NTR   blockade significantly decreased bladder capacity in control and CYP-treated 
rats. Changes in micturition and threshold pressure, and non-voiding contractions were 
also demonstrated.   
In conclusion, these dissertation studies demonstrate that CYP-induced bladder 
inflammation alters expression of inflammatory mediators and neurotrophin receptors in 
micturition pathways.   This altered expression can affect overall urinary bladder 
function. 
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Chapter 1: Comprehensive Literature Review 
I. Introduction 
  Micturition is an important process requiring complex neuronal organization that 
involves the storage and periodic elimination of urine.  Micturition is highly regulated 
and involves peripheral and central innervation and pathways that are prone to injury and 
disease.  While much is now understood of normal micturition reflex circuitry, there is 
much less information available about how the micturition reflex changes with injury or 
disease.  Bladder outlet obstruction, multiple sclerosis, Parkinson’s disease, overactive 
bladder, spinal cord injury, and interstitial cystitis/painful bladder syndrome (IC/PBS) are 
all conditions that affect the organized processes of bladder storage and efficient 
elimination.  Thus, neural injury or disease can affect the lower urinary tract and result in 
pain, hyperreflexia, incontinence, or even bladder underactivity, which can severely 
affect the quality of life of those affected (Michael et al., 2000).          
 IC/PBS is a syndrome characterized by urgency, frequency and pelvic pain 
including pain at low to moderate bladder pressure.  The cause of IC/PBS is unknown, 
although many theories of etiology exist, including toxic agents in the urine, autoimmune 
disorder, deficiency in the bladder wall, urothelial cell deficiency, pelvic floor injury, and 
neurogenic causes (Erickson, 1999).  Whatever the cause, inflammation of the bladder 
has been implicated as a factor in IC/PBS; most patients with IC/PBS often show some 
degree of inflammation, as evidence by the infiltration of inflammatory cells and 
mediators in the bladder (Erickson, 1999).  Chronic tissue inflammation can lead to 
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neuroplasticity, involving the sensitization of primary afferents or changes in central 
synapses, resulting in hyperalgesia and allodynia (Cheppudira, 2006; Thompson et al., 
1995; Yoshimura and de Groat, 1999).  In bladder, this could translate to uncomfortable 
sensation/pain and increased frequency of elimination.  It has already been shown that 
bladder inflammation results in a multitude of effects centrally and peripherally, 
including changes in neurochemistry, neurotrophin expression, prostaglandin expression, 
electrophysiology of bladder afferents, and the re-organization of micturition reflex 
pathways, among many others (Hu et al., 2003; Vizzard, 2000b; 2001; Yoshimura and de 
Groat, 1999).  The overall goal of this project was to further understand and characterize 
the changes associated with bladder inflammation and specifically, the role that both 
cyclooxygenase-2 (COX-2) and the neurotrophin receptor p75Neurotrophin receptor (NTR) play.  
This project focused on COX-2 and p75NTR in micturition reflex pathways as well as the 
role of p75NTR in bladder function.   
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II. Anatomy and Function of the Lower Urinary Tract 
A. Lower Urinary Tract Anatomy 
The lower urinary tract is made up of the urinary bladder and urethra (Figure 1).  
The urinary bladder is divided into two main parts.  Most superiorly, the body of the 
bladder is located above the ureteral orifices.  The bladder base consists of the trigone, 
urethrovesical junction (bladder neck) and anterior bladder wall (Andersson and Arner, 
2004; Elbadawi, 1996).  The trigone is the area of bladder bounded by the ureteral 
orifices and the urethrovesical junction.     
The wall of the urinary bladder is organized in layers (Figure 1), with the 
urothelium as the closest layer to the bladder lumen.  Below the urothelium is the lamina 
propria layer, which contains the suburothelial plexus of nerves (containing mostly 
afferent nerves) and blood vessels (Andersson and Arner, 2004).  The outermost layer of 
the bladder is the detrusor smooth muscle, which consists of circular as well as 
longitudinal smooth muscle layers.  The urethra is also surrounded by smooth muscle, 
although this is structurally and functionally different than bladder smooth muscle 
(Andersson and Arner, 2004).  There is an internal urethral sphincter that is under 
involuntary control at the inferior end of the bladder and the superior end of the urethra 
(Elbadawi, 1996).  The external urethral sphincter is made of striated muscle to allow for 
conscious control of bladder function and this is located inferior to the prostate in males 
and at the inferior end of the urethra in females (Andersson and Arner, 2004).       
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Figure 1: Basic bladder anatomy and the suburothelial plexus. 
  
(A) Basic bladder anatomy includes the dome as the most superior part of the bladder.  The body 
is the part of the bladder located above the ureteral orifices.  The neck is the base of the bladder.  
The urethral outlet allows for the release of urine.  (B) The bladder wall consists of urothelial 
cells closest to the bladder lumen.  The lamina propria layer is underneath the urothelium and it 
contains the suburothelial plexus of nerves and blood vessels.  The smooth muscle layer is the 
furthest from the bladder lumen and contains longitudinal as well as circular muscle.  (C) 
Example of a urinary bladder taken from a female rat.  The bladder is pinned out on Sylgard, and 
detrusor (yellow arrows) is carefully separated from the inner urothelial layer (red arrows).  The 
suburothelial plexus comes off attached to the urothelial layer (Zvarova et al., 2004).  (D) 
Staining in the suburothelial plexus for PGP9.5, a neuronal marker.  The suburothelial plexus 
contains most of the afferent nerves in the urinary bladder. 
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The urothelium has three basic layers of cells: a basal cell layer with a basement 
membrane underneath, an intermediate layer of cells, and a layer of transitional 
epithelium made of hexagonal cells (also known as “umbrella cells”)  that provide the 
luminal lining of the urinary bladder (Birder, 2005; Cohen, 1995).  A band of tight 
junctions connects the cells to act as a barrier from the contents of the urine (Cohen, 
1995).   
Urothelial cells were once thought to simply provide a barrier between urine and 
the underlying tissues.  However, many recent studies have shown that urothelial cells 
express receptors and ion channels associated with neuronal function, specifically 
afferent neuronal function, which include bradykinin receptors, neurotrophin receptors 
TrkA, TrkB and p75NTR, purinergic receptors P2X and P2Y, α- and β-adrenergic 
receptors, and transient receptor potential (TRP) channels such as TRPV1 (Kullmann et 
al., 2008; Murray et al., 2004).  Urothelial cells also release neuroactive compounds (i.e. 
acetylcholine, ATP, nitric oxide) (Birder, 2005).  Bladder afferent nerves are located in 
close proximity to urothelial cells, suggesting that signaling likely occurs between 
afferents and urothelium (Birder, 2005; Kullmann et al., 2008).     
 The urine itself is made of multiple organic and inorganic substances, including 
urea (formed from ammonia and CO2), uric acid (the product of the oxidation of purines), 
creatinine (hydrated creatine), sodium, potassium, phosphates, sulfates, bicarbonate, and 
ammonia (Cohen, 1995).  Levels of each constituent as well as urinary pH vary widely 
with food consumption and time of day (Cohen, 1995).  It has been suggested that some 
constituents of urine could impact the bladder by way of the urothelium (Cohen, 1995).   
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B. Micturition Reflex 
 The urinary bladder always exists in one of two modes: storage mode and 
elimination mode.  The bladder smooth muscle and the urethral outlet must function 
reciprocally for the efficient elimination of urine (Fowler et al., 2008).  During storage 
mode, the bladder smooth muscle must remain relaxed to allow for filling, while the 
urethral outlet is contracted (Fowler et al., 2008).  Elimination mode requires contraction 
of the bladder smooth muscle with relaxation of the urethral outlet, to allow urine flow 
(Andersson and Arner, 2004).  Precise organization of the reciprocal functions of the 
urinary bladder and urethra and complex neural organization are required (Fowler et al., 
2008).  
Storage mode 
 During storage mode, the detrusor smooth muscle must remain relaxed while the 
urethral outlet remains contracted to ensure the retention of urine and continence.  
Storage mode involves the slow filling of the urinary bladder, signaled by low-level 
afferent firing of myelinated Aδ fibers (Figure 3) (Holstege, 2005).  The sympathetic 
pathway has a role in inhibition of parasympathetic efferent input to the detrusor smooth 
muscle and in inhibition of parasympathetic activity in the autonomic ganglia (Fowler et 
al., 2008).  Sympathetic outflow and reflex pathways keep the urethra and urethral 
sphincters contracted (Fowler et al., 2008).  Conscious control of continence is provided 
by cholinergic motor neurons to the striated muscle in the external urethral sphincter 
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(Fowler et al., 2008) (Elbadawi, 1996; Holstege, 2005).  Studies have also shown that 
there is activation of the periaqueductal gray (PAG) during bladder filling in humans, 
which in turn influences the pontine micturition center (PMC), a part of the brainstem 
involved in the switch between filling and voiding (Figure 3) (Blok and Holstege, 2000; 
Fowler et al., 2008) (Holstege, 2005).   
 The PMC, located in the brainstem, is thought to be involved in coordinating the 
switch between storage and elimination activity (Holstege, 2005).  Drugs applied to the 
PMC can change the bladder volume set point (i.e. threshold) to induce bladder voiding 
activation (Fowler et al., 2008).  The PMC receives bladder afferent projections and in 
turn sends excitatory projections to the bladder motoneurons in the preganglionic 
parasympathetic nucleus of the spinal cord (Holstege, 2005).  The PMC also excites 
GABA-ergic and glycinergic inhibitory interneurons of urethral sphincter (Holstege, 
2005).   In humans and cats, bladder filling afferent information most likely is relayed 
first to the PAG, which then has projections to the PMC (Blok and Holstege, 2000; 
Fowler et al., 2008).  In rats, there is likely direct access between lumbosacral afferent 
neurons and the PMC, possibly making rat voiding behavior less easily extrapolated to 
human conditions with respect to the supraspinal elements of the micturition reflex (Blok 
and Holstege, 2000).   
Elimination mode 
 The elimination of urine involves the coordinated contraction of the detrusor and 
relaxation and dilation of the urethral outlet.  This involves inhibition of the sympathetic 
output to the bladder and urethral outlet, and activation of the parasympathetic pathway.  
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Relaxation of the urethral smooth muscle is achieved by removal of adrenergic and 
cholinergic excitatory inputs and the release of nitric oxide (NO) to elicit smooth muscle 
relaxation (Fowler et al., 2008).  Contraction of the detrusor smooth muscle is activated 
by parasympathetic cholinergic efferent input to this muscle.  The PMC has also been 
shown to exhibit firing during bladder voiding activity (Fowler et al., 2008; Holstege, 
2005). 
Components of the micturition reflex as seen during cystometry 
Cystometry is a technique used to measure bladder function in vivo.  Cystometry 
involves the constant infusion of saline into the urinary bladder of an experimental 
animal through tubing that is secured in the dome of the bladder.  The tubing is connected 
to a pressure transducer, which then measures the changes in pressures associated with 
micturition cycles.   
Both conscious cystometry and cystometry in anesthetized animals are used 
experimentally.  There are some differences between methods, not the least of which is a 
difference in bladder capacity (Cannon and Damaser, 2001; Ghoniem et al., 1996).  
Animals under anesthesia have a significantly larger bladder capacity than conscious rats 
(Cannon and Damaser, 2001; Ghoniem et al., 1996).  It is also said that anesthesia may 
compromise urodynamic parameters and may have profound effects on bladder function, 
perhaps because general anesthesia may block glutamate transmission in the brain 
(Cannon and Damaser, 2001; Ghoniem et al., 1996; Yokoyama et al., 1997).  Careful 
interpretation must be exercised when interpreting data from experiments using 
anesthetized animals (Ghoniem et al., 1996).  It is also true that conscious cystometry 
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might more closely reflect normal bladder functions.  However, in both models, the 
implantation of the tubing into the bladder may affect urothelial sensation or bladder 
capacity.  This is why a period of several days is recommended for the recovery of the 
animal from surgery.   
Figure 2 illustrates an example of one micturition cycle during a typical 
cystometrogram recording in a conscious rat.  Important parameters of cystometry 
include filling pressure (the pressure during the filling phase of the micturition cycle), 
threshold pressure (pressure at the beginning of the void event), micturition pressure (the 
peak in pressure during the void event), inter-micturition interval (the amount of time 
between the end of one void event and the end of the next), the frequency of non-voiding 
contractions, and void volume (Maggi et al., 1986).  
Changes that are detected in certain urodynamic parameters with experimentation 
can be attributed to changes in afferent or efferent function.  Experiments involving 
blockade of nicotinic receptors in the pelvic ganglia in order to impair the efferent branch 
of the micturition reflex (Maggi et al., 1986) demonstrated that threshold pressure, void 
volume and inter-micturition interval are associated with the afferent limb of the 
micturition reflex.  Changes in micturition pressure are associated with changes in 
efficiency of neurotransmission in the efferent branch of the micturition reflex (Maggi et 
al., 1986).   
Multiple possibilities exist for changes in the number of non-voiding contractions 
with cystometry, including myogenic or neurogenic activities.  Non-void contractions 
during the filling phase could mean an increase in detrusor activity, including 
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Figure 2: Important parameters of cystometry 
 
ICI: inter-contraction interval, FP: filling pressure, TP: threshold pressure, MP: micturition 
pressure. 
 
spontaneous contractions of the detrusor smooth muscle.  This is often seen in spinal 
cord-injured rats (Brading, 1997; Herrera et al., 2003; Yoshimura et al., 2006).  Other 
explanations include changes in the response of the urothelium to bladder distension, 
possibly affecting the bladder afferents located in the suburothelial plexus (Herrera et al., 
2003).  Experimental effects on afferent or efferent nerves are also possible sources of 
neurogenic changes in the number of non-void contractions (Herrera et al., 2003).   
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C. Urinary Bladder Innervation  
Sympathetic Innervation 
 Preganglionic sympathetic neurons are located in the intermediolateral (IML) 
region (laminae V-VII) of the thoracolumbar spinal cord (L1-L2 in rats; T11-L2 in 
humans) (Fowler et al., 2008).  Sympathetic efferents travel in the hypogastric nerve to 
the inferior mesenteric ganglia, then traveling in the hypogastric nerve to the pelvic 
ganglia and lower urinary tract, where they  activate α-adrenergic excitatory receptors in 
the bladder base and urethral smooth muscle and β-adrenergic inhibitory receptors on the 
detrusor smooth muscle (Figure 3)(Fowler et al., 2008).    
Parasympathetic Innervation 
 Parasympathetic preganglionics are located in the sacral parasympathetic nucleus 
(SPN) of the IML region (laminae V-VII) of sacral spinal cord (L6-S1 in rats; S2-S4 in 
humans).  Parasympathetic efferents travel in the pelvic nerve, with postganglionics 
located in the major pelvic ganglion of rats (Keast et al., 1989).  Postganglionic 
parasympathetic nerves have an excitatory effect on detrusor smooth muscle and an 
inhibitory effect on bladder base and urethra (Fowler et al., 2008).  Post-junctional M3 
muscarinic receptors expressed on the bladder smooth muscle are the receptors thought to 
be most involved in excitatory transmission in the detrusor (Fowler et al., 2008).  
However, a recent experiment showed that activation or inhibition of muscarinic 
acetylcholine receptors (mAChRs) at the luminal surface of the bladder can affect bladder 
function.  This is presumably through interactions between the urothelium and the C-fiber 
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sensory nerves located within close proximity, demonstrating that parasympathetic 
muscarinic transmission could be important not only in the detrusor smooth muscle, but 
in the urothelium as well (Kullmann et al., 2008).  Non-cholinergic parasympathetic 
innervation involves adenosine triphosphate (ATP) activation of P2X receptors and NO 
transmission, which is inhibitory to urethral smooth muscle (Fowler et al., 2008).   
Somatic Innervation 
 Cholinergic neurons also innervate the striated muscle of the external urethral 
sphincter, keeping the sphincter under conscious control (Fowler et al., 2008).  These 
neurons originate in the ventral horn of lumbosacral spinal cord (lamina IX) in the 
dorsolateral nucleus and travel via the pudendal nerve to synapse on external urethral 
sphincter muscle (Figure 3).  
Bladder Afferent Pathways 
 Bladder afferent nerve fibers travel in both the hypogastric and pelvic nerves, 
with their cell bodies in dorsal root ganglia (DRG) at spinal segment levels S2-S4 and 
T11-L2 in humans and L6-S1 and L1-L2 in rats (Fowler et al., 2008).  Bladder afferents 
consist of lightly myelinated Aδ fibers and unmyelinated C-fibers.  As stated above, 
sensations of bladder filling are conveyed by Aδ fibers, the most important 
mechanoreceptors of the bladder.  C-fibers are normally “silent” but they do respond to 
chemical or noxious stimuli (Figure 3) (Fowler et al., 2008).  Aδ and C-fibers terminate 
in the urothelium, suburothelium, and smooth muscle layers of the bladder (Kullmann et 
al., 2008).  Most of the bladder afferents project to lumbosacral spinal cord levels, as this 
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is the most important region for signaling the micturition reflex (Holstege, 2005).  In the 
bladder, most of the sensory nerves are located in a dense suburothelial plexus just 
beneath the urothelium (Andersson and Arner, 2004)(Figure 1).   
Bladder primary afferent fibers in the pelvic nerve project to the lumbosacral 
spinal cord via Lissauer’s tract.  Afferents from urinary bladder, uterus, and colon project 
along the lateral side of the dorsal horn, forming the lateral collateral pathway (LCP) 
(Kawatani et al., 1990).  Afferent projections from the pudendal nerve and genital 
structures project along the medial edge of the dorsal horn into the dorsal commissure 
region, forming the medial collateral pathway (MCP) (Kawatani et al., 1990).  
Many bladder afferents further project to the SPN, synapsing with preganglionic 
parasympathetic neurons as well as interneurons (Morgan et al., 1981) (Fowler et al., 
2008).  Primary bladder afferents from the pelvic and hypogastric nerves also project to 
dorsal commissure and the superficial dorsal horn (Fowler et al., 2008).  Lumbosacral 
dorsal commissure, superficial dorsal horn and the parasympathetic nucleus all contain 
interneurons important to urinary bladder function (Fowler et al., 2008).  These 
interneurons project locally in the spinal cord or to the brain (Fowler et al., 2008).  Some 
bladder afferents synapse with ascending pathways in the spinal cord which project to 
neuronal populations in the brain involved in micturition control, including the PMC 
(Fowler et al., 2008).  Neuronal tracing studies using horseradish peroxidase showed that 
the dorsal commissure and sacral parasympathetic nucleus are located periodically at 
approximately 200 µm intervals (Morgan et al., 1981).   
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Figure 3: Neural circuitry involved in the micturition reflex. 
 
During filling, there is low-level Aδ afferent firing, stimulating sympathetics in the hypogastric 
nerve to keep the detrusor smooth muscle relaxed and the urethra contracted.  The pudendal nerve 
provides conscious control to keep the external urethral sphincter contracted.  C-fiber 
unmyelinated afferents do not respond to normal bladder filling, but are “awakened” and 
activated after spinal cord injury or by noxious stimulants, such as cold.  Intense afferent firing 
during bladder filling activates spinobulbospinal pathways, with afferent input to the 
periaqueductal grey (PAG) and pontine micturition center (PMC), which in turn activate 
preganglionics in the sacral parasympathetic nucleus (SPN) of lumbosacral spinal cord.  
Postganglionics in the pelvic nerve then excite the detrusor smooth muscle, whereas sympathetic 
and pudendal input to the urinary bladder and urethra are inhibited.  The cerebral cortex also 
provides conscious control over micturition. 
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The use of the rat model in studying micturition reflex pathways is very common, 
as the comparison of rat anatomy to human anatomy is well known.  Analogous spinal 
cord segments involved in micturition reflex circuitry exist in rats, including the L1-L2 
spinal cord segment that is analogous to the human T11-L2 spinal cord region which 
contains the sympathetic outflow and some of the bladder afferent input.  Analogous to 
the human S2-S4 region is the L6-S1 region in rat, which contains the parasympathetic 
outflow and receives most of the bladder afferent input (Shefchyk, 2002).  It is also true 
that rats, like humans and cats, have supraspinal control over the micturition reflex, with 
a distinct region in the pons analogous to the PMC; the destruction of this region leads to 
total urinary retention (Blok and Holstege, 2000; Maggi et al., 1986).  However, rats 
appear to have direct lumbosacral input to their PMC, perhaps the reason for a more 
reflexic voiding behavior than “guarded” reflex behavior as seen in humans and cats 
(Blok and Holstege, 2000).  Guarded reflex behavior in humans and cats involves voiding 
in a safe location.
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III. Bladder Inflammation and Associated Changes 
 Bladder inflammation is often experimentally induced to study the effects of acute 
and chronic bladder inflammation on bladder function and micturition reflex pathways in 
experimental animals (Westropp and Buffington, 2002).  Multiple models of cystitis are 
in use, including cystitis that results from the intraperitoneal injection of 
cyclophosphamide (CYP).  The CYP model has been widely studied in order to 
characterize the changes associated with this purely visceral inflammation model 
(Lanteri-Minet et al., 1995).  The results of experiments done in the CYP-treated animals 
may have relevance to human conditions that involve bladder inflammation, including 
IC/PBS (Westropp and Buffington, 2002).   
A. Cyclophosphamide (CYP) Cystitis 
 CYP was originally used as an anti-tumor chemotherapeutic agent that had an 
unfortunate side effect of painful hemorrhagic cystitis (Bautista et al., 2006; Cox, 1979b; 
Maggi et al., 1992).  Side effects of CYP therapy also include painful voiding, bladder 
hyperreflexia and gross hematuria (Stillwell and Benson, 1988; Watson and Notley, 
1973).  Symptoms of CYP cystitis can also include increased somatic sensitivity (Guerios 
et al., 2006).  CYP is often used to model bladder inflammation because of its ease of 
observation behaviorally and histologically, and because the inflammation is confined 
specifically to the bladder (Bon et al., 2003; Lanteri-Minet et al., 1995).  Experimental 
CYP cystitis in animals results in histological changes in the urinary bladder that include 
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edema, vasodilation, infiltration of inflammatory cells such as mast cells, and 
proliferation of nerve fibers (Yoshimura and de Groat, 1999).  Bladder hyperreflexia is 
seen as an increase in voiding frequency with CYP-induced cystitis, resulting in a shorter 
inter-micturition interval and a decreased void volume; the presence of non-voiding 
contractions during the filling phase is also seen (Hu et al., 2003; Maggi et al., 1992).  
The causative agent of this effect of CYP was proven to be acrolein, a metabolite of CYP 
that accumulates in the urine and contacts the bladder wall while being stored before 
elimination (Cox, 1979b).   
The activation of capsaicin-sensitive primary afferents by acrolein in urinary 
bladder plays a significant role in the hyperreflexia associated with CYP-induced cystitis, 
leading to neurogenic inflammation and nociception (Ahluwalia et al., 1994; Geppetti et 
al., 2008; Maggi et al., 1992).  Capsaicin is the pungent component of spicy chili peppers.  
Pretreatment with capsaicin abolished the hyperreflexia seen with CYP (Maggi et al., 
1992).  The TRPA1 channel was found to underlie responsiveness to acrolein toxicity 
(Bautista et al., 2006; Dinis et al., 2004; Geppetti et al., 2008).  Activation of this channel 
in capsaicin-sensitive primary afferents by acrolein in the bladder leads to depolarization 
of sensory neurons (Bautista et al., 2006; Dinis et al., 2004).  This leads to numerous 
effects, including the release of neuropeptides, vasodilation and other neurogenic 
inflammatory effects, which in turn lead to hypersensitivity to mechanical stimuli and 
bladder hyperreflexia (Ahluwalia et al., 1994; Bautista et al., 2006; Maggi et al., 1992).  
This accounts for the initial steps of acrolein toxicity seen in urinary bladder (Bautista et 
al., 2006).  Neurochemical and electrophysiological changes in afferents also occur in 
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response to activation of primary afferents by acrolein exposure (Maggi et al., 1992; 
Vizzard, 2000c; 2001; Yoshimura and de Groat, 1999).   
Both TRPV1 and TRPA1 receptors are expressed by a subset of capsaicin-
sensitive afferents and both have been examined for their potential role in responding to 
acrolein exposure (Bautista et al., 2006).  The TRPV1 channel is activated by heat as well 
as capsaicin (Bautista et al., 2006).  While the TRPV1 channel is involved in the progress 
of bladder hyperreflexia and peripheral mechanical hypersensitivity associated with CYP 
cystitis, it is not as a direct result of acrolein exposure (Ahluwalia et al., 1994; Dinis et 
al., 2004; Wang et al., 2008).  It has been shown that TRPA1 is the presumptive channel 
required for the inflammatory effects of acrolein exposure in the urinary bladder 
(Geppetti et al., 2008).   
TRPA1 is known to be activated by isothiocyanate or thiosulfinate compounds, 
the pungent components of mustard oil and garlic (Bautista et al., 2006).  Recent in vitro 
studies have shown that cells expressing TRPA1 were responsive to acrolein application, 
while cells expressing only TRPV1 were not (Bautista et al., 2006; Dinis et al., 2004).  
Also, TRPV1-expressing neurons did not produce any current in response to acrolein 
exposure, while TRPA1-expressing neurons did produce current (Bautista et al., 2006).   
This demonstrated that TRPA1 is the receptor responsible for the depolarization of 
afferents in response to acrolein, thus eliciting inflammatory pain (Dinis et al., 2004).   
Other experimental approaches to induce cystitis include intravesical instillation 
of lipopolysaccharide (LPS), acetic acid, mustard oil, hydrochloric acid (HCl), or 
turpentine.  Instillation of all of these compounds leads to bladder irritation and 
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inflammation by various methods.  While there is no perfect model of human bladder 
inflammation or of the human condition of IC/PBS, these models do provide the 
opportunity to examine the effects of acute and chronic bladder inflammation and the 
mechanisms of inflammation including structural, neurochemical and functional changes 
in micturition reflexes (Westropp and Buffington, 2002).  These models also often mimic 
the inflammation-related histological changes seen in patients with IC/PBS, and many 
also lead to bladder hyperreflexia, also a part of the constellation of symptoms seen with 
IC (Kirimoto et al., 2007; Wheeler et al., 2001).  However, some of these models induce 
damage or effects that are not present in the human condition of IC/PBS, including 
detrusor damage (Westropp and Buffington, 2002).  Also, some models do not mimic all 
of the symptoms of IC/PBS (Westropp and Buffington, 2002).  However, IC/PBS does 
occur naturally in cats.  This feline IC model reproduces more features of human IC/PBS 
than any other animal model previously described, including a waxing and waning course 
(Westropp and Buffington, 2002).  Limitations of the feline model include limited 
availability of cats diagnosed with the disease and the fact that it is unknown how 
widespread feline IC really is.  These cats also do not provide the ability to examine acute 
aspects of inflammation (Westropp and Buffington, 2002).   
B. CYP-induced cystitis: Changes in the micturition reflex pathway 
 The inflammation or irritation of tissue can result in chronic pathological 
conditions that induce changes in somatic sensory pathways, leading to hyperalgesia and 
allodynia.  This increased sensation can be caused by sensitization of peripheral afferents 
(Dmitrieva and McMahon, 1996; Woolf et al., 1997) or changes in central synaptic 
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connections that process nociception (Lewin et al., 1992; Yoshimura and de Groat, 1999).  
A multitude of changes in the micturition reflex pathway have been documented with 
CYP-induced cystitis.  These include bladder hyperreflexia, as mentioned above, and also 
organizational changes, electrophysiological changes, neurochemical changes as well as 
changes in somatic sensation (Hu et al., 2003; Vizzard, 2000b; 2001; Yoshimura and de 
Groat, 1999).   
The protein product of the immediate early gene c-fos (Fos) has been used to 
mark the postsynaptic activation of spinal cord neurons receiving afferent input from the 
lower urinary tract (Birder and de Groat, 1992; 1993).  Growth-associated protein-43 
(GAP-43) is a calmodulin-binding protein associated with synapse formation and an 
ongoing capability for synaptic plasticity in adults (Vizzard and Boyle, 1999).  With CYP 
treatment in rats, changes in the distribution of the Fos protein in lumbosacral spinal cord 
segments and expansion of spinal cord segments involved in micturition reflexes have 
been demonstrated (Lanteri-Minet et al., 1995; Vizzard, 2000a).  This suggests a change 
in the organization of micturition reflex pathways, resulting in changes in synaptic 
connections, afferent excitability or pain modulation systems (Vizzard, 2000a).  Chronic 
CYP treatment in rats also leads to increased expression of GAP-43 in micturition 
pathways in the dorsal commissure, dorsal horn and IML cell column of the spinal cord, 
suggesting the possibility of synaptic plasticity with CYP cystitis (Vizzard and Boyle, 
1999).   
Electrophysiological changes documented in bladder afferent cells with chronic 
CYP-induced cystitis demonstrate an enhanced electrical excitability of C-fiber bladder 
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afferents, as well as significant hypertrophy of afferent cell bodies in rats in the L6-S1 
DRG (Yoshimura and de Groat, 1999).  CYP treatment in rats also leads to the increased 
afferent firing in the pelvic nerve in response to distension, decreased the firing threshold 
and increased the area of evoked action potentials (Yu and de Groat, 2008).  Increased 
excitability of bladder afferent neurons to stimulation could certainly contribute to pain 
and hyperactivity of the urinary bladder as seen with CYP cystitis.   
Neurochemical changes with CYP cystitis include an increase in the expression of 
the neuropeptides calcitonin gene-related peptide (CGRP) and substance P as well 
pituitary adenylate cyclase-activating polypeptide (PACAP) in lumbosacral DRG and 
spinal cord regions involved in micturition afferent pathways (in rats: L1-L2, L6-
S1)(Vizzard, 2000c; 2001).  The expression of the neurotrophin tropomyosin receptor 
kinases A and B (TrkA and TrkB) and phosphorylated Trk (pTrk) also change in bladder 
afferent neurons with CYP cystitis in rats, and this could occur in response to the changed 
expression of neurotrophic factors in the inflamed urinary bladder (Qiao and Vizzard, 
2002; Vizzard, 2000b).  Bladder afferents in lumbosacral DRG exhibit an increased 
expression of the transcription factor cAMP responsive-element binding protein (CREB) 
with CYP-induced cystitis (Qiao and Vizzard, 2004).  Phosphorylated CREB (p-CREB) 
is co-localized with phosphorylated Trk receptors in lumbosacral DRG cells, suggesting 
that p-CREB activity may be related to a neurotrophin/Trk signaling pathway in bladder 
afferents (Qiao and Vizzard, 2004).  Enhanced expression and function of the ATP 
receptor purinergic 2X (P2X) in pelvic and lumbar splanchnic pathways has been 
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reported, suggesting a role for ATP signaling through this receptor in hyperreflexia and 
hypersensitivity with CYP (Dang et al., 2008). 
Sprouting of CGRP and vesicular acetylcholine transporter-immunoreactive (IR) 
fibers were reported in the bladder urothelium and peptidergic sensory fibers were seen in 
the detrusor smooth muscle with CYP cystitis, (Dickson et al., 2006) suggesting the 
possibility that an increase in these fibers could result in bladder hyperreflexia and 
hypersensitivity. 
Symptoms of CYP cystitis can also include increased somatic sensitivity, as 
evidenced by mechanical hypersensitivity of the hind limbs induced by application of von 
Frey filaments in experimental animals (Bielefeldt et al., 2006; Guerios et al., 2006; 
Guerios et al., 2008; Lamb et al., 2006)(Cheppudirah and Vizzard, unpublished 
observations).  Sensitization of pain pathways by inflammation can result in the 
hypersensitization of neighboring organs and referred somatic cutaneous sites (Bielefeldt 
et al., 2006).   
These changes may play a role in the altered visceral sensation and bladder 
hyperreflexia involved in human clinical syndromes, such as IC/PBS. 
C. How CYP cystitis can relate to human conditions 
 The CYP-induced experimental model of urinary bladder inflammation could be 
useful in modeling such syndromes as IC/PBS, which involves a persistent inflammatory 
state in some patients.  IC/PBS is more recently being called painful bladder syndrome 
(PBS), so as to use a more symptom-oriented description (FitzGerald et al., 2006).  
IC/PBS is a painful chronic disorder of the urinary bladder that exhibits urinary 
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frequency, urgency, and suprapubic pressure and pain with only small amounts of bladder 
filling (Erickson, 1999).   
IC/PBS affects anywhere from 44,000 to 1 million people in the United States 
(Erickson and Davies, 1998) and bladder dysfunction in general affects an estimated 17 
million Americans.  The cost of treating urinary incontinence was estimated at $25 
million in 1995.   
Patients with IC/PBS show hypersensitivity to somatic stimuli, including 
sensitivity to deep tissue pressure, the ischemic forearm test of pain tolerance, and 
bladder distension (Ness et al., 2005).  Some patients even report discomfort to sites other 
than suprapubic, including lower back, buttocks, and upper thighs (FitzGerald et al., 
2005).  Patients with IC/PBS also have more non-bladder related symptoms, such as 
tingling of the fingers and toes and headaches, than age-matched controls (Westropp and 
Buffington, 2002). 
Most biopsies of bladders from patients with IC/PBS show some degree of 
inflammation, as evidence by the infiltration of inflammatory cells and inflammatory 
mediators such as lymphocytes, T cells, B cells, mast cells, interleukin-6 and interleukin-
2 (Erickson, 1999).  The etiology of IC/PBS is unknown, although various theories have 
been proposed, including neurogenic causes, infection, toxic agents in the urine, 
deficiency in bladder wall lining, urothelial disorder, disorder of the pelvic floor 
musculature, underlying endocrine abnormality, and autoimmune disorder (Buffington, 
2004; Erickson, 1999).  IC/PBS often shows comorbidity with arthritis, allergies, 
endometriosis, fibromyalgia, migraine, irritable bowel syndrome and panic syndrome, all 
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of which become worsened by stress (Buffington, 2004; Theoharides, 2007; Westropp 
and Buffington, 2002).   
 A link between chronic stress and the onset of symptoms of IC/PBS has been 
reported (Million et al., 2007; Rothrock et al., 2001).  Corticotropin-releasing factor 
(CRF)-over-expressing mice were examined in order to investigate this link.  CRF 
initiates the activation of the hypothalamic-pituitary-adrenal (HPA) axis, which leads to 
acute behavioral and visceral stress responses; an overactive HPA axis has also been 
implicated in the pathogenesis of PBS/IC (Buffington, 2004; Million et al., 2007).  CRF-
over-expressing mice show a significant increase in frequency of elimination in a novel 
environment and an overall enhanced pelvic response to stressors (Million et al., 2007).  
The CRF receptor type 1 has been implicated in visceral hyperalgesia seen in stressed rats 
(Larauche et al., 2008).  CRF has also been implicated in overactive bladder and the 
stimulation of bladder activity, and a link has been shown between bladder disorders and 
anxiety (Klausner and Steers, 2004).  
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IV. Cyclooxygenase-2 (COX-2) and inflammation 
A. General Background 
 The cyclooxygenase enzymes are responsible for the synthesis of prostaglandins 
from arachidonic acid.  Prostaglandins have many roles in physiological functions, 
including physiological “housekeeping” as well as inducible inflammatory functions.  
Arachidonic acid is found in cell membrane phospholipids and must be liberated from the 
membrane-bound phospholipids by phospholipase enzymes before COX enzymes can 
form prostaglandins (Figure 4) (Mitchell and Warner, 1999).  Two isoforms of COX have 
been identified: COX-1 and COX-2.  While both COX enzymes are involved in 
beneficial, homeostatic functions as well as inflammatory and pain effects, a distinction is 
often drawn between the two.  In general, COX-1 is thought of as the constitutive 
isoform, involved with many of the physiological functions of gastrointestinal, renal, 
immune and cardiovascular systems (Parente and Perretti, 2003).  COX-2 is thought of as 
the inducible isoform, with its metabolites being released locally in sites of inflammation 
or systemically after infection (Figure 5) (Mitchell and Warner, 1999).  Cytokines and 
growth factors have been implicated in the induction of COX-2 expression (Mitchell and 
Warner, 1999).  However, more research has shown that the story is not really as simple 
as this.    
Both COX-1 and COX-2 are responsible for the production of prostaglandin G2 
(PGG2) and prostaglandin H2 (PGH2) (Mitchell and Warner, 1999).  The presence of 
different downstream enzymes then determines the formation of further prostaglandins  
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Figure 4: The production of prostaglandins from arachidonic acid. 
 
Arachidonic acid is produced from membrane-bound phospholipids by the enzyme phospholipase 
A2.  Cyclooxygenase (COX) enzymes then produce the prostaglandins PGG2 and PGH2 from 
arachidonic acid.  PGH2  is then formed into multiple other prostaglandins, some of which are 
involved in inflammatory processes. 
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Figure 5: The cyclooxygenase concept. 
 
The COX enzymes are involved in homeostatic functions (COX-1) as well as inducible 
inflammatory functions (COX-2).  The presence of inflammatory cytokines and growth factors 
contributes to the induction of COX-2, which then produces prostaglandins, which sensitize 
nociceptors and lead to increased pain sensation.  However, recent studies have also shown an 
inducible role for COX-1 in pain. 
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from PGG2 and PGH2 (Figure 4) (Mitchell and Warner, 1999).  PGH2 can be further 
transformed into PGI2, thromboxane A2 (TXA2), PGE2, PGD2 and PGF2α (Parente and 
Perretti, 2003).  Important for inflammation, PGE2 is involved in pain sensitization 
centrally and at nerve terminals in the periphery, and acts as a hyperalgesic and 
vasodilator (Ahmadi et al., 2002; Mitchell and Warner, 1999; Parente and Perretti, 2003).  
PGE2 also could function in a positive feedback loop, inducing the expression of more 
COX-2 at inflammatory sites (Nantel et al., 1999; Parente and Perretti, 2003).  PGI2 acts 
as a vasodilator and both PGE2 and PGI2 are known to be hyperalgesic, potentiating 
nociception induced by other factors via the cAMP pathway and activation of protein 
kinase A (PKA) (Parente and Perretti, 2003; Richardson and Vasko, 2002).  Among other 
functions, TXA2 and PGD2 are involved in platelet aggregation, and PGF2 is involved in 
vasoconstriction and broncoconstriction (Parente and Perretti, 2003). 
 While a clear distinction between the roles of COX-1 and COX-2 remains to be 
established, it is known that selective inhibition of COX-2 does reduce inflammatory pain 
in animal models and in humans (Morrison et al., 1999; Parente and Perretti, 2003; 
Riendeau et al., 1997).  In most mammalian tissues, COX-2 is undetectable in normal 
conditions.  COX-2 is then rapidly induced in inflammatory cells such as fibroblasts, 
monocytes, and vascular endothelium in response to inflammatory mediators such as 
growth factors and cytokines (Figure 5) (Parente and Perretti, 2003).  Still, a role for 
COX-1 in nociception and inflammation has also been reported and it is likely that 
inflammation and inflammatory hyperalgesia result from cooperation between 
prostaglandins produced by both COX enzymes (Parente and Perretti, 2003).  The 
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biological functions of the two COX enzymes are much more complex and interrelated 
than initially thought (Parente and Perretti, 2003). 
B.  COX-2 and urinary bladder inflammation 
 COX pathways and prostaglandins have a cytoprotective role in urinary bladder 
and also are involved in micturition reflex (Wheeler et al., 2001).  Prostaglandins 
modulate the basal tone of the detrusor and influence detrusor contraction as well as 
target primary bladder afferents, thus influencing the micturition reflex (Angelico et al., 
2006; Maggi, 1992).  Endogenous prostaglandins are produced in the bladder wall during 
distension and these may have an influence on afferent input, leading to alterations in 
void contractions (Maggi, 1992; Wheeler et al., 2001).  Application of prostaglandins to 
the detrusor stimulates the micturition reflex (Maggi et al., 1984).  PGE2 and PGI2 are the 
predominant prostaglandins found in the rat and human urinary bladder, although PGD2 
is also expressed (Hu et al., 2003; Wheeler et al., 2001).  Treatment with systemic non-
steroidal anti-inflammatory drug (NSAID), which specifically targets the COX enzymes, 
increases bladder capacity in experimental rats and NSAID application in vitro leads to 
detrusor muscle relaxation (Abrams et al., 1979; Maggi et al., 1984; Maggi et al., 1988b).  
Prostaglandins TXA2, PGE2, PGD2 and PGF2α influence contractile activity of detrusor 
smooth muscle in vitro (Angelico et al., 2006).  COX inhibitors have been shown to 
attenuate detrusor instability in humans (Lecci et al., 2000).  Furthermore, intravenous 
administration of non-selective COX inhibitors reduces bladder activity in both control 
rats and rats with bladders inflamed by intravesical administration of acetic acid 
(Angelico et al., 2006).  It has been postulated that COX-1 could be involved in 
 30
modulating the contraction threshold, while COX-2 could have more involvement in the 
inflammatory response (Lecci et al., 2000).   
In addition to the roles of COX pathways and prostaglandins in normal bladder 
function, numerous studies have suggested a role for COX-2 in bladder inflammation and 
even in the associated bladder hyperreflexia.   We know that LPS bladder inflammation 
in rats leads to the elevation of COX-2 protein in urinary bladders, but does not elevate 
levels of COX-2 mRNA or COX-1 protein or mRNA (Wheeler et al., 2001).  Urinary 
levels of PGE2 and synthesis of PGE2 in bladder are also increased with LPS, suggesting 
the importance of this molecule in the LPS inflammatory process (Wheeler et al., 2001).  
Acute CYP-induced cystitis in female rats increased the expression of COX-2 
immunoreactive cell profiles throughout the urinary bladder wall as well as increased 
protein expression of PGD2 and PGE2 in the whole bladder (Hu et al., 2003).  
Functionally, it has been shown that a COX-2 specific inhibitor, 5,5-dimethyl-3-(3-
fluorophenyl)-4-(4-methylsulfonyl)phenyl2(5H)-furanone (DFU) attenuates the bladder 
hyperreflexia associated with CYP-induced cystitis in rats and rescues bladder capacity 
(Hu et al., 2003).  Prostaglandins and COX-2 may play a prominent role in bladder 
function as well as a pathophysiological role in bladder inflammation and the associated 
hyperreflexia.     
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V. Nerve Growth Factor (NGF) and the p75 neurotrophin receptor (p75NTR) 
NGF was first discovered by Rita Levi-Montalcini in the 1950s as a target-derived 
factor vital to the survival and outgrowth of sensory neurons (Aloe, 2004).  Since then, 
the specific receptor for NGF, TrkA, has been discovered and attributed as the receptor 
required for the important neuronal survival functions of NGF.  More recently, the 
discovery of a pan-neurotrophin receptor, p75NTR, has made the study of neurotrophins 
and NGF more interesting.   p75NTR was initially discovered as a receptor for proNGF, 
which led to apoptosis (Barker, 2004).  Since then, p75NTR has been implicated in myriad 
neuronal processes, including apoptosis and regeneration.  For our purposes, p75NTR has 
also been implicated as a co-receptor for TrkA, possibly enhancing TrkA binding and 
specificity for NGF.  Both NGF and TrkA are implicated in the processes of bladder 
inflammation, NGF inducing bladder hyperreflexia and TrkA upregulated after CYP-
induced cystitis.  The next step is to determine what role p75NTR may play, if any, in 
bladder inflammation and hyperreflexia.  
A. NGF 
 NGF is one of a family of four mammalian neurotrophins that also includes brain-
derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and NT-4/5.  Neurotrophins 
are often target-derived and their retrograde transport to the perikaryon is thought to be 
required for the neurotrophin effect on the neuron (Zweifel et al., 2005).  NGF was the 
first neurotrophin identified and it is involved in the development and survival of 
peripheral sympathetic and sensory neurons (Chao et al., 2006; Frossard et al., 2004).  
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Centrally, NGF is involved in survival and maintenance of cholinergic neurons in the 
basal forebrain (Chao et al., 2006).  It has been shown that in the adult, NGF maintains 
the normal properties of C-fiber afferents as well as all small size sensory neurons 
(Chuang et al., 2001a).  Other NGF functions include neuronal differentiation, neurite 
outgrowth and sprouting, modulation of synaptic activity, gene regulation, survival 
maintenance in the adult, and inflammatory pain (Friedman and Greene, 1999).   
 NGF has a prominent role in inflammation, central and peripheral pain 
processing, and in the hyperalgesic effects of inflammation.  Nociceptors continue to 
express NGF receptors into adult life in humans and animals and NGF is now 
additionally thought of as a “peripheral pain mediator” (Pezet and McMahon, 2006); 
NGF is upregulated in many chronic pain conditions and inflamed tissues.  Upregulation 
of NGF is seen with peripheral inflammation and tissue injury (Lindholm et al., 1987; 
Micera et al., 2007; Woolf et al., 1997).  The induction of NGF expression is caused in 
part by the actions of pro-inflammatory cytokines, including interleukin-1 and tumor 
necrosis factor (Hefti et al., 2006).  NGF levels can remain increased with chronic 
inflammation (Hefti et al., 2006).  Mast cells are an important inflammatory cell type; 
mast cells stimulate the release of NGF, and NGF in turn stimulates mast cells under 
conditions of tissue injury or inflammation, possibly creating a positive feedback loop for 
inflammatory responses (Hefti et al., 2006).  NGF also sensitizes TRPV1 receptors, by 
initiating post-translational changes in the receptor, resulting in greater excitability (Hefti 
et al., 2006).  TRPV1 is a non-selective cation channel originally identified as the 
capsaicin receptor (Hefti et al., 2006).  Retrograde transport of NGF to the perikaryon 
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also increases the transcription of several nociception-related molecules, including 
substance P, BDNF, the Nav1.8 Na+ ion channel and TRPV1 (Hefti et al., 2006).  
Substance P and BDNF are involved in central sensitization to increase the excitability of 
second-order spinal neurons; the Nav1.8 Na+ channel is expressed solely in nociceptors 
(Hefti et al., 2006).   
Injection of NGF into rat hindpaw creates allodynia and heat hyperalgesia due to 
a wind-up response in the spinal cord (Thompson et al., 1995).  Injection of carrageenan 
or complete Freund’s adjuvant into the hindpaw of mice leads to a rise in endogenous 
levels of NGF as well as the development of mechanical and heat hyperalgesia (Guerios 
et al., 2006).  Administration of NGF to DRG neurons or afferent terminals leads to 
sensitization of these primary afferents by increasing the transcription levels of TRPV1, 
upregulating neuropeptides (CGRP, substance P) and BDNF (Allen and Dawbarn, 2006; 
Pezet and McMahon, 2006).  The neuropeptides substance P and CGRP are released in 
the periphery and centrally from activation of small-diameter sensory afferents and 
through actions on endothelial cells, mast cells, immune cells and arterioles, they initiate 
such inflammatory effects as vasodilation, plasma extravasation, and sensory neuron 
hyperexcitability, resulting in redness, swelling, and hypersensitivity (Richardson and 
Vasko, 2002).  Exogenously applied NGF can also lead to the rapid sensitization of 
Nav1.8 sodium channel that is expressed only on nociceptors, contributing to the 
sensitization of primary afferent neurons after injury or inflammation (Allen and 
Dawbarn, 2006).  NGF protein levels are also increased on colonic epithelium after 
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trinitrobenzene sulphonic acid (TNBS)-induced colitis (Stanzel et al., 2008).  NGF likely 
serves as a link between inflammation and hyperalgesia (Lewin and Mendell, 1993). 
 There is a large body of evidence that supports the concept that NGF also has a 
role in mediating the micturition reflex.  NGF is expressed under normal conditions in the 
urinary bladder, and part of its function is likely in the maintenance of sensory afferents 
there (Chao and Hempstead, 1995; Chuang et al., 2001b).  It also can interact with 
afferents and contribute to pathological conditions including inflammation and bladder 
hyperreflexia.  Sources of NGF in the bladder include urothelium, detrusor smooth 
muscle and inflammatory infiltrates, especially mast cells (Steers and Tuttle, 2006; 
Vizzard, 2000b; Zvara and Vizzard, 2007).  Mechanical stretch of the detrusor smooth 
muscle results in the release of NGF mRNA and protein from the muscle (Vaidyanathan 
et al., 1998).   
There is also a wide range of evidence supporting the role of NGF in lower 
urinary tract disorders: NGF levels are increased in the urine of patients with IC (Okragly 
et al., 1999) and increased levels of NGF are seen in the bladders of patients with sensory 
urgency (Lowe et al., 1997).  NGF mRNA levels are increased in rat bladders with 
chemically-induced cystitis (Oddiah et al., 1998; Vizzard, 2000b) and with bladder outlet 
obstruction (Steers and Tuttle, 2006).  While NGF levels in urinary bladder are reduced 
with CYP cystitis, this could be attributed to retrograde transport of NGF to cell bodies in 
the major pelvic ganglion or DRG (Birder et al., 2007; Murray et al., 2004; Vizzard, 
2000b). 
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There is much functional evidence to support the role of NGF in bladder reflexes 
as well as sensation.  It has been shown that intravesical instillation of NGF sensitizes 
bladder afferents, increasing their response to stimuli and making some responsive that 
were not responsive before the instillation of NGF (Dmitrieva and McMahon, 1996).  
Over-expression of NGF in detrusor in rats leads to hyperreflexia (Clemow et al., 1998; 
Zvara and Vizzard, 2007).  Sequestration of NGF reduces inflammation-induced 
hyperreflexia in a rat model (Dmitrieva et al., 1997).  Blockade of NGF reduces the 
peripheral hypersensitivity seen with CYP cystitis also (Guerios et al., 2008).  Systemic 
administration of REN1820, an NGF scavenging agent and a recombinant protein of the 
D5 extracellular domain of the NGF receptor tyrosine kinase TrkA, also reduces bladder 
hyperreflexia in a CYP-induced inflammation model in rats (Hu et al., 2005).  Intrathecal 
administration of NGF increases NGF expression in bladder afferents, sensitizes bladder 
afferents as well as increases bladder hyperreflexia, demonstrating that increased NGF 
levels in micturition afferent pathways can contribute to bladder afferent plasticity, 
contributing to changes in the micturition reflex (Yoshimura et al., 2006).  Exogenous 
NGF application to the rat bladder detrusor through an osmotic pump reduced bladder 
capacity as well as increased expression of CGRP and Fos in lumbosacral spinal cord, 
suggesting re-organization of micturition reflex pathways (Zvara and Vizzard, 2007).  It 
has also been suggested that Aδ fibers play a more important role in NGF-induced 
bladder hyperreflexia than C-fibers (Chuang et al., 2001b).   
 
 36
NGF BDNF NT-3NT-4/5
All 4
D1
D2
D3
D4
D5
TrkB TrkCTrkA
kinase 
domain
Type II 
death 
domain
p75NTR
 
 
 
 
 
 
 
 
 
 
Figure 6: Neurotrophins and their receptors. 
 
Each neurotrophin binds specifically to a Trk receptor.  They all also bind p75NTR, which is 
known as the pan-neurotrophin receptor.  p75NTR is a member of the tumor necrosis factor-α 
family of receptors.  Trk receptors have five extracellular domains.  The D5 domain is important 
for binding ligands (Allen and Dawbarn, 2006). 
 
B. Receptor tyrosine kinase A (TrkA) 
 Neurotrophins bind with greater affinity to certain receptors.  NGF specifically 
binds TrkA, BDNF and NT-4/5 specifically bind TrkB, and NT-3 binds TrkC (Figure 6).  
The Trk receptors have an intracellular structure consisting of a transmembrane domain,  
a kinase domain and a 15-residue C-terminal tail.  Extracellularly, Trk receptors can be 
divided into five distinct domains D1-D5, where D5 is the closest to the cell membrane 
and also serves as the binding domain (Allen and Dawbarn, 2006).  Neurotrophin binding 
to Trk receptors results in receptor dimerization and transphosphorylation of the 
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intracellular kinase domains (Allen and Dawbarn, 2006).  Phosphorylated tyrosines then 
can become docking sites for many signaling molecules, including those for the Ras, 
phosphoinositide 3-kinase (PI3K) and phospholipase C-γ (PLC- γ) pathways (Allen and 
Dawbarn, 2006; Chao and Hempstead, 1995; Kalb, 2005).  Induction of p38 MAPK, 
ERK and c-JUN N-terminal kinase are also achieved by NGF and possibly involved in 
NGF-mediated hyperalgesia (Hefti et al., 2006).  This signaling through MAP kinases 
alters and influences post-translational processes as well as transcription (Richardson and 
Vasko, 2002).   
Neurotrophin signaling also often requires retrograde transport of neurotrophins 
from the periphery to the perikaryon, resulting in retrograde effects on the cell body from 
what are often great distances from the nerve terminals (Allen and Dawbarn, 2006; Miller 
and Kaplan, 2001; Zweifel et al., 2005).  It is unclear if internalization of a complete 
ligand-receptor complex is necessary or if other modes of signal propagation are used for 
the neurotrophin signal (Zweifel et al., 2005).  However, there is considerable evidence 
for a clathrin/dynamin dependent process of NGF-TrkA ligand-receptor internalization 
and transport, although pincher-mediated endocytosis as well as caveolin-mediated 
endocytosis have also been implicated (Zweifel et al., 2005).   
As explained above, a role for NGF in sensory and sympathetic cell development, 
maintenance, and inflammatory pain states has been described extensively.  All of these 
functions of NGF are mediated through the TrkA receptor.  Perhaps underlining the 
importance of NGF-TrkA signaling to pain sensation, the condition known as congenital 
insensitivity to pain with andhidrosis (CIPA) results from a rare autosomal-recessive 
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genetic mutation in the TrkA gene (Allen and Dawbarn, 2006).  NGF is involved in 
regulating the gene expression of nociception-related molecules in TrkA-expressing 
neurons (Allen and Dawbarn, 2006; Pezet and McMahon, 2006).  Many have been 
described above.  These include substance P, CGRP, sodium channels and TRPV1 as 
well as ion channels, and the P2X3 purinergic receptor (Allen and Dawbarn, 2006; Pezet 
and McMahon, 2006).  Post-translationally, increased neuronal sensitivity is achieved 
through increased expression of CGRP and substance P release and the phosphorylation 
of TRPV1 seen after NGF treatment of TrkA-expressing cells (Pezet and McMahon, 
2006).  It has also been demonstrated that TrkA-mediated activation of the MEK1-
ERK1/2 and PI3K pathways is involved in local axonal sprouting (Miller and Kaplan, 
2001).   
In urinary bladder afferents, TrkA immunoreactivity was upregulated in bladder-
projecting afferent cells in DRG neurons at spinal cord levels L1 and L6 after acute and 
chronic CYP-induced cystitis (Qiao and Vizzard, 2002).  TrkA is also upregulated in the 
major pelvic ganglion after CYP-induced cystitis (Murray et al., 2004).  Phosphorylated 
Trk expression is also increased in CYP cystitis, suggesting that the increased 
phosphorylation of TrkA may be increasing the response of neurons to target-derived 
NGF (Qiao and Vizzard, 2002).  Also, the systemic administration of k252a, a Trk 
specific antagonist, decreased the bladder activity associated with CYP-induced cystitis, 
suggesting a role for NGF-TrkA signaling in CYP-induced bladder hyperreflexia (Hu and 
Vizzard, unpublished observations).   
 39
C. p75NTR 
  While all neurotrophins NGF, BDNF, NT-3 and NT-4/5 bind to their specific Trk 
receptors, they also all bind to p75NTR with comparable affinity (Allen and Dawbarn, 
2006).  As well as binding all neurotrophins and functioning independently, p75NTR also 
regulates the affinity of Trk receptors for their specific ligands, thus leading to enhanced 
Trk function and ligand specificity (Chao and Hempstead, 1995; Chao et al., 2006).  
p75NTR has an extracellular domain that contains 4 cysteine-rich domains that are required 
for ligand binding (Allen and Dawbarn, 2006; Barker, 2004).  The intracellular portion of 
p75NTR contains a type II death domain that is implicated in apoptosis.  This domain is 
common in members of the tumor necrosis factor-α (TNF-α) family of receptors, 
although the structure of the death domain of p75NTR is distinct from other receptors in 
the TNF-α family (Barker, 2004).  p75NTR often acts as a co-receptor for activating 
signaling cascades (especially with Trk receptors), but also functions on its own (Chao 
and Hempstead, 1995).  The results of the multiple interactions with co-receptors and 
ligands of p75NTR often depend on the developmental stage and cell type where signaling 
is occurring.    
 While p75NTR functions in the presence of Trk receptors are very important, 
p75NTR has many other interesting binding partners and functions, including apoptosis 
and neuronal growth regulation.  For example, sortilin is a co-receptor for p75NTR binding 
the NGF precursor molecule proNGF, and this signaling partnership results in apoptosis 
(Barker, 2004; Chao and Hempstead, 1995).  The affinity of proNGF for p75NTR  is higher 
than that of mature NGF (Barker, 2004).  This cell death function of p75NTR may also be 
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important in regulating the development of central nervous system cell populations 
(Friedman and Greene, 1999).  It has also been shown that p75NTR stimulation activates 
the transcription factor NFκB in Schwann cells and oligodendrocytes and the c-Jun N-
terminal kinase (c-JNK) pathway in oligodendrocytes, facilitating cell survival (Chao and 
Hempstead, 1995; Freund-Michel and Frossard, 2008; Friedman and Greene, 1999).  The 
consequences of this signaling are not yet fully understood (Friedman and Greene, 1999).  
p75NTR also may form a three-receptor complex with the Nogo receptor and with Lingo-1 
which results in neuronal growth inhibition (Barker, 2004).  This p75NTR complex can 
bind myelin-based growth inhibitors including Nogo, myelin-associated glycoprotein 
(MAG) and oligodendrocyte myelin glycoprotein (OMgP) and result in the regulation of 
RhoA, thus affecting neuronal growth (Barker, 2004; Dechant and Barde, 2002; Wong et 
al., 2002).   
The mechanisms of the internalization and movement of the p75NTR signal are as 
yet poorly understood and many possibilities exist (Bronfman and Fainzilber, 2004).  
Internalization of the receptor could result in lysosomal degradation or recycling of the 
ligand-receptor complex or adaptor proteins could form a retrograde transport complex 
with or without a signaling endosome (Bronfman and Fainzilber, 2004).  A clathrin-
dependent internalization of p75NTR has been demonstrated in PC12 cells, with 
internalization occurring 3-fold slower than TrkA internalization in PC12 cells (Freund-
Michel and Frossard, 2008).  This possibly leads to recycling of p75NTR at the cell 
membrane (Freund-Michel and Frossard, 2008).  p75NTR can also be subjected to 
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regulated intramembrane proteolysis, which means that the intracellular cleavage of 
p75NTR could have its own signaling capabilities (Bronfman and Fainzilber, 2004).   
 In neurons expressing Trk receptors, p75NTR is typically thought to function as an 
assistant to NGF signaling through TrkA.  In studies in thoracic rat DRG, p75NTR was 
found exclusively expressed in cells that also expressed TrkA (Wright and Snider, 1995).  
Co-expression of p75NTR  with members of the Trk family is thought to enhance binding, 
increase sensitivity and to sharpen the discrimination of Trks for their specific 
neurotrophin ligand (Barker, 2004; Chao and Hempstead, 1995; Lee et al., 2001; Teng 
and Hempstead, 2004).  It is also possible that p75NTR forms a complex with TrkA and 
NGF, allowing for increased ligand selectivity of TrkA (Chao et al., 2006; Kahle et al., 
1994; Verdi et al., 1994).  However, through analysis of the crystal structures of the 
extracellular domains of TrkA and NGF, a recent study has determined that the formation 
of an actual trimeric NGF- p75NTR-TrkA structure cannot occur (Wehrman et al., 2007).  
However, a ligand-passing model has been suggested that involves the rapid binding of 
NGF to the extracellular domain of p75NTR, and then NGF binding to TrkA.  NGF can 
then bind a second TrkA molecule, allowing for dimerization of TrkA upon NGF binding 
(Barker, 2007; Wehrman et al., 2007).  It is possible that TrkA-p75NTR signaling 
pathways are different from TrkA signaling alone (Nykjaer et al., 2005).  Convergence of 
downstream signaling pathways of TrkA and p75NTR is also a likely possibility for the 
communication between TrkA and p75NTR (Freund-Michel and Frossard, 2008).   
While in some systems, p75NTR increases TrkA binding affinity for NGF, in other 
systems, p75NTR also could function to reduce NGF-TrkA signaling by sequestering NGF, 
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leaving less available to bind TrkA (Coome et al., 1998; Dhanoa et al., 2006; Hannila et 
al., 2004; Nykjaer et al., 2005).  This scenario is possible in pathophysiological 
conditions such as tissue injury or inflammation that involve the increased expression of 
NGF; it is possible that TrkA and p75NTR no longer work synergistically in these 
situations (Dhanoa et al., 2006).  Sprouting is an NGF-mediated process of peripheral 
axons.  Mice that do not express p75NTR show increased sprouting in cerebellar and spinal 
cord sensory neurons (Coome et al., 1998; Scott et al., 2005).  p75NTR expression in 
sympathetic neurons is important to ensure normal target sympathetic innervation and to 
limit axonal arborization in tissues where NGF is elevated, such as in inflammation or 
injury (Dhanoa et al., 2006).  Increased sprouting in the p75NTR knockout mice has also 
been shown for postganglionic sympathetic projections into cerebellum and trigeminal 
ganglia (Dhanoa et al., 2006).  Mice that over-express NGF and do not express p75NTR 
show an increase in sympathetic fiber sprouting in target peripheral tissues, and the 
authors suggest that NGF-TrkA signaling is enhanced in situations without p75NTR and 
with the over-expression of NGF (Dhanoa et al., 2006).  Enhanced sprouting of central 
sensory processes is also seen in p75NTR knockout mice after dorsal rhizotomy, again 
suggesting that the TrkA-NGF-dependent process of sensory neuron sprouting is 
enhanced in the absence of p75NTR.  It has been suggested that the binding of NGF to 
p75NTR leaves less NGF available to signal via TrkA, thus permitting more NGF-TrkA-
mediated sprouting (Coome et al., 1998; Hannila and Kawaja, 2005; Miller et al., 1994).  
The ratio of p75NTR to TrkA may determine neuronal responsiveness and survival (Chao 
et al., 2006).   
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In a knockout mouse model involving the deletion of exon III from the p75NTR 
gene, distinct changes were seen in the sensory innervation phenotype (Lee et al., 1992).  
The mice had decreased sensory innervation of CGRP and substance P-expressing 
neurons in their footpads, which led to loss of heat sensitivity and ulceration of distal 
limbs (Lee et al., 1992).  This effect was rescued by crossing a human transgene encoding 
p75NTR into mutant mice, indicating that p75NTR has an important role in sensory 
innervation (Lee et al., 1992).  A second line of transgenic mice involves deletion of exon 
IV from the p75NTR gene.  This line demonstrated a similar decrease in sensory 
innervation and decreased temperature sensation as the exon III knockout mice did 
(Dhanoa et al., 2006).  Changes in levels of sympathetic axonal sprouting have since been 
demonstrated in both lines of p75NTR transgenic mice (Coome et al., 1998; Dhanoa et al., 
2006). 
It is possible that p75NTR functions in the sensation of pain as well as in 
inflammatory plasticity, including long-term changes in sensory pathways after 
inflammation.  p75NTR is increased in DRG after nerve injury and may be associated with 
the neuropathic pain seen after nerve injury (Obata et al., 2006).  The neuropeptide 
substance P is upregulated and released from sensory neurons after exposure to high 
levels of NGF.  An in vitro experiment using sensory neurons showed that blockade of 
TrkA and p75NTR  independently inhibited the release of substance P from these neurons, 
suggesting that both TrkA and p75NTR are required for the upregulation and release of 
substance P in this system (Skoff and Adler, 2006).  Freund’s adjuvant-induced arthritis 
is a chronic inflammatory pain model that results from injection of complete Freund’s 
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adjuvant (CFA) into the hindpaw of an experimental animal.  This treatment increases 
TrkA and p75NTR protein expression in DRG cells and in the dorsal horn of lumbar spinal 
cord levels L3-L5, which receive afferents from hind paws (Pezet et al., 2001).  This 
suggests that this chronic inflammatory pain model involves NGF, which may signal via 
TrkA and p75NTR receptors, thus contributing to central neuroplasticity (Pezet et al., 
2001).  The mRNA expression of p75NTR is also increased in DRG with peripheral 
inflammation resulting from the injection of CFA into the hindpaws of rats (Cho et al., 
1996).  The same technique was used in neonatal rats and mRNA expression of p75NTR 
and TrkA were upregulated in the DRGs of rat pups, implicating the signaling pathways 
of p75NTR and TrkA in the development of sensory and sympathetic neurons and in the 
neuroplasticity associated with inflammation in newborn pups (Chien et al., 2007).   
 The roles o f p75NTR  have not been completely resolved, but there are lines of 
evidence indicating that it is an active player in neuronal plasticity.  Research examining 
p75NTR expression in the bladder includes experiments in the streptozotocin (STZ)-
induced diabetes model, neuropathic bladder in human patients, in experimental nerve 
regeneration and in bladder inflammation models (Cho et al., 1996; Elsasser-Beile et al., 
2000; Tong and Cheng, 2005; Vaidyanathan et al., 1998; Wakabayashi et al., 1998; 
Wakabayashi et al., 1996; Wakabayashi et al., 1995).  STZ is used to model diabetes in 
experimental rats and diabetes is often associated with bladder dysfunction (Tong and 
Cheng, 2005).  Both protein and mRNA expression of NGF were down-regulated in the 
bladder of rats with STZ-induced diabetes, and p75NTR mRNA expression is also down-
regulated (Delcroix et al., 1998; Tong and Cheng, 2005).  This reduction in neurotrophic 
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factor as well as neurotrophin receptor could indicate the importance of NGF and the 
p75NTR receptor in the maintenance of bladder afferents, and may indicate that the loss of 
these in the bladder could lead to the bladder pathology seen with diabetes (Delcroix et 
al., 1998; Tong and Cheng, 2005).  It is also possible that target-derived changes in NGF 
levels drive changes in p75NTR expression (Delcroix et al., 1998).  Biopsies taken from 
patients with neuropathic bladder were examined with immunohistochemistry for 
p75NTR-immunoreactivity (IR) and IR was seen in urothelium as well as in nerve fibers 
located near to the urothelium (Vaidyanathan et al., 1998).  Nerve crush injury was 
performed at the major pelvic ganglion of experimental male rats and regeneration 
occurred after about 60 days (Wakabayashi et al., 1998).  After this time, bladders were 
examined for p75NTR–IR and GAP-43-IR.  The density of both p75NTR–IR and GAP-43-
IR nerve fibers was increased in the bladders 30 days after the crush, implicating both 
GAP-43 and p75NTR in nerve regeneration and neuroplasticity in the urinary bladder after 
nerve injury (Wakabayashi et al., 1998).  A few other studies have examined p75NTR –IR 
in the rat urinary bladder with or without CYP-induced cystitis (Wakabayashi et al., 
1996; Wakabayashi et al., 1995).  Most of the p75NTR staining found in control bladders 
was in nerve fibers running freely in the lamina propria, on the surface of Schwann cells, 
and in the vicinity of blood vessels (Wakabayashi et al., 1996; Wakabayashi et al., 1995).  
A few nerve fibers were also labeled in the control detrusor and some p75NTR-IR fibers 
also co-labeled with tyrosine hydroxylase (Wakabayashi et al., 1995).  No staining was 
seen in the urothelium (Wakabayashi et al., 1995).  Staining after 2 or 3-day CYP 
treatment was increased in thick nerve fiber bundles in the smooth muscle.  The authors 
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suggested that p75NTR expression in the muscle could be involved in the hyperalgesia 
associated with CYP cystitis due to the increased expression of NGF in the urinary 
bladder smooth muscle (Wakabayashi et al., 1996).   
 While it is clear that p75NTR is expressed in urinary bladder reflex pathways and 
that its expression is plastic with some pathological conditions, much remains to be 
determined.  It is likely that the ratio of expression of TrkA to p75NTR receptors 
influences the overall NGF binding affinity and signaling effects (Chao and Hempstead, 
1995). 
While the importance of p75NTR is becoming more clear in many tissue types and 
in NGF signaling, virtually nothing is known about p75NTR signaling in the bladder, even 
though NGF signaling appears to have importance in bladder activity with and without 
bladder inflammation.  This dissertation focused on determining the expression and 
functional role of p75NTR in the urinary bladder.
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VI. Project aims and hypotheses 
 The goal of this project was to examine changes in micturition reflex pathways, 
including the urinary bladder, lumbosacral spinal cord and DRG and bladder function 
with bladder inflammation using the CYP model of cystitis.  The overall hypothesis of 
this project is that urinary bladder inflammation induces expression of inflammatory 
enzymes and changes in neurotrophin receptor expression that contribute to functional 
changes in the urinary bladder.  This project focused specifically on the expression of 
COX-2 (Aim 1) and p75NTR (Aim 2) in the urinary bladder and micturition reflex 
pathways, and on the functional role of p75NTR (Aim 3) in the urinary bladder of 
experimental animals.   
 COX-2 has been implicated in normal bladder function as well as in bladder 
hyperreflexia seen with bladder inflammation (Wheeler et al., 2001).  Systemic 
administration of a COX-2 inhibitor resulted in the attenuation of bladder hyperreflexia 
seen with CYP cystitis (Hu et al., 2003).  Inflammatory stimuli increases COX-2 
expression in inflamed tissues, and COX-2 protein and mRNA expression in the urinary 
bladder are increased with CYP treatment (Hu et al., 2003), but the localization and 
cellular sources of the COX-2 upregulation remained to be shown.  We hypothesized 
increased COX-2 expression in specific tissue compartments of the urinary bladder 
(urothelium or detrusor) with CYP-induced inflammation. This was the goal of Aim 1, 
described in Chapter 2.  
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 NGF is also implicated in normal bladder function as well as in the plasticity of 
bladder function with cystitis (Chao and Hempstead, 1995; Chuang et al., 2001b).  NGF 
is increased in the urine of patients with IC/PBS and in experimentally induced 
inflammation, and exogenous application of NGF results in bladder hyperreflexia and 
increased afferent sensitivity (Clemow et al., 1998; Dmitrieva and McMahon, 1996; 
Dmitrieva et al., 1997; Okragly et al., 1999; Zvara and Vizzard, 2007).  The specific NGF 
tyrosine kinase receptor, TrkA, is increased in bladder afferent cells with CYP.  While 
there is evidence for a role of NGF and NGF-TrkA signaling in inflammatory responses 
as well as in bladder inflammation, thus far very little attention has been paid to the role 
that the pan-neurotrophin receptor p75NTR might play in normal micturition reflexes and 
how this might change in response to bladder inflammation.  Thus, aims 2 and 3 of this 
project focused on the expression and function of p75NTR in bladder and micturition reflex 
pathways in control and CYP-treated rats.  We hypothesized that p75NTR is constitutively 
expressed in micturition pathways and upregulated with cystitis.  Based on bladder 
function effects of TrkA blockade with cystitis, we also hypothesized that p75NTR 
blockade in the urinary bladder would also decrease bladder hyperreflexia with cystitis.  
The functional role of p75NTR was studied by intravesical blockade by 
immunoneutralization with a monoclonal antibody to p75NTR and by PD90780, known to 
block NGF-p75NTR binding.  A summary of aims and hypotheses for this dissertation 
follows below. 
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Aim 1: To determine the expression of COX-2 in urinary bladder urothelium, 
suburothelium and detrusor smooth muscle in control animals and after acute and chronic 
CYP-induced cystitis.   
Hypothesis:  COX-2 expression is increased in specific tissue compartments of the 
urinary bladder with the bladder inflammation with CYP-induced cystitis.   
 
Aim 2:  To determine the expression p75NTR in micturition reflex pathways in control 
animals and after CYP-induced cystitis. 
Hypothesis:  p75NTR is constitutively expressed in micturition reflex pathways and 
expression is upregulated with urinary bladder inflammation. 
 
Aim 3:  To determine the effect of intravesical p75NTR blockade on bladder function in 
both control and CYP treated animals. 
Hypothesis:  Blockade of p75NTR in urinary bladder decreases voiding frequency in 
control rats and decreases bladder hyperreflexia in CYP-treated rats. 
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Abstract 
These studies examined the expression of cyclooxygenase-2 (COX-2) expression in the 
urothelium and suburothelial space and detrusor from rats treated with cyclophosphamide 
(CYP) to induce acute (4 hr), intermediate (48 hr) or chronic (10 day) cystitis.  Western 
blotting and immunohistochemistry were used to demonstrate COX-2 expression.  In 
whole mount preparations of urinary bladder, nerve fibers in the suburothelial plexus and 
inflammatory cell infiltrates were characterized for COX-2 expression after CYP-induced 
cystitis. COX-2 expression significantly (p ≤ 0.01) increased in the urothelium + 
suburothelium and detrusor smooth muscle with acute, intermediate and chronic (10 day) 
CYP-induced cystitis but expression in urothelium + suburothelium was significantly 
greater.  CYP-induced upregulation of COX-2 showed by immunostaining in the 
urothelium + suburothelium was similar to that observed with western blotting and also 
demonstrated COX-2 inflammatory cell infiltrates (CD86+) and nerve fibers (PGP+) in 
the suburothelial plexus.  Although COX-2 expression was significantly (p ≤ 0.01) 
increased in detrusor smooth muscle, immunohistochemistry failed to demonstrate an 
obvious change in COX-2-IR in detrusor muscle but COX-2 inflammatory infiltrates 
were present throughout the detrusor.  COX-2-IR nerve fibers exhibited increased density 
in the suburothelial plexus with acute or chronic CYP-induced cystitis.  COX-2-IR 
macrophages (CD86+) were present throughout the urinary bladder with acute and 
chronic CYP-induced cystitis.  These studies demonstrate cellular targets in the urinary 
bladder where COX-2 inhibitors may act. 
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 Introduction 
  Experiments involving a chemically (cyclophosphamide, CYP)-induced urinary 
bladder inflammation have demonstrated alterations in neurochemical (Braas et al., 2006; 
Dattilio and Vizzard, 2005; Vizzard, 2001), organizational (Vizzard, 2000b; Vizzard and 
Boyle, 1999) and electrophysiological (Yoshimura and de Groat, 1999) properties of 
micturition reflex pathways. Possible mechanisms underlying the neural plasticity 
following CYP-induced cystitis may involve altered expression of neurotrophic factors 
(Murray et al., 2004; Vizzard, 2000b), cytokines (Malley and Vizzard, 2002) and/or 
neural activity in the urinary bladder. The presence of proinflammatory cytokines and 
growth factors can induce cyclooxygenase-2 (COX-2), an inflammatory response gene 
(Mitchell and Warner, 1999).  CYP-induced cystitis induces a number of neurotrophic 
factors (Murray et al., 2004; Vizzard, 2000b), including nerve growth factor, in the 
urinary bladder and pelvic ganglia.  
 
  In addition to COX-2 being induced in response to inflammatory stimuli 
(Fujisawa et al., 2005; Hu et al., 2003; Linden et al., 2004; Mitchell and Warner, 1999; 
Schafers et al., 2004; Yiangou et al., 2006), studies have demonstrated upregulation of 
COX-2 in the urinary bladder as a result of urinary bladder outlet obstruction (Park et al., 
1999; Park et al., 1997) and postnatal development (Park et al., 1997).  Complete bladder 
outlet obstruction in mice significantly upregulated COX-2 expression in detrusor smooth 
muscle cells and this has been suggested to be a result of mechanical stretch (Park et al., 
1999).  During development, embryonic expression of COX-2 transcript in bladder is 
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100-fold higher compared to postnatal or adult bladder (Park et al., 1997). In our previous 
studies, COX-2 mRNA was increased in the whole urinary bladder after acute and 
chronic CYP treatment (Hu et al., 2003).  COX-2 protein expression in inflamed bladders 
paralleled that of COX-2 mRNA (Hu et al., 2003). Prostaglandins generated by the COX-
2 enzyme are also mediators of altered neuronal activity in inflamed tissues and have 
been demonstrated to stimulate the micturition reflex, possibly through activation of 
capsaicin sensitive bladder afferents (Andersson and Wein, 2004; Maggi, 1992; Maggi et 
al., 1988a). Prostaglandins have been suggested to play a physiological role in 
contributing to the basal tone of the detrusor and modulating activity of bladder nerves 
(Andersson and Wein, 2004; Maggi, 1992; Maggi et al., 1988a).  A number of COX-2 
inhibitors have also been shown to increase bladder capacity in experimental cystitis 
induced by CYP (Hu et al., 2003; Lecci et al., 2000).   
An increase in COX-2 expression induced by complete bladder outlet obstruction 
has been specifically localized to the detrusor smooth muscle cells (Park et al., 1999).  
With respect to COX-2 upregulation induced by CYP-induced cystitis (Hu et al., 2003), 
there is currently no information that addresses the cellular sources in the urinary bladder 
that express COX-2 with bladder inflammation of varying duration.  The purpose of this 
study was to determine: (1) COX-2 protein expression in the urothelium + suburothelium 
compared to detrusor smooth muscle by western blotting after CYP-induced cystitis of 
varying duration; (2) cellular location of COX-2 in urinary bladder of control rats or after 
CYP-induced cystitis using immunohistochemistry with an emphasis on urothelial cell, 
nerve fiber and inflammatory cell infiltrate expression; (3) intensity of COX-2 
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immunoreactivity in the urothelium after CYP-induced cystitis using semi-quantitative 
image analysis.  In contrast to COX-2 expression in detrusor smooth muscle cells with 
outlet obstruction (Park et al., 1999), the present study demonstrates robust expression of 
COX-2 protein in the urothelium, inflammatory cell infiltrates and to a lesser extent, 
detrusor smooth muscle with CYP-induced cystitis.  
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Materials and Methods 
Adult female Wistar rats (150 - 250g) were purchased from Charles River Canada 
(St. Constant, Canada).  Chemicals used in these studies were purchased from Sigma 
ImmunoChemicals (St. Louis, MO). Primary antibodies for immunohistochemistry were 
purchased from commercial sources (Tables 1).  Secondary antibodies were purchased 
from Jackson ImmunoResearch, West Grove, PA (Table 1).  
Cyclophosphamide (CYP)-Induced Cystitis-Acute, Intermediate or Chronic 
 Chemical cystitis was induced in adult female Wistar rats by CYP treatment.  
CYP is metabolized to acrolein, an irritant eliminated in the urine (Cox, 1979a).  CYP 
was administered in one of the following ways (Corrow and Vizzard, 2007a): (1) 4 hr 
(150 mg/kg; i.p.) prior to euthanasia of the animals to elicit acute inflammation (n = 21); 
(2) 48 hr (150 mg/kg; i.p.) prior to euthanasia to examine an intermediate inflammation 
(n = 21) or (3) administered every third day for 10 days to elicit chronic inflammation (n 
= 21; 75 mg/kg; i.p).  All injections of CYP were performed under isoflurane (2%) 
anesthesia. Control animals (n= 21) were gender matched to the experimental groups and 
received a corresponding volume of saline (0.9%) or distilled water injected (i.p.) under 
isoflurane (2%) anesthesia.  Animals were euthanized by isoflurane anesthesia (4%) plus 
thoracotomy at the indicated time points and the urinary bladder was harvested and 
weighed.  The University of Vermont IACUC approved all experimental procedures 
(#06-014) involving animal use.  Animal care was under the supervision of UVM’s 
Office of Animal Care in accordance with AAALAC and NIH guidelines.  All efforts 
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were made to minimize animal stress/distress and suffering and to use the minimum 
number of animals.  
 
 Western Blotting for COX-2 
 The urothelium + suburothelium was dissected from the detrusor smooth muscle 
using fine forceps under a dissecting microscope (Dattilio and Vizzard, 2005).  
Urothelium + suburothelium or detrusor were homogenized separately in tissue protein 
extraction agent with protease inhibitors (Roche, Indianapolis, IN) and aliquots were 
removed for protein assay.  Samples (20 µg) were suspended in sample buffer for 
fractionation on gels and subjected to SDS-PAGE.  Proteins were transferred to 
nitrocellulose membranes and efficiency of transfer was evaluated.  Membranes were 
blocked overnight in a solution of 5% milk, 3% bovine serum albumin in Tris-Buffered 
Saline with 0.1% Tween.  Membranes were incubated in goat anti-COX-2 (Table 1) 
overnight at 4 oC.  Washed membranes were incubated in a species-specific secondary 
antibody (Table 1) for 2 hr at room temperature for enhanced chemiluminescence 
detection (Pierce, Rockford, IL).  Blots were exposed to Biomax film (Kodak, Rochester, 
NY), and developed.  The intensity of each band was analyzed and background 
intensities subtracted using Un-Scan It software (Silk Scientific, Orem, UT).  Human 
recombinant COX-2 (1:1000; Cayman Chemical Co., Ann Arbor, MI) was used as a 
positive control and Western blotting of erk1 and erk2 (1:1000; Cell Signaling 
Technology, Danvers, MA) in samples was used as a loading control.  Additional loading 
controls including GAPDH and L32 revealed identical results to those obtained with 
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erk1/2.  Preabsorption of COX-2 antisera with appropriate immunogen (1 µg ml-1) 
reduced staining in blots to background levels.   To confirm the specificity of our split 
bladder preparations, urothelium + suburothelium and detrusor samples were examined 
for the presence of α-smooth muscle actin and uroplakin II by western blotting.  In 
urothelium + suburothelium samples, only uroplakin II was present.  Conversely, in 
detrusor samples, only α-smooth muscle actin was present. 
Immunohistochemistry 
Cryostat sections of the bladder (10 µm) from control (n = 7) and experimental 
treatments (acute, intermediate, chronic CYP-induced cystitis; n = 7 each) were examined 
for COX-2 immunoreactivity (IR).  The urinary bladder was post-fixed in 4% 
paraformaldehyde, placed in ascending concentrations of sucrose (10-30%) in 0.1 M PBS 
for cryoprotection, sectioned on a freezing cryostat and directly mounted on gelled 
(0.5%) microscope slides for on-slide processing (Vizzard, 1997).  Briefly, sections were 
incubated overnight at room temperature with mouse anti-COX-2 (Table 1) in 1% donkey 
serum and 0.1 M PBS, and then washed (3 × 10 min) with 0.1 M PBS, pH 7.4. The 
tissues were then incubated with secondary antibody (Table 1) for 2 hr at room 
temperature. Following washing, the slides were coverslipped with Citifluor (Citifluor 
Ltd., London). Control sections incubated in the absence of primary or secondary 
antibody were also processed and evaluated for specificity or background staining levels.  
In the absence of primary antibody, no positive immunostaining was observed.  
Whole Mount Bladder Preparation 
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The urinary bladder from control (n = 5) and experimental treatments (n = 5 each) 
was dissected and placed in Krebs solution.  The bladder was cut open along the midline 
and pinned to a sylgard-coated dish. The bladder was incubated for 1.5 hr at room 
temperature in cold fixative (2% paraformaldehyde + 0.2% picric acid) and urothelium 
removed as previously described (Zvarova and Vizzard, 2005).  Urothelium and bladder 
musculature were processed for COX-2-IR (as described above). Whole mounts stained 
for COX-2 were also stained with antiserum to the pan-neuronal marker, protein gene 
product (PGP)9.5.  COX-2-immunoreactive cells and associated processes in the 
suburothelial space were obvious with CYP treatment but were not PGP positive.  To 
determine the cell types expressing COX-2-IR in the suburothelial region and throughout 
the urinary bladder, additional immunostaining for COX-2 and markers of intermediate 
filaments (GFAP, vimentin), glial and Schwann cells (S-100), interstitial cells (c-kit), 
macrophages, dendritic cell populations and monocytes (CD86), and activated B 
lymphocytes (CD80) was performed (Table 1).  For single staining for COX-2-IR, we 
used a mouse anti-COX-2 antibody (Table 1).  For double staining procedures, either a 
mouse anti-COX-2 or rabbit anti-COX-2 antibody was used depending upon the host of 
the other primary antibody (Table 1).  COX-2-IR in the urinary bladder was equivalent 
with either the mouse anti-COX-2 or rabbit anti-COX-2 antibody. Control (n = 4) and 
CYP-treated tissues (n = 4 each) were incubated overnight at room temperature in a 
cocktail of COX-2 antiserum (as above) plus PGP, vimentin, GFAP, S-100, c-kit, CD80 
or CD86 (Table 1).  After washing, the tissues were incubated in a cocktail of species-
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specific secondary antibodies (Table 1) for 2 h at room temperature, followed by washing 
and coverslipping.   
Assessment of Positively Stained Urinary Bladder Regions 
 Immunohistochemistry on bladder sections or whole mounts was performed on 
control and experimental tissues simultaneously to reduce the incidence of staining 
variation that can occur between tissues processed on different days.  Staining observed 
in experimental tissue was compared to that observed from experiment-matched negative 
controls.  Urinary bladder sections or whole mounts exhibiting immunoreactivity that was 
greater than the background level observed in experiment-matched negative controls 
were considered positively stained.  
Visualization and quantitative analysis of COX-2 –IR in urothelium  
Six to 10 urinary bladder sections from control and experimental groups were 
examined under an Olympus fluorescence photomicroscope with a multiband filter set for 
simultaneous visualization of the Cy3 and Cy2 fluorophores.  Cy3 was visualized with a 
filter with an excitation range of 560-596 nm and an emission range from 610-655 nm. 
Cy2 was viewed by using a filter with an excitation range of 447-501 nm and an emission 
range from 510-540 nm. Quantification of COX-2-IR in the urothelium was performed as 
previously described (LaBerge et al., 2006a; Yuridullah et al., 2006).  Grayscale images 
acquired in tiff format were imported into Meta Morph image analysis software (version 
4.5r4; Universal Imaging, Downingtown, PA).  The opened image was first calibrated for 
pixel size by applying a previously created calibration file. The free hand drawing tool 
was selected and the urothelium was drawn and measured in total pixels area.  A 
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threshold encompassing an intensity range of 100-250 grayscale values was applied to the 
region of interest in the least brightly stained condition first.  The same threshold was 
subsequently used for all images. Percent COX-2 expression above threshold in the total 
area selected was then calculated.  Quantification of COX-2 expression in nerve fibers in 
the suburothelial plexus was performed as previously described (Corrow and Vizzard, 
2007a; LaBerge et al., 2006a; Yuridullah et al., 2006) and modified from Brady et al. 
(Brady et al., 2004).  Grayscale images acquired in tiff format were imported into Image J 
(Abramoff et al., 2004) and images were thresholded.  Images were acquired from the 
trigone region of the suburothelial plexus in control and treated rats.  A rectangle of fixed 
dimension (500 x 500 pixels) was placed on the section according to a random selection 
of x and y coordinates.  This process was repeated 7 times for each image.  The average 
density of COX-2-IR nerve fibers was then calculated.  
Statistics 
 All values are means ± S.E.M.  Comparisons of COX-2 densitometry values from 
western blots of urinary bladder samples were made using ANOVA. Percentage data 
from image analysis were arcsin transformed to meet the requirements of this statistical 
test.  Animals, processed and analyzed on the same day, were tested as a block in the 
ANOVA.  When F ratios exceeded the critical value (p ≤ 0.05), the Dunnett’s post-hoc 
test was used to compare the control means with each experimental mean. 
Figure Preparation 
Digital images were obtained using a CCD camera (MagnaFire SP; Optronics; 
Optical Analysis Corp., Nashua, NH) and LG-3 frame grabber attached to an Olympus 
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microscope (Optical Analysis Corp.).  Exposure times were held constant when acquiring 
images from control and experimental animals processed and analyzed on the same day.  
Images were imported into Adobe Photoshop 7.0 (Adobe Systems Incorporated, San 
Jose, CA) where groups of images were assembled and labeled.  
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Results 
COX-2 protein expression in detrusor smooth muscle, urothelium + suburothelium  
with CYP-induced cystitis  
COX-2 protein expression in detrusor as determined by western blotting significantly (p 
≤ 0.01) increased (6-fold) with acute (4 h), intermediate (48 h; 4.2-fold) or chronic CYP-
treatment (6.3-fold)(Fig. 1A, B).  COX-2 protein expression in urothelium + 
suburothelium also significantly (p ≤ 0.01) increased with acute (15-fold), intermediate 
(16-fold) or chronic (17-fold) CYP treatment (Fig. 1C, D).  Basal COX-2 expression in 
detrusor was significantly (p ≤ 0.01) greater than that in urothelium + suburothelium.  
The fold-increase in COX-2 expression in the urothelium + suburothelium induced by 
CYP-induced cystitis was significantly (p ≤ 0.01) greater at all time points examined 
compared to detrusor (Fig. 1E).   
  COX-2-Immunoreactivity (IR) in Urinary Bladder with CYP-Induced Cystitis  
The expression of COX-2-IR was virtually absent in the urothelium of urinary 
bladder sections from control rats (Fig. 2A).  However, some COX-2-IR was present in 
the detrusor smooth muscle of control rats (Fig. 2A).  With acute (4 hr; Fig. 2B, C), 
intermediate (48 hr) and chronic CYP-treatment (Fig. 2D, E), COX-2-IR was increased 
primarily in the urothelium and in the suburothelial region.  COX-2-IR in the urothelium 
and suburothelial regions induced by cystitis was non-homogenous throughout the 
urothelium; patchy in appearance and intensity.  COX-2-IR was present in detrusor 
smooth muscle with CYP-treatment but changes in COX-2 staining intensity were not 
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obvious.  We chose to focus the quantitation of COX-2 expression on the urothelium 
because expression was dramatically and obviously upregulated in the urothelium with 
CYP-treatment.  COX-2 expression in the urothelium significantly (p ≤ 0.001) increased 
in the urothelium with acute (4 hr; 2.4-fold), and chronic CYP-treatment (3.5-fold).  
COX-2 expression in urinary bladder nerve fibers and inflammatory infiltrates 
after CYP treatment  
To determine if COX-2-IR was present in the suburothelial nerve plexus, whole 
mount preparations of urinary bladder were prepared to aid in the visualization of the 
nerve plexus.  COX-2-IR nerve fibers were observed in the suburothelial plexus from 
control rats (Fig. 3A) and the density significantly (p ≤ 0.01) increased with CYP-
induced cystitis (4 hr; Fig. 3B and chronic; Fig. 3D, Fig. 3E).  COX-2-IR nerve fibers 
were most obvious in the trigone region. COX-2-IR nerve fibers in suburothelial nerve 
plexus exhibited colocalization with the pan-neuronal marker, PGP9.5 (Fig. 4).  In whole 
mount and sections of the urinary bladder after CYP treatment of all durations, fusiform 
cells with short processes in the suburothelial region were observed to exhibit COX-2-IR 
(Fig. 2C-F).  In whole mounts, these cells and processes were located in a different focal 
plane compared to the suburothelial plexus (Fig. 3, Fig. 5B). COX-2-IR cells were 
abundant within the suburothelial region (Fig. 2B-E) and scattered throughout the 
detrusor smooth muscle in bladder sections.  These cells displayed a similar morphology 
to macrophages previously described in the urinary bladder after CYP-induced cystitis 
(Corrow and Vizzard, 2007a) but we pursued additional double-labeling studies with 
markers of other cellular candidates based upon morphology to determine the identity of 
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these cells (Table 2).  Double-labeling experiments of urinary bladder sections or whole 
mount preparations demonstrated that these COX-2-IR cells expressed the CD86 antigen 
(e.g., macrophages, dendritic cells) (Fig. 2F; Fig. 5B) (Table 2) but did not express 
immunoreactivity for vimentin, GFAP, c-kit, S-100 or CD80 (Table 2).  
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Discussion 
These studies demonstrate several novel findings with respect to COX-2 expression in 
micturition reflexes with CYP-induced cystitis.  COX-2 expression is significantly 
increased in the urothelium + suburothelium and detrusor smooth muscle with acute (4 
hr), intermediate (48 hr) and chronic (10 day) CYP-induced cystitis as determined by 
western blotting but expression in urothelium + suburothelium is significantly greater.  
COX-2 immunostaining in the urothelium + suburothelium generally mirrored that 
observed by western blotting and also demonstrated COX-2 inflammatory cell infiltrates 
and nerve fibers in the suburothelial plexus.  Although COX-2 expression was 
significantly increased in detrusor smooth muscle as determined by western blotting, 
immunostaining failed to demonstrated an obvious change in COX-2-IR in detrusor 
muscle but COX-2 inflammatory infiltrates were present throughout the detrusor.  COX-
2-IR nerve fibers exhibited increased density in the suburothelial plexus in whole mount 
preparations with acute or chronic CYP-induced cystitis.  Migration of macrophages 
(CD86+) in the suburothelial space and detrusor with CYP-induced cystitis is dramatic 
and expression of COX-2-IR is present in both acute and chronic inflammation of the 
urinary bladder.  Inhibitors of COX-2 that have been shown to reduce bladder 
overactivity (Hu et al., 2003; Jang et al., 2006; Lecci et al., 2000) with bladder 
inflammation are likely to exert effects on the urothelium, inflammatory cell infiltrates 
and suburothelial nerve plexus among other targets. 
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A number of previous studies have demonstrated roles for COX-2 and 
prostaglandins in bladder overactivity induced by bladder inflammation (Angelico et al., 
2006; Hu et al., 2003; Jang et al., 2006; Lecci et al., 2000; Maggi, 1992; Maggi et al., 
1988a). It has previously been suggested that prostanoids are key mediators following the 
induction of CYP-induced cystitis (48 hr) (Hu et al., 2003; Lecci et al., 2000).   Our 
previous studies (Hu et al., 2003) have also demonstrated mRNA and protein for COX-2 
upregulation in whole urinary bladder with CYP-induced cystitis.  PGE2 and PGD2 
expression in the urinary bladder with acute, intermediate and chronic CYP-induced 
cystitis is also increased (Hu et al., 2003).   Previous studies using selective or non-
selective inhibitor of COX-2 demonstrated an increase in bladder capacity in rodents 
treated with CYP (Angelico et al., 2006; Hu et al., 2003; Lecci et al., 2000).  In these 
studies (Angelico et al., 2006; Hu et al., 2003; Lecci et al., 2000), COX-2 inhibitors were 
delivered systemically and any understanding of potential sites of action was limited.  In 
addition, our previous study (Hu et al., 2003) used whole urinary bladder with no 
emphasis on cell types in the urinary bladder that may express COX-2 with CYP-induced 
cystitis.  In the present study, we demonstrate several potential sites of action of such 
inhibitors in the urinary bladder including the urothelium, macrophages and suburothelial 
nerve plexus.  The functional studies are consistent with an effect of COX-2 inhibitors on 
bladder afferents or urothelium (increased bladder capacity, reduced micturition 
frequency) (Hu et al., 2003; Lecci et al., 2000).  The present studies also provide 
anatomical data to support the use of an intravesical route of administration of COX-2 
inhibitors (Jang et al., 2006) in reducing bladder overactivity induced by CYP.  
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A number of reports have demonstrated upregulation of COX-2 in response to 
inflammatory stimuli (Fujisawa et al., 2005; Hu et al., 2003; Linden et al., 2004; Mitchell 
and Warner, 1999; Schafers et al., 2004; Yiangou et al., 2006).  A recent report (Liu et 
al., 2006) emphasizes the inclusion of a number of controls to be certain that a signal 
obtained by western blotting, is, indeed, reflective of COX-2.  We have performed each 
of these suggested controls.  [1] We have included a purified, recombinant COX-2 
protein as a positive control in our western blots that is located at 74-kD.  A review of the 
literature reveals that the mature, enzymatically active form of COX-2 is located in the 
70- to 74-kD range on denaturing acrylamide gel electrophoresis. This is consistent with 
the COX-2 protein identified from urinary bladders in the present and previous (16) 
study.  The difference in band location for the positive control and the samples may be 
attributed to several issues:  species differences as the positive control is from human, 
nonglycosylated forms of COX-2 and/or incomplete proteolysis. [2] We have identified 
(16) increased COX-2 mRNA in urinary bladder induced by CYP treatment to further 
support our western blot results.  [3] We have demonstrated upregulation of two 
prostaglandins (PG), PGE2 and PGD2, in urinary bladder with CYP treatment as further 
evidence that COX-2 may affect bladder function through downstream activation of PG 
(16).  
  Immunohistochemical studies demonstrated that increases in COX-2 protein 
determined by western blotting are a reflection of increased urothelial cell expression of 
COX-2, COX-2-IR macrophages (CD86+), and COX-2-IR nerve fibers in the 
suburothelial plexus.  A number of studies have demonstrated COX-2-IR in nerves (i.e., 
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endoneurium) in response inflammatory stimuli alone or as a result of neural injury 
(Durrenberger et al., 2006; Pesce et al., 2006).  In the present study, we have confirmed 
that COX-2-IR is present in nerve in the suburothelial plexus and that COX-2-IR nerve 
fibers increase in density in the trigone region of the urinary bladder with acute and 
chronic CYP-induced cystitis.  One limitation to this study is the method used to 
determine density of innervation.  All COX-2-IR structures in the whole mount within the 
same plane of focus are captured in the frame and density determination is performed on 
all COX-2-IR structures.  Therefore, COX-2-IR macrophages or other COX-2-IR 
inflammatory cell infiltrates of unknown cellular phenotype may have increased the 
density determinations that we have attributed to nerve fibers.  However, a large 
proportion of the COX-2-IR nerve fibers were not located in the same focal plane as the 
macrophages so we feel that this possibility is limited in the present study.  Afferent 
nerve fibers make a large contribution to this neural plexus although some contribution 
from efferent sources cannot be ruled out (Dixon et al., 2000).  Previous studies have 
shown COX-2-IR in primary afferent cells in dorsal root ganglia (Vizzard et al., 
preliminary data) (Dou et al., 2004; Durrenberger et al., 2006) and therefore there is 
precedent for COX-2 expression in afferent nerves.   
  Urothelial cells share a number of similarities with sensory neurons and the 
urothelium has been suggested (Birder, 2005; 2006) to have ‘neuronal-like’ properties.  
Urothelial cells express a number of receptors and ion channels similar to those found in 
sensory neurons (Birder, 2005; 2006; Corrow and Vizzard, 2007a; LaBerge et al., 2006a; 
Murray et al., 2004) and it was therefore not surprising to observe COX-2 expression in 
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the urothelium after CYP-induced cystitis.  COX-2-IR in the urothelium was observed in 
apical, intermediate and basal cells.  Immortalized human urothelial cells express COX-2 
and inducible nitric oxide synthase (iNOS) after stimulation of β-adrenergic receptors 
(Harmon et al., 2005).  The present study adds to the growing list of similarities between 
urothelial cells and sensory neurons and may also suggest that urothelial cells participate 
in the transduction of inflammatory signals to the central nervous system (Birder, 2005; 
2006).   
  A number of previous studies have also demonstrated COX-2 expression in 
macrophages (Tsai et al., 2007; Yamashita et al., 2007; Yiangou et al., 2006).  
Surprisingly, in our previous study (Hu et al., 2003), we failed to demonstrate COX-2-IR 
in macrophages, although present in the bladder after CYP-induced cystitis, but 
demonstrated COX-2-IR in mast cells in the inflamed bladder.  In the present study, the 
immunostaining confirms that a proportion of COX-2-IR in the suburothelial space and 
detrusor express the antigen CD86.  Although our present study does not rule out a 
contribution from mast cells, the prominent, cellular staining in the suburothelial region 
largely represents macrophages.  The reason for this difference is not known but likely 
reflects our choice of COX-2 antiserum as has been suggested in the COX-2 literature 
(Yiangou et al., 2006).  We used a monoclonal COX-2 antibody in the present study 
because the polyclonal antibody used in our previous study was inconsistent in its 
staining for this study.    
Previous studies have demonstrated robust COX-2 expression in the detrusor 
smooth muscle after complete bladder outlet obstruction in mice and this increase has 
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been attributed to mechanical stretch (Park et al., 1999; Park et al., 1997).  In contrast, no 
COX-2 expression was present in the urothelium or suburothelial region in control tissues 
or after outlet obstruction (Park et al., 1999; Park et al., 1997).  The present study clearly 
demonstrates a larger COX-2 contribution from the urothelium and suburothelial region 
in response to CYP-induced cystitis.  This difference probably is a reflection of COX-2 
protein induced by an inflammatory stimulus versus a mechanical stimulus.  In both 
bladder inflammation and outlet obstruction, COX-2 is either demonstrated or 
hypothesized to contribute to bladder overactivity/hyperactivity (Hu et al., 2003; Lecci et 
al., 2000; Park et al., 1999; Park et al., 1997) although the source of COX-2 and resultant 
production of prostaglandins is likely to be different.  It is interesting that COX-2 is 
highly expressed in the urinary bladder during development and that bladder outlet 
obstruction represents reactivation of this gene (Park et al., 1997).  The urinary bladder 
during early postnatal development exhibits spontaneous bladder contractions (Ng et al., 
2007; Park et al., 1997) but the contribution of COX-2 to this function is presently 
unknown.   
COX-2 expression can be stimulated by growth factors, proinflammatory 
cytokines and chemokines (Khanapure et al., 2007; Yermakova and O'Banion, 2000). 
Changes in neurotrophic factor expression in the urinary bladder with cystitis including 
β-nerve growth factor, brain-derived neurotrophic factor, glial cell line-derived 
neurotrophic factor, neurotrophin (NT)-3 and NT-4 (Murray et al., 2004; Vizzard, 2000b) 
have been demonstrated. Robust (Malley and Vizzard, 2002) changes in a number of 
urinary bladder cytokines including IL-1-β, IL-2, IL-4, IL-6 and more modest changes in 
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TNF-α/ or TNF-β with CYP-induced cystitis have also been demonstrated.  Most 
recently, we have demonstrated upregulation of the chemokine, fractalkine, and 
fractalkine receptor in the urinary bladder and specifically in the urothelium with CYP-
induced cystitis (Yuridullah et al., 2006).  Separately or in combination, neurotrophic 
factors, proinflammatory cytokines and chemokines expressed in the inflamed urinary 
bladder may also contribute to COX-2 upregulation.    
In summary, these studies have demonstrated significant changes in COX-2 
expression in the urinary bladder after CYP-induced cystitis examined at three time 
points (acute, intermediate and chronic).  Specifically, COX-2 expression is significantly 
increased in the urothelium, in nerve fibers in the suburothelial plexus and in 
macrophages in the suburothelial space.  Although western blotting demonstrates COX-2 
expression in detrusor smooth muscle, this change likely reflects COX-2 expression in 
inflammatory cell infiltrates as immunostaining for COX-2 in detrusor smooth muscle 
did not exhibit robust changes in COX-2 expression.  A number of cellular sources in the 
urinary bladder express COX-2 after CYP-induced cystitis that may be induced by 
neurotrophic factors, cytokines and chemokines in the inflamed bladder.  The present 
study defines some bladder cellular sources that are likely targets of COX-2 inhibitors. 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Western blot in detrusor and urothelium/suburothelium 
A.  Representative example of a western blot of detrusor smooth muscle (20 µg) for COX-2 expression in 
control rats and those treated with cyclophosphamide (CYP) for varying duration.  Total ERK staining was 
used as a loading control. B.  Histogram of relative COX-2 band density in all groups examined normalized 
to total ERK in the same samples.  COX-2 expression in detrusor smooth muscle is significantly increased 
with acute (4 hr), intermediate (48 hr) and chronic (10 day) CYP-treatment.  *, p ≤ 0.01.  n = 5-7.  C.  
Representative example of a western blot of urothelium + suburothelium (20 µg) for COX-2 expression in 
control rats and those treated with cyclophosphamide (CYP) for varying duration.  Total ERK staining was 
used as a loading control. D.  Histogram of relative COX-2 band density in all groups examined normalized 
to total ERK in the same samples.  COX-2 expression in urothelium + suburothelium is significantly 
increased with acute (4 hr), intermediate (48 hr) and chronic (10 day) CYP-treatment.  *, p ≤ 0.01.  n = 5-7.  
E.  The fold change in COX-2 expression in the urothelium (U) and suburothelium (SubU; white bars) is 
greater compared to that in detrusor (black bars) with CYP-induced cystitis.  *, p ≤ 0.01 with statistical 
analyses performed on raw data.   
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Figure 2: COX-2 expression in urinary bladder sections 
Fluorescence images of COX-2 expression in urinary bladder sections of control (A), 4 hr (B, C), and 
chronic (D, E) CYP treated rats.  For all images, exposure times were held constant and all tissues were 
processed simultaneously.  In control rats, little if any COX-2 expression was visible in the urothelium (U; 
A).  CYP treatment (4 hr, B, C; chronic, D, E) upregulated expression of COX-2 in the urothelium in all 
layers (apical, intermediate and basal) of the urothelium. CYP-induced cystitis (all time points) also 
increased COX-2-IR in the suburothelium (Sub U; C, D, E).  In normal urinary bladder, the detrusor 
smooth muscle expressed basal COX-2 but increases with cystitis were not obvious.  F. COX-2-IR 
inflammatory cell infiltrates were present in the urinary bladder of rats with CYP treatment (4 hr (C), 
chronic (D, E).  Merged image of double-label immunostaining revealed that COX-2-IR (red) was present 
in cells that expressed the cytoplasmic antigen, CD86 (e.g., macrophages, dendritic cells) (F, arrows). L, 
lumen; Sub U, suburothelium; sm, smooth muscle. Calibration bar represents 50 µm. 
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Figure 3: COX-2-IR nerve fibers in suburothelial plexus 
Fluorescence photographs of COX-2-IR nerve fibers in the suburothelial plexus in whole mount 
preparations of the urothelium/suburothelium in control (A), acute (B), intermediate (C) and chronic CYP 
treated rats (D).  COX-2-IR nerve fibers in the suburothelial plexus in the urothelium/suburothelium whole 
mount preparation in the trigone region increased in density with CYP-induced cystitis (4 hr (B) and 
chronic (D). Single COX-2-IR nerve fibers (arrows) as well as COX-2-IR nerve bundles (asterisks) were 
observed in the suburothelial plexus.  E. Summary histogram of increase in COX-2-IR nerve fiber density 
with CYP-induced cystitis.  *, p ≤ 0.01. Calibration bar represents 80 µm.   
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Figure 4: COX-2 and PGP9.5 expression in urinary bladder whole mounts 
COX-IR fibers (A, C) expressed immunoreactivity for the pan neuronal marker, protein gene product 
(PGP9.5; B, D).  Fluorescence images of COX-2-IR (A, C) processes in urinary bladder whole mounts with 
CYP-induced cystitis and PGP9.5 staining (B, D) in the same whole mounts to demonstrate colocalization 
of COX-2-IR and PGP9.5 staining.  COX-2-IR was present in single nerve fibers (A, B, arrowheads) and 
nerve bundles (A-D, arrows).  Some COX-2-IR nerve fibers exhibited a winding trajectory (A-D, arrows) 
whereas other COX-2-IR nerve fibers coursed linearly and lacked obvious varicosities  (A, B, arrowheads).  
Numerous COX-2-IR macrophages were also present (C).  Calibration bar represents 40 µm.   
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Figure 5: Whole mount preparation of urinary bladder.   
A.  Dissection of urinary bladder into urothelium + suburothelium and detrusor components.  The 
urothelium and suburothelium layer (red arrows) is reflected back from the detrusor (yellow arrows). B.  
Numerous CD86+ macrophages were present in whole mount preparations of the urinary bladder with 
CYP-induced cystitis (4 hr). Calibration bar represents 80 µm in B.  
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Primary 
Antibody 
Source Primary 
Dilution 
Secondary 
Antibody 
Secondary 
Dilution 
Application 
Goat anti-
COX-2 
Santa Cruz, 
Santa Cruz, CA 
1:200 HRP donkey 
anti-goat 
1:15K WB 
Mouse anti-
COX-2 
Cayman, Ann 
Arbor, MI 
1:50 Cy3 donkey 
anti-mouse 
1:100 IHC 
Rabbit anti-
COX-2 
Santa Cruz 1:500 Cy3 donkey 
anti-mouse 
1:100 IHC 
Mouse anti-
GFAP 
Sigma-Aldrich, 
St. Louis, MO 
1:5000 Cy2 donkey 
anti-mouse 
1:100 IHC 
Rabbit anti-S-
100 
DAKO 
Cytomation, 
Denmark 
1:200 Cy2 goat 
anti-rabbit 
1:500 IHC 
Rabbit anti-c-
kit 
Santa Cruz  1:1000 Cy2 goat 
anti-rabbit 
1:500 IHC 
Mouse anti-
CD86 
Biolegend, San 
Diego, CA 
1:25 Cy2 donkey 
anti-mouse 
1:100 IHC 
Mouse anti-
CD80 
Biolegend 1:25 Cy2 donkey 
anti-mouse 
1:100 IHC 
Mouse anti-
PGP 
Abcam, Inc., 
Cambridge, 
MA 
1:15 Cy2 donkey 
anti-mouse 
1:100 IHC 
 
 
Table 1: Primary and secondary antibodies used, sources and applications 
 
Table 2: Experiments of urinary bladder sections or whole mount preparations 
 
 
The phenotype of COX-2-IR cells in the suburothelial space and detrusor in bladder sections and whole 
mounts induced by CYP-induced cystitis was determined using a number of antisera.  COX-2-IR cell 
bodies in the suburothelial space and throughout the detrusor only expressed immunoreactivity to the CD86 
antigen. +, presence of staining; - absence of staining; ND, not determined.   
Antibody Staining of cryostat bladder 
sections 
Staining of bladder whole-
mounts  
vimentin - - 
GFAP - - 
S-100 - - 
c-kit - -  
CD86 + + 
CD80 - ND 
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Chapter 3: p75NTR Expression in Rat Urinary Bladder Sensory Neurons 
and Spinal Cord with Cyclophosphamide-Induced Cystitis 
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Abstract 
 A role for nerve growth factor (NGF) in contributing to increased voiding 
frequency and altered sensation from the urinary bladder has been suggested.  Previous 
studies have examined the expression and regulation of tyrosine kinase receptors (Trks) 
in micturition reflexes with urinary bladder inflammation.  The present studies examine 
the expression and regulation of another receptor known to bind NGF, p75NTR, after 
various durations of bladder inflammation induced by cyclophosphamide (CYP).  CYP-
induced cystitis increased (p ≤ 0.001) p75NTR expression in the superficial lateral and 
medial dorsal horn in L1-L2 and L6-S1 spinal segments.  The number of p75NTR-IR cells 
in the lumbosacral dorsal root ganglia (DRG) also increased (p ≤ 0.05) with CYP-induced 
cystitis (acute, intermediate and chronic).  Quantitative, real-time polymerase chain 
reaction also demonstrated significant increases (p ≤ 0.01) in p75NTR mRNA in DRG with 
intermediate and chronic CYP-induced cystitis. Retrograde dye-tracing techniques with 
Fastblue were used to identify presumptive bladder afferent cells in the lumbosacral 
DRG.  In bladder afferent cells in DRG, p75NTR-IR was also increased (p ≤ 0.01) with 
cystitis.  In addition to increases in p75NTR-IR in DRG cell bodies, increases (p ≤ 0.001) 
in pericellular (encircling DRG cells) p75NTR-IR in DRG also increased.  Confocal 
analyses demonstrated that pericellular p75NTR-IR was not colocalized with the glial 
marker, glial fibrillary acidic protein (GFAP).  These studies demonstrate that p75NTR 
expression in micturition reflexes is present constitutively and modified by bladder 
inflammation.  The functional significance of p75NTR expression in micturition reflexes 
remains to be determined. 
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Introduction 
 Neurotrophic factors are important in the maintenance and survival of peripheral 
neurons as well as in neuronal plasticity (Allen and Dawbarn, 2006; Dmitrieva et al., 
1997). Nerve growth factor (NGF) binds to two receptors with high-affinity, the p75NTR 
receptor, a member of the tumor necrosis factor family of receptors and TrkA, a receptor 
tyrosine kinase. The majority of NGF-responsive cells express both p75NTR and TrkA 
(Chao and Hempstead, 1995) and TrkA is exclusively expressed with p75NTR in DRG 
(Wright and Snider, 1995). NGF selectively binds TrkA whereas p75NTR can bind all 
neurotrophins and precursor molecules with the same affinity (Huang et al., 1999). The 
ability of NGF to bind two very distinct receptors and the resulting signaling via this 
receptor complex has puzzled researchers (Barker, 2007).  The original function 
attributed to p75NTR was as an accessory protein that modulates Trk receptors to regulate 
their affinity for their appropriate ligand (Barker, 2007; Chao et al., 2006).  It has become 
a prevailing concept that p75NTR and TrkA combine to form a receptor complex that 
results in high-affinity NGF binding (Chao et al., 2006; Kahle et al., 1994; Verdi et al., 
1994).  However, a recent study (Wehrman et al., 2007) provides structural and 
mechanistic evidence for a ligand-passing model in which NGF rapidly associates with 
p75 NTR and then is presented to TrkA (Wehrman et al., 2007).  
At sites of tissue injury, inflammation or target organ hypertrophy, growth factors 
including NGF are upregulated (Lewin and Mendell, 1993; Lindholm et al., 1987; Meller 
et al., 1994; Thompson et al., 1995; Woolf et al., 1997). An increase in NGF and brain-
derived neurotrophic factor (BDNF) in the urine and/or bladder are among previously 
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documented changes with bladder inflammation (Lowe et al., 1997; Oddiah et al., 1998; 
Okragly et al., 1999; Steers et al., 1994; Steers and Tuttle, 2006).  Excess NGF in the 
urinary bladder may increase voiding frequency (Chuang et al., 2001b) secondary to 
neurochemical and other neurophenotypic responses.  Intravesical administration of 
exogenous NGF in animals facilitates afferent firing and increases voiding frequency that 
can be blocked by anti-NGF (Dmitrieva et al., 1997). Exogenous administration of NGF 
into the detrusor smooth muscle also increased voiding frequency, augmented central 
responses to bladder distention and increased neuropeptide expression in the urinary 
bladder and lumbosacral spinal cord (Zvara and Vizzard, 2007).  We have demonstrated 
(Hu et al., 2005) that the NGF scavenging agent (REN1820) reduces voiding frequency 
and pain behaviors in rats with cyclophosphamide  (CYP)-induced bladder inflammation.  
Our previous studies (Qiao and Vizzard, 2002) have demonstrated significant 
upregulation of TrkA and TrkB in bladder afferent cells in lumbosacral DRG with CYP-
induced bladder inflammation.  The potential interactions between TrkA and p75NTR in 
micturition reflex pathways under control (non-inflamed) or inflamed conditions have not 
been investigated. 
Few studies have examined the role of p75NTR in LUT pathways (Elsasser-Beile et 
al., 2000; Jahed and Kawaja, 2005) and only one (Wakabayashi et al., 1996) has 
examined expression in urinary bladder after inflammation. p75NTR expression in bladder 
afferent cells in the dorsal root ganglia (DRG) and central micturition pathways 
mediating micturition have not been examined.  The present study was designed to 
determine p75NTR expression in bladder afferent pathways, including lumbosacral spinal 
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cord, and bladder afferent cells in DRG.  We examined changes in p75NTR expression in 
micturition pathways and p75NTR mRNA in L6-S1 DRG with varying durations (4 hours 
(hr; acute), 48 hr (intermediate), and 10 days (chronic) of bladder inflammation induced 
by CYP.    
Materials and Methods 
Cyclophosphamide (CYP)-Induced Cystitis 
 
 Acute, intermediate and chronic CYP-induced cystitis rat models were examined 
in these studies (Corrow and Vizzard, 2007b; Klinger et al., 2007; Qiao and Vizzard, 
2002; Vizzard, 2000b). Chronic CYP (Sigma)-induced cystitis: rats received drug 
injection (75 mg/kg, intraperitoneal, i.p.) every third day for 10 days. Intermediate CYP-
induced cystitis: rats received a single injection (150 mg/kg, i.p.) and tissues were 
examined 48 hours (hr) later.  Acute CYP-induced cystitis: rats received a single injection 
(150 mg/kg, i.p.) and survived for 4 hours (hr). Control rats received volume-matched 
injections of saline (0.9%; i.p.) or no treatment and no difference among the control 
groups was observed. All injections were performed under isoflurane (2%) anesthesia. 
All experimental protocols involving animal use were approved by the University of 
Vermont Institutional Animal Care and Use Committee (IACUC # 06-014). Animal care 
was under the supervision of the University of Vermont's Office of Animal Care 
Management in accordance with the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) and National Institutes of Health guidelines. All 
efforts were made to minimize the potential for animal pain, stress or distress. 
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Retrograde labeling of bladder afferent neurons 
 Four to six days prior to CYP injection, saline or no treatment, Fast-blue (FB; 4%, 
weight/volume; Polyol, Gross-Umstadt, Germany) was injected into the bladder to 
retrogradely label bladder afferent neurons in control (n=4) and CYP-treated (n=4 for 
each group) rats. As previously described (Qiao and Vizzard, 2002; Vizzard, 2000c), a 
total volume of 40 µl divided into six to eight injections was injected into the dorsal 
surface of the bladder wall with particular care to avoid injections into the bladder lumen, 
major blood vessels, or overlying fascial layers. At each injection site, the needle was 
kept in place for several seconds after injection, and the site was washed with saline to 
minimize contamination of adjacent organs with FB.  
Tissue processing 
 After CYP treatment (4 hr, 48 hr, or chronic), animals were deeply anesthetized 
with isoflurane (3–4%) and then euthanized via thoracotomy.  The spinal cord and DRG 
were quickly removed and postfixed in 4% paraformaldehyde for 3 hr or 1 hr, 
respectively. Tissue was then placed overnight in sucrose (30%) in 0.1 M PBS for 
cryoprotection. In pilot studies, intracardiac perfusion combined with post-fixation was 
also performed and p75NTR-IR was compared between different fixation protocols.  
p75NTR-IR was most consistent and robust with the post-fixation protocol.  Thus, this 
method was used for all subsequent studies.  Spinal cord segments were identified based 
upon at least two criteria: (1) the T13 DRG was present after the last rib, and (2) the L6 
vertebra was the last moveable vertebra followed by the fused sacral vertebrae. Another 
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less precise criterion is the observation that the L6 DRG are the smallest ganglia 
following the largest DRG, L5. DRG and spinal cord segments (L1, L2, L5–S1) were 
sectioned parasagittally at a thickness of 20 or 30 µm, respectively, on a cryostat. Some 
DRG (L1, L2, L6, S1) were specifically chosen for analysis based upon the previously 
determined segmental representation of urinary bladder circuitry (Donovan et al., 1983; 
Keast and De Groat, 1992; Nadelhaft and Vera, 1995). Bladder afferents are not 
distributed within the L4–L5 DRG (Donovan et al., 1983; Keast and De Groat, 1992) that 
contain only somatic afferents nor are neurons that are involved in urinary bladder 
function observed in the L4–L5 spinal segments (Nadelhaft and Vera, 1995). Thus, the 
L5 DRG served as an internal control for these studies. Tissues from control animals 
were handled in an identical manner to that described above.  
p75NTR immunohistochemistry 
 Spinal cord and DRG sections for both control and CYP-treated rats were 
processed for p75NTR immunoreactivity (IR) using an on–slide processing technique 
(Vizzard, 1997). Groups of control animals and experimental animals were processed 
simultaneously to decrease the possible incidence of variation in staining and background 
between tissues and between animals. Spinal cord and DRG sections were incubated 
overnight at room temperature with rabbit anti–p75NTR antibody (1:15,000, Advanced 
Targeting Systems, San Diego, CA) in 1% goat serum and 0.1 M KPBS (Phosphate 
Buffer Solution with potassium), and then washed (3×15 min) with 0.1 M KPBS, pH 7.4. 
Tissue was then incubated with Cy3-conjugated goat anti–rabbit IgG (1:500; Jackson 
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ImmunoResearch) for 2 hr at room temperature. After several rinses with 0.1 M KPBS, 
tissues were mounted with Citifluor (Citifluor, London, UK) on slides and coverslipped. 
Control tissues incubated in the absence of primary or secondary antibody were also 
processed and evaluated for specificity or background staining levels. In the absence of 
primary antibody, no positive immunostaining was observed.  Although the rabbit 
polyclonal antibody (1:15,000, Advanced Targeting Systems, San Diego, CA) was used 
in this study, staining with a mouse monoclonal antibody (1:500, Advanced Targeting 
Systems, San Diego, CA) was also performed and showed similar staining patterns in 
DRG and spinal cord but with reduced staining intensity. 
p75NTRexonIII deficient mice 
 Breeding pairs of p75NTRexonIII+/- mice were generously provided by Dr. Hermes 
Yeh (Dept. of Physiology, Dartmouth Medical School).  Mice were bred locally and 
DNA genotyping performed on tail snips.  Wildtype and p75NTRexonIII deficient mice from 
the same litters were used to characterize the specificity of the antiserum to p75NTR.  
DRG and spinal cord were harvested and immunohistochemical processing was 
performed as described above.  Tissues from littermate wildtype and p75NTRexonIII  
deficient mice were processed simultaneously using identical antibodies from start to 
finish. 
Antibody characterization 
 Polyclonal anti-p75NTR is a purified rabbit polyclonal antibody.  The antisera was 
developed in rabbit against an extracellular fragment from the mouse p75NTR (amino 
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acids 43-161; manufacturer’s technical information).  This is a well-characterized 
antibody that was originally developed and the specificity demonstrated by Huber and 
Chao (Huber and Chao, 1995a; b) using a variety of approaches including the 
demonstration of p75NTR expression in transgenic mice expressing p75NTR gene 
sequences (Huber and Chao, 1995a; b).  Specificity has also been demonstrated according 
to the manufacturer.  This antibody also produces a similar pattern of immunoreactivity 
in rodent spinal dorsal horn and DRG as demonstrated in numerous previous publications 
(Delcroix et al., 1998); King et al., 2000; Hu and McLachlan, 2003; Obata et al., 2006) 
and in our pilot studies using a mouse monoclonal antibody to p75NTR.  Mice with 
different splice variants of p75NTR  are available (Dhanoa et al., 2006) and carry null 
mutations for p75NTRexonIII  or p75NTRexonIV .   These strains lack full-length p75NTR 
expression and exhibit loss of p75NTR function.  In wildtype littermates and in mice with a 
null mutation for p75NTRexonIII , we examined p75NTR expression in DRG and spinal cord.  
Staining in the wildtype DRG was robust (Fig. 1A) whereas staining in DRG from 
p75NTRexonIII  deficient mice revealed extremely faint and sparse p75NTR-IR (Fig. 1B).  To 
obtain images that were not completely black, the exposure time for p75NTRexonIII-/- DRG 
images was increased to 4 times longer than that used to acquire wildtype images.  These 
results are similar to previous studies where reduced intensity and appearance of p75NTR-
IR was observed in superior cervical ganglia in p75NTRexonIII deficient mice (Dhanoa et al., 
2006).   
 Monoclonal anti-glial fibrillary acidic protein (GFAP) is a purified mouse 
monoclonal antibody.  The antibody is derived from the hybridoma produced by the 
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fusion of mouse myeloma cells and splenocytes from an immunized mouse.  The 
immunogen was purified GFAP from pig spinal cord (manufacturer’s technical 
information).  The antibody recognizes the 50 kDa intermediate filament protein, GFAP, 
but not other intermediate filaments (manufacturer’s technical information).  The epitope 
recognized by the monoclonal anti-GFAP is localized on the carboxy terminal Cys II 
fragment of GFAP and the N-terminal part of the tail sequence of the molecule (Debus et 
al., 1983; Shaw and Hawkins, 1992). This antibody produced the same pattern of 
immunoreactivity in rodent DRG as demonstrated in numerous previous publications (Hu 
and McLachlan, 2003; Karchewski et al., 2004; Obata et al., 2006; Xie et al., 2006). 
Assessment of positive staining in lumbosacral spinal cord and DRG 
 Staining observed in experimental tissue was compared with that observed from 
experiment-matched negative controls. Tissues exhibiting immunoreactivity that was 
greater than the background level observed in experiment-matched negative controls 
were considered positively stained.  
Data analysis of p75NTR and FB-labeled DRG 
 Tissues were examined under an Olympus fluorescence photomicroscope for 
visualization of Cy3 and FB. Cy3 was visualized with a filter with an excitation range of 
560–596 nm and an emission range of 610–655 nm. In DRG from control and CYP-
treated rats, p75NTR –immunoreactive (IR) cell profiles were counted in 5-8 sections of 
each selected DRG (L1, L2, L5–S1). Only cell profiles with a nucleus were quantified. 
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DRG sections with FB-labeled cells were viewed with a filter with an excitation 
wavelength of 340–380 nm and an emission wavelength of 420 nm. Cells colabeled with 
FB and p75NTR –IR were similarly counted. Numbers of p75NTR –IR cell profiles per 
DRG section are presented (mean ± SEM). The percentage of presumptive bladder 
afferent cells (FB-labeled) expressing p75NTR –IR in each DRG examined is also 
presented (mean ± SEM). The results were not corrected for double-counting.  p75NTR-IR 
cells were quantified in a blinded fashion and p75NTR-IR and FB-labeled cells were 
quantified by two individuals. Comparisons between control and CYP-treated groups 
were made by using analysis of variance (ANOVA). Percentage data were arcsin-
transformed to meet the requirements of this statistical test. Animals, processed and 
analyzed on the same day, were tested as a block in the ANOVA. Thus, day was treated 
as a blocking effect in the model. Two variables were tested in the analysis: (1) duration 
of inflammation versus none (control), and (2) the effect of day (i.e., tissue from 
experimental and control groups of animals were processed on different days). When F 
ratios exceeded the critical value (p ≤ 0.05), the Newman–Keuls test was used for 
multiple comparisons among means.  
Quantitative analysis of pericellular p75NTR–IR in DRG 
 Six to 10 DRG sections from each of L1, L2, L5-S1 in control and experimental 
groups were examined under an Olympus fluorescence photomicroscope (Optical 
Analysis, Nashua, NH) with a multiband filter set for visualization of the Cy3 
fluorophore.  Grayscale images acquired in tiff format were imported into Meta Morph 
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image analysis software (version 4.5r4; Universal Imaging, Downingtown, PA) as 
previously described (Laberge et al., 2006b; Yuridullah et al., 2006).  Four boxes of equal 
size were drawn and placed randomly over the DRG images.  A threshold within an 
intensity range of 100–250 grayscale values was applied to the region of interest in the 
least brightly stained condition first. The same threshold was subsequently used for all 
images. Average intensity was calculated within the selected areas. The average intensity 
represents the average value of all of the pixels above the threshold value. Percent p75NTR 
expression above threshold in the total area selected was then calculated and averaged for 
all samples from control (n = 4) and CYP-treated (n = 4 for each experimental condition) 
rats.  The percentage of p75NTR–IR expression in CYP-treated rats was therefore 
expressed as a percentage of control. 
 
p75NTR-IR and glial fibrillary acidic protein (GFAP)-IR in lumbosacral DRG 
 To more fully characterize the pericellular p75NTR-IR seen in lumbosacral DRG, 
double-labeling was performed with anti-p75NTR (as described previously) as well as 
mouse monoclonal anti-GFAP (1:5,000; Sigma-Aldrich, Inc., St. Louis, MO).  Primary 
and subsequently, secondary antibodies (Cy3-conjugated goat anti-rabbit (1:500) and 
Cy2-conjugated goat anti-mouse (1:50; Jackson ImmunoResearch), were applied as a 
cocktail to tissue sections for on-slide processing.  Tissue was examined and optical 
sections were acquired using a Zeiss LSM 510 confocal scanning system attached to a 
Zeiss LSM 510 microscope using a plan Fluor 40x oil objective.  Excitation wavelengths 
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of 488 nm and 543 nm were used.  Control experiments demonstrated that the Cy2 and 
Cy3 fluorochromes had no overlap in emission when sequential scanning was performed.  
To determine the degree of colocalization of GFAP with p75NTR , release 3.2 of the Carl 
Zeiss LSM software was used in optical sections.  For these analyses, we demonstrated 
absence of bleed-through and background staining and autofluorescence was removed 
from all images, and analyses were performed only on optical sections.  Changes in 
pericellular staining were most dramatic in L5-S1 DRG and thus, the colocalization 
analyses from control and CYP-treated rats were restricted to these DRG. 
Data analyses of p75NTR–IR in lumbosacral spinal cord 
 Tissues were examined under an Olympus fluorescence photomicroscope for 
visualization of Cy3.  Grayscale images were obtained in 8-bit monochrome tiff format 
files.  No adjustments were made to the grayscale images.  The density of p75NTR–IR in 
specific regions of spinal cord was determined by densitometry analysis (ImageJ, v. 
1.34s).  Spinal cord segments (L1-L2, L5-S1) were sectioned throughout the rostral-
caudal extent of the segment. All tissue sections were then processed for p75NTR–IR as 
previously described. A 1:4 series of spinal cord sections was then used for semi–
quantitative analysis of p75NTR –IR. Spinal cord sections were not selected based upon 
staining intensity, and no sections were discarded from the analysis because of low 
staining.  The following regions of spinal cord from both CYP-treated and control 
animals were analyzed: superficial, lateral dorsal horn (LDH), medial dorsal horn 
(MDH), and dorsal commissure (DCM) regions, the region of the sacral parasympathetic 
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nucleus (SPN; L6, S1), the region of the intermediolateral nucleus (IML; L1, L2), and the 
region of the lateral collateral pathway (LCP; L6, S1). Spinal cord sections were viewed 
with a 20× objective and captured through a video camera attachment to the microscope 
with the exposure time, brightness, and contrast being held constant. The image was 
converted into grayscale. The spinal cord section was centered in the field, and four 
standard size squares were overlaid on the areas of interest (LDH, MDH, DCM, SPN, 
IML, and LCP regions).  The labeled area within the square was measured. Transmittance 
(t) was calculated as t = (gray level + 1/256). Optical density (OD) was derived from 
OD=–log t.  The background staining for each section was subtracted from the images.  
Differences in p75NTR expression in L1-L2  and L6-S1 spinal segments with cystitis were 
similar; these data (L1-L2 and L6-S1) were pooled for data presentation. Comparisons 
among control and experimental groups were made by ANOVA. When F ratios exceeded 
the critical value (p ≤ 0.05), Newman-Keuls test was used for multiple comparisons 
among means. 
Real-time quantitative reverse transcription-polymerase chain reaction  
(Q RT-PCR) 
L6 and S1 DRG were dissected under RNase-free conditions and total RNA was 
extracted using the STAT-60 total RNA/mRNA isolation reagent (Tel-Test ‘B’, 
Friendswood, TX, USA). Complementary DNA was synthesized using SuperScript II 
reverse transcriptase and random hexamer primers with the SuperScript II 
Preamplification System (Invitrogen, Carlsbad, CA, USA) in a 20 µl final reaction 
volume.  The quantitative PCR standard for p75 and L32 transcripts was prepared with 
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the amplified p75 cDNA products ligated directly into pCR2.1 TOPO vector using the 
TOPO TA cloning kit (Invitrogen). The nucleotide sequences of the inserts were verified 
by automated fluorescent dideoxy dye terminator sequencing (Vermont Cancer Center 
DNA Analysis Facility). To estimate the relative expression of the receptor transcripts, 
10-fold serial dilutions of stock plasmids were prepared as quantitative standards. The 
range of standard concentrations was determined empirically. 
Real-time quantitative PCR was performed using SYBR Green I detection as 
previously described (Girard et al., 2006). Complementary DNA templates, diluted 5-fold 
to minimize the inhibitory effects of the reverse transcription reaction components, were 
assayed using SYBR Green I JumpStartTM. Taq ReadyMix (Sigma, St. Louis, MO, 
USA) containing 3.5 mM MgCl2, 200 mM dATP, dGTP, dCTP and dTTP, 0.64 U Taq 
DNA polymerase and 300 nM of each primer in a final 25 µl reaction volume. The real-
time quantitative PCR was performed on an Applied Biosystems 7500 Fast real-time 
PCR system (Applied Biosystems, Foster City, CA, USA) using the following standard 
conditions: (i) initial heating 94 °C for 2 min; (ii) amplification over 40 cycles at 94 °C 
for 15 seconds (s) and 65 °C or 60 °C for 30 s. 
The amplified product from these amplification parameters was subjected to SYBR 
Green I melting analysis by ramping the temperature of the reaction samples from 60 °C 
to 95 °C. A single DNA melting profile was observed under these dissociation assay 
conditions demonstrating amplification of a single unique product, free of primer dimers 
or other anomalous products. Oligonucleotide primer sequences for p75NTR and the 
housekeeping gene, L32, used in these studies are described in Table 1.  
 119
For data analyses, a standard curve was constructed by amplification of serially 
diluted plasmids containing the receptor target sequence. Data were analyzed at the 
termination of each assay using the Sequence Detection Software version 1.3.1 (Applied 
Biosystems, Norwalk, CT). In standard assays, default baseline settings were selected. 
The increase in SYBR Green I fluorescence intensity (DRn) was plotted as a function of 
cycle number and the threshold cycle was determined by the software as the 
amplification cycle at which the DRn first intersects the established baseline.  
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Results 
p75NTR-IR in spinal cord in control rats and after CYP-induced cystitis 
 In spinal cord levels examined (L1-L2, L5-S1), p75NTR was expressed in certain 
regions of the spinal cord in both control rats and after CYP-induced cystitis.  In the 
spinal cord of control animals (L1-L2, L5-S1), p75NTR-IR was present in superficial 
dorsal horn (medial and lateral laminae I-II; Fig. 2).  Faint p75NTR-IR was expressed in 
the dorsal commissure (DCM), located dorsal to the central canal and in the lateral 
collateral pathway of Lissauer (LCP) in L6-S1 spinal cord segments in control animals. 
p75NTR –IR was also observed in the SPN (L6-S1) or IML (L1-L2) regions in control rats. 
p75NTR staining in all regions was punctate in appearance and probably represented 
staining in nerve terminals because p75NTR-IR was not observed in any neuronal cell 
bodies in the dorsal or lateral horn.  On rare occasions, p75NTR-IR ventral horn 
motoneurons were observed. 
 Following CYP treatment of varying duration, the intensity of p75NTR staining 
significantly increased in both medial (MDH) and lateral superficial dorsal horn (LDH) 
(Fig. 2B, C).  In spinal cord segments L1-L2, p75NTR staining intensity increased 
significantly in both MDH and LDH for all CYP treatment durations examined (4 hr, 48 
hr, or chronic; p ≤ 0.001)(Fig. 2E).  p75NTR staining intensity in the LDH of L6-S1 also 
increased significantly (p ≤ 0.001) at all durations of CYP treatment (Fig. 2D).  In 
addition to changes in the density of p75NTR –IR in the superficial laminae of the LDH 
and MDH, p75NTR –IR also extended into deeper laminae of the DH with CYP-induced 
cystitis (Fig. 2B, C).  Although spinal cords demonstrated p75NTR-IR in DCM and LCP, 
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this staining was not different (Fig. 2) among control and experimental groups. p75NTR –
IR in the SPN region in the L6-S1 spinal cord or IML region of the L1-L2 spinal 
segments was also not changed with CYP-induced cystitis of any duration examined.  No 
changes in p75NTR-IR in the L5 spinal cord were demonstrated with CYP-induced cystitis 
of any duration examined.  
  
p75NTR-IR is increased in lumbosacral dorsal root ganglion (DRG) cells after CYP-
induced cystitis 
 p75NTR expression was observed in the cytoplasm of DRG cells in all levels 
examined (L1-L2; L5-S1).  The number of cells that showed positive staining for p75NTR 
(Fig. 3A-D; Fig. 4) increased significantly (p ≤ 0.05) in all levels examined after chronic 
CYP treatment.  This increase in numbers of p75NTR-IR  DRG cells was also significant 
in L1 and S1 DRG after 48 hr CYP treatment and in L5-S1 DRG with acute (4 hr) CYP 
treatment (p ≤ 0.05) (Fig. 4).   
 
Pericellular p75NTR-IR in lumbosacral DRG 
 In addition to the p75NTR expression seen in the cytoplasm, p75NTR –IR was also 
observed surrounding individual DRG cells (Fig. 5B, D, F).  This pericellular staining 
was observed in control animals as well as after acute (4 hr and 48 hr) and chronic CYP-
induced cystitis in lumbosacral DRG (L5-S1)(Fig. 5B, D, F).  The intensity of the 
staining was significantly (p ≤ 0.001) increased after chronic in L5-S1 DRG, after 48 hr 
CYP in L5 and L6 DRG and after 4 hr CYP treatment in L6 DRG (Fig. 5A, C, E, H).   
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To determine whether the pericellular staining was associated with glial cells in 
the DRG, DRG were stained with the antibodies to the glial cell marker, glial fibrillary 
acidic protein (GFAP), as well as with anti-p75NTR  and optical sections were used to 
determine colocalization.  Upon examination with confocal microscopy (Fig. 5G; Fig. 
6G), co-localization with these antibodies was not observed.   Separate, non-overlapping 
GFAP-IR and p75NTR-IR was observed in all DRG examined.  Using colocalization 
software on the metaconfocal system, we determined that the greatest coefficient of 
colocalization for GFAP and p75NTR in DRG examined from control or CYP-treated rats 
was 0.3 (range 0.05-0.3) indicating very little colocalization of GFAP with p75NTR.  As a 
comparison, a coefficient of colocalization of 1 is indicative of complete colocalization 
whereas 0 indicates no colocalization.  Thus, we conclude that pericellular p75NTR 
represents DRG cell membrane staining. 
 
p75NTR-IR in bladder afferents 
To determine whether p75NTR-IR is expressed in bladder afferent cells in DRG 
from control or after bladder inflammation, Fastblue (FB) was injected into the urinary 
bladder to retrogradely label bladder afferent cells in the L1, L2, L6 and S1 DRG (Fig. 
6B, E).  In control animals (Fig. 6A-C), 25-43% of bladder afferent cells expressed 
p75NTR-IR in L1, L2 and L5-S1 DRG (Fig. 6G).  After 4 hr CYP (Fig. 6H), there was a 
significant (p ≤ 0.01) increase in the percentage of bladder afferent cells that expressed 
p75NTR-IR in L1 (58.4% ± 3.5), L2 (42.3% ± 1.6), L6 (53.3% ± 3.8), and S1 (71.3% ± 
3.8) DRG.  After 48 hr CYP treatment (Fig. 6D-F), a significant (p ≤ 0.01) increase in the 
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percentage of bladder afferent cells expressing p75NTR-IR was demonstrated in L1 
(63.2% ± 2.4), L6 (57.7% ± 4.8) and S1 (66.5% ± 3.0) DRG.  After chronic CYP 
treatment (Fig. 6G, H), a significant (p ≤ 0.01) increase in the percentage of bladder 
afferent cells expressing p75NTR-IR was demonstrated in L1 (67.6% ± 1.5), L2 (71.4% ± 
4.5), L6 (69.4% ± 4.3), and S1 (67.5% ± 7.6).  No changes were observed in the 
percentage of bladder afferents expressing p75NTR-IR in the L2 DRG with 48 hr CYP 
treatment (Fig. 6H).   
 
p75NTR  mRNA expression in DRG with CYP-induced cystitis 
Acute (4 hr) CYP-induced cystitis produced a significant (p ≤ 0.01) reduction in p75NTR 
mRNA in the L6 DRG (Fig. 7).  In contrast, a significant (p ≤ 0.01) increase in p75NTR 
mRNA was observed 48 hr after CYP-treatment (Fig. 7).  With chronic CYP-treatment, 
no additional change in transcript expression was observed compared to control (Fig. 7).  
There was a significant (p ≤ 0.01) increase in p75NTR transcript with 48 hr and chronic 
CYP treatment compared to acute (4 hr) treatment (Fig. 7).  A similar biphasic change in 
p75NTR mRNA expression in the S1 DRG with CYP treatment was also observed but 
these changes did not reach significance (Fig. 7).  
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Discussion 
 These studies demonstrate several novel findings:  (1) constitutive p75NTR 
expression in spinal pathways involved in micturition reflexes in control rats is 
significantly increased after acute, intermediate or chronic CYP-induced cystitis; (2) 
constitutive  p75NTR -immunoreactivity (IR) in lumbosacral dorsal root ganglia (DRG) is 
significantly upregulated with CYP-induced cystitis of varying duration; (3) bladder 
afferent cells retrogradely labeled with Fastblue (FB) express p75NTR-IR in control rats 
and the percentage of bladder afferents expressing p75NTR is significantly increased with 
CYP-induced cystitis; (4)  CYP-induced cystitis also increased pericellular p75NTR -IR in 
DRG and this staining did not exhibit colocalization with the glial marker, GFAP; (5)  
p75NTR transcript in DRG exhibited a biphasic response to CYP-induced cystitis with 
acute cystitis decreasing p75NTR mRNA whereas intermediate and chronic CYP-induced 
cystitis increased p75NTR transcript with respect to the acute condition.  These studies 
demonstrate p75NTR expression in micturition pathways that is modifiable with varying 
degrees of bladder inflammation.  
 Although numerous studies have suggested a central or peripheral role for p75NTR 
after axotomy (Hannila and Kawaja, 2005; Keast and Kepper, 2001; Obata et al., 2006; 
Scott et al., 2005; Wakabayashi et al., 1998) or peripheral somatic inflammation (Chien 
et al., 2007; Cho et al., 1996; Pezet et al., 2001) few studies have examined the role of 
p75NTR in normal or inflamed lower urinary tract pathways (Elsasser-Beile et al., 2000; 
Jahed and Kawaja, 2005; Tong and Cheng, 2005; Vaidyanathan et al., 1998; 
Wakabayashi et al., 2002; Wakabayashi et al., 1998) (Wakabayashi et al., 1996). To our 
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knowledge, no studies have examined changes in p75NTR expression in central or 
peripheral micturition reflex pathways after bladder inflammation.  In contrast, p75NTR 
expression in the urinary bladder has been examined in rodent and human conditions of 
neuropathic bladder inflammation and diabetes.  Acute cystitis resulted in increased 
p75NTR-IR in nerve bundles in the detrusor smooth muscle (Wakabayashi et al., 1996).  In 
patients with neuropathic bladder, increased expression of p75NTR has been shown in the 
umbrella and basal layers of the urothelium in addition to being expressed in bladder 
nerves (Vaidyanathan et al., 1998). In contrast, p75NTR  mRNA is decreased in urinary 
bladder or sensory neurons in the DRG (Delcroix et al., 1998) of streptozotocin-induced 
diabetic rats but restoration of normal blood glucose level or exogenous, systemic 
treatment with NGF returned transcript expression to normal in urinary bladder (Tong 
and Cheng, 2005) or DRG (Delcroix et al., 1998).  Thus, a number of studies have 
demonstrated that p75NTR expression is modifiable in the urinary bladder. 
 The current studies demonstrate significant increases in p75NTR in the superficial 
laminae of the dorsal horn; however, changes in p75NTR expression in other regions of the 
lumbosacral spinal cord involved in bladder reflex function (i.e., SPN, LCP, DCM) were 
not observed.  Previous studies have suggested a role for p75NTR in both restraining and 
facilitating axonal growth in the dorsal horn after dorsal rhizotomy, spinal cord injury and 
during development (Hannila and Kawaja, 2005; Scott et al., 2005). p75NTR expression 
and upregulation with CYP-induced cystitis in the lumbosacral DH may represent central 
projections of sensory neurons, terminals of projection neurons and/or descending p75NTR 
systems (Pioro and Cuello, 1990; Sobreviela et al., 1994) exhibiting p75NTR–IR whereas 
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interneuronal expression of p75NTR is less likely (Bothwell, 1995). Most recently it has 
been demonstrated that p75NTR is anterogradely transported by the dorsal roots to central 
terminals in the spinal cord DH (Delcroix et al., 1998; Zweifel et al., 2005).  Increased 
expression of p75NTR was observed in the superficial laminae of the DH in rostral lumbar 
(L1-L2) and caudal lumbosacral (L6-S1) spinal segments known to innervate the urinary 
bladder. Previous studies in this laboratory (Vizzard, 2001; Zvarova et al., 2004) have 
also demonstrated changes in calcitonin gene-related peptide, substance P, pituitary 
adenylate cyclase activating polypeptide and galanin expression in superficial laminae of 
the DH in the lumbosacral spinal cord after CYP-induced cystitis.  
 
 In support of p75NTR-IR nerve terminals in the DH of the spinal cord representing, 
in part, the central projections of sensory neurons in the lumbosacral DRG, the present 
study demonstrated p75NTR expression in DRG cells.  Similar to what we observed in the 
DH of the spinal cord, CYP-induced cystitis increased p75NTR expression in lumbosacral 
DRG examined.  Previous studies have demonstrated p75NTR-IR in DRG cells with 
increased expression after nerve injury (Obata et al., 2006).  Previous studies have 
demonstrated p75NTR expression in both cell bodies in DRG (Bennett et al., 1996; Hu and 
McLachlan, 2000; Obata et al., 2006) and encircling (pericelluar staining) (Hu and 
McLachlan, 2000; Obata et al., 2006)   DRG cells.  These two types of staining patterns 
are consistent with that observed in the present study.  Previous studies have 
demonstrated co-labeling of the glial marker, GFAP and pericellular p75NTR expression in 
DRG (Hu and McLachlan, 2000; Obata et al., 2006).  It was concluded that the 
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pericellular p75NTR staining was expressed in satellite glial cells after peripheral nerve 
lesion.  In contrast, the present studies did not demonstrate significant overlap of p75NTR 
pericellular staining in lumbosacral DRG in control rats or after CYP-induced cystitis.  It 
should be noted that our conclusions were based upon confocal imaging of DRG sections 
and determination of a coefficient of colocalization using optical sections.  Previous 
studies have concluded colabeling of GFAP and pericellular p75NTR staining in DRG 
based upon the use of traditional epifluoresence microscopy (Hu and McLachlan, 2000; 
Obata et al., 2006).  In addition, when DRG sections in the present study are imaged with 
epifluorescence microscopy and merged images are created, we would also conclude, 
incorrectly, that the pericellular p75NTR -IR was colocalized with GFAP.  In addition to 
changes in p75NTR protein expression in DRG cells, we also demonstrated a biphasic 
response in p75NTR mRNA with CYP-induced cystitis.  Increases in p75NTR mRNA were 
demonstrated with intermediate and chronic CYP-induced cystitis.  In contrast, decreases 
in p75NTR mRNA were observed with acute CYP treatment.  This decrease in p75NTR 
mRNA is at odds with the observed increase in p75NTR –IR in DRG with acute cystitis.  
Differences in transcript and protein expression are not uncommon and likely reflect an 
increase in translation efficiency, additional changes in posttranslational mechanisms, or 
increased stability of mRNA transcript (Kruttgen et al., 1998; Sherer et al., 1998a; Sherer 
et al., 1998b; Vizzard, 2000b). 
 Increased p75NTR expression was also observed in the L5 DRG known not to be 
involved in micturition reflexes but to receive sensory information from the hindpaw.  It 
is interesting to note that the CYP-induced cystitis model in the rodent produces somatic 
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sensitization in the hindpaw (Guerios et al., 2006)(Vizzard and Cheppudirah, unpublished 
observations).  Mechanical sensitivity as assessed with von Frey monofilaments is 
increased although thermal sensitivity remains unchanged (Guerios et al., 2006)(Vizzard 
and Cheppudirah, unpublished observations).  Thus, increased p75NTR expression in the 
L5 DRG may be related to increased sensitivity in this referred site (Guerios et al., 
2006)(Vizzard and Cheppudirah, unpublished observations).  No changes in p75NTR 
expression in the L5 spinal segment were present with any duration of CYP treatment 
used in the present study.  This may reflect a lack of anterograde transport of p75NTR in 
L5 DRG to central terminals in the spinal cord (Delcroix et al., 1998; Zweifel et al., 
2005).    
 
 Although p75NTR expression has been demonstrated in sensory neurons in the 
DRG, the innervation targets of the DRG cells expressing p75NTR -IR have not been 
previously identified.  In the present study, presumptive bladder afferent cells in the DRG 
were identified by injection of Fastblue into the urinary bladder and subsequent 
retrograde transport to lumbosacral DRG innervating the urinary bladder.  These studies 
demonstrate that approximately 25-43% of bladder afferent cells express p75NTR -IR 
under control conditions.   This percentage is in very close agreement with previous 
studies demonstrating a similar percentage of bladder afferent cells expressing the 
tropomyosin related tyrosine kinase receptors (Trk) TrkA or TrkB (Qiao and Vizzard, 
2002).  Previous studies have demonstrated almost complete colocalization of p75NTR and 
Trk receptors in DRG (Chao and Hempstead, 1995; Wright and Snider, 1995).  CYP-
 129
induced cystitis increased p75NTR expression in bladder afferent cells in all lumbosacral 
DRG examined (L1, L2, L6, S1).  Increased expression occurred with acute, intermediate 
and chronic CYP-induced cystitis.  The increased p75NTR expression observed in bladder 
afferent cells with cystitis was different than that observed for either TrkA or TrkB (Qiao 
and Vizzard, 2002).  Increased TrkA expression was restricted to L1 and L6 DRG with 
varying durations of cystitis and increased TrkB expression was broadly distributed 
among L1, L2, L6 and S1 but only demonstrated an increase with acute CYP-induced 
cystitis (Qiao and Vizzard, 2002).  Thus, although basal expression of p75NTR in bladder 
afferent cells resembled the percentage of bladder afferent cells expressing TrkA or 
TrkB, the response to CYP-induced cystitis differed.  This difference may reflect the 
numerous, potential independent roles that p75NTR may play with neurotrophins and other 
receptors including, Trk, Nogo, LINGO-1 and sortilin (Allen and Dawbarn, 2006; 
Bronfman and Fainzilber, 2004; Nykjaer et al., 2005).  
  Target-derived changes in NGF with bladder inflammation may drive changes in 
p75NTR expression in central and peripheral micturition reflexes.  Previous studies have 
demonstrated that exogenous or elevated endogenous NGF can alter p75NTR expression 
(Delcroix et al., 1998; King et al., 2000; Mousa et al., 2007).  The exact contribution of 
NGF to bladder function is not known but a correlation between increased voiding 
frequency and elevated urinary bladder NGF has been suggested. Experimentally-induced 
cystitis increases voiding frequency and alters bladder NGF protein and transcript. 
Intrathecal (Yoshimura et al., 2006), intravesical delivery of NGF (Dmitrieva et al., 1997) 
or adenovirus-mediated NGF overexpression (Lamb et al., 2004) in the bladder increase 
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voiding frequency and bladder afferent cell hyperexcitability (Yoshimura et al., 2006; 
Yoshimura et al., 2002) in control rats. NGF scavenging methods (Dmitrieva et al., 1997; 
Hu et al., 2005) reduce voiding frequency in rats with experimentally induced 
inflammation. Elevated levels of neurotrophins are detected in the urine of women with 
painful bladder syndrome (Okragly et al., 1999) (PBS)/interstitial cystitis (IC) or in the 
urothelium of individuals with neuropathic bladder (Lowe et al., 1997).  However, a 
recent study failed to demonstrate an association between increased 
urothelium/suburothelium NGF with detrusor overactivity or bladder sensation (Birder et 
al., 2007).  
 Neurotrophins, through interactions with Trk and/or p75NTR receptors, may 
contribute to neurochemical (Vizzard, 2000a; 2001), electrophysiological (Yoshimura et 
al., 2002) and organizational (Steers and Tuttle, 2006; Vizzard, 2000c) plasticity of lower 
urinary tract pathways after CYP-induced cystitis. Neurotrophin/Trk/p75NTR interactions 
could induce long-term changes in cells (Steers and Tuttle, 2006), including: (1) 
mediating neurotransmitter phenotype; (2) influencing dendrite size and synaptic 
reorganization; (3) increasing synaptic efficacy; and (4) controlling innervation density 
and target organ function.  Additional p75NTR functions independent of Trk may also 
include myelination, axonal growth and regeneration (Nykjaer et al., 2005).  Although 
p75NTR has been shown to increase binding affinity of TrkA for NGF and increase the 
activities of the TrkA receptor in some systems (Chao and Hempstead, 1995), p75NTR 
may also hinder TrkA binding to NGF by sequestering increased amounts of NGF, 
leaving less available to bind TrkA (Dhanoa et al., 2006; Hannila and Kawaja, 2005; 
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Nykjaer et al., 2005).  Previous studies have demonstrated that expression of p75NTR and 
TrkA can result in synergistic and antagonistic functions (Schweigreiter, 2006). It is 
likely that the role of p75NTR in micturition reflexes is dependent on the balance between 
NGF/p75NTR and NGF/TrkA signaling in bladder afferents and the extent to which this 
balance is altered with bladder inflammation.  The function of p75NTR in micturition 
reflex function in control rats and after CYP-induced cystitis is the subject of ongoing 
physiological studies. 
 132
Other Acknowledgements: 
We gratefully acknowledge the generous gift of p75NTRexonIII+/- mice from Dr. Hermes 
Yeh, Dartmouth Medical School. 
 
 
 133
Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: p75NTRexonIII-/- mice   
p75NTRexonIII-/- mice exhibit minimal p75NTR-IR when tested with antisera used in the present study. 
Lumbosacral (L6-S1) dorsal root ganglion (DRG) sections from littermate wildtype and p75NTRexonIII-/- mice 
were used to determine the specificity of p75NTR antisera used in the present study.  All DRG sections were 
reacted simultaneously using identical reagents.  A.  In wildtype S1 DRG, robust p75NTR-IR was present in 
neuronal cell bodies.  B.  In contrast, S1 DRG sections from p75NTRexonIII-/- mice only exhibited the faintest 
p75NTR-IR.  Panels A and B represent images captured at different exposure times.  To see any p75NTR-IR in 
the null mice, exposure times were increased to 4X that used to capture images from wildtype sections 
further demonstrating the faint p75NTR-IR.  Calibration bar represents 80 µm.  
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Figure 2: p75NTR -IR in lumbosacral spinal cord   
p75NTR-IR is increased in specific regions of the lumbosacral (L1, L2, L6, S1) spinal cord with 
cyclophosphamide (CYP)-induced cystitis.  Fluorescence images of p75NTR expression in the dorsolateral 
quadrant of lumbosacral (L6) spinal cord from control (A), 4 hour (B) and chronic (C) CYP treated rats.  A-
C. p75NTR-IR is constitutively expressed in the superficial lateral (LDH) and medial dorsal horn (MDH); 
faint p75NTR-IR was expressed in lateral collateral pathway (LCP) and dorsal commissure (DCM). With 
CYP-induced cystitis, p75NTR-IR significantly (p ≤ 0.001) increased in the LDH and MDH of L6-S1 and 
L1-L2 spinal segments.  D.  Summary histogram of p75NTR staining in L1-L2 spinal segments induced in 
LDH and MDH with varying duration of CYP-induced cystitis presented as a percentage of p75NTR staining 
intensity in control tissues.  E. Summary histogram of p75NTR staining in L6-S1 spinal segments induced in 
LDH and MDH with varying duration of CYP-induced cystitis presented as a percentage of p75NTR staining 
intensity in control tissues. Statistical analyses were performed on raw data.  F.  Drawing of a hemisection 
of lumbosacral spinal cord section for orientation purposes. *, p ≤ 0.001.  n=4.  SPN, sacral 
parasympathetic nucleus; CC, central canal.  Calibration bar represents 100 µm. 
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Figure 3: p75NTR-IR cells in the lumbosacral dorsal root ganglia   
CYP-induced cystitis increases the number of p75NTR-IR cells in the lumbosacral dorsal root ganglia 
(DRG).  Fluorescence images of p75NTR-IR in L1 DRG in control (A), 4 hour (B), 48 hour (C) and chronic 
(D) CYP treated rats.  White arrows indicate cells demonstrate some examples of p75NTR–IR cells. Yellow 
arrowheads demonstrate some examples of DRG cells that did not exhibit p75NTR-IR.  Calibration bar 
represents 60 µm.   
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Figure 4: numbers of p75NTR-IR cells in the lumbosacral dorsal root ganglia   
Summary histogram of numbers of dorsal root ganglion (DRG) cells that exhibit p75NTR-IR under control 
conditions and after induction of CYP-induced cystitis (4 hour, 48 hour, chronic).  (n = 5 for each; *, p ≤ 
0.05) 
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Figure 5: Pericellular p75NTR-IR in DRG from control and CYP-treated rats.   
Pericellular p75NTR-IR increased in lumbosacral dorsal root ganglia (DRG) with CYP treatment.  A 
threshold encompassing an intensity range of 100-250 grayscale values was applied to the region of interest 
in control DRG (A).  The same threshold was subsequently used for all images (C, E).  Four boxes of fixed 
dimension were randomly placed in DRG images. Percent p75NTR expression above threshold was then 
calculated.  Grayscale versions of p75NTR-IR in control DRG (A), or with 48 hour or chronic CYP-
treatment (E).  Images are thresholded and little p75NTR-IR (absence of purple within the outlined region) is 
above threshold in control DRG compared to significant p75NTR-IR that is above threshold after 48 hr CYP 
treatment (C, presence of purple) or chronic treatment (E).  Fluorescence images of p75NTR-IR in S1 DRG 
from control (B), 48 hour (D), and chronic (F) CYP treatments.  H.  Summary histogram of p75NTR 
expression above threshold in selected regions was calculated and presented as a percentage of control 
(n=4; *, p ≤ 0.01).  Calibration bar represents 40 µm (A-F), 20 µm (G).  
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Figure 6:  p75NTR –IR in bladder afferent cells in lumbosacral dorsal root ganglion 
CYP-induced cystitis increases p75NTR-IR in bladder afferent (Fastblue, FB-labeled) cells in the 
lumbosacral DRG. A-C.  L6 DRG section from control rat demonstrating p75NTR-IR (A), bladder afferent 
cells (FB-labeled) in same section (B) and merged image (C) demonstrating bladder afferent cells with 
p75NTR-IR (pinkish-purple/magenta).  D-F. L6 DRG section from rat with 48 hour induced cystitis (D), 
bladder afferent cells (FB-labeled) in same section (E) and merged image (F) demonstrating bladder 
afferent cells with p75NTR-IR (pinkish-purple/magenta). White arrows indicate some examples of bladder 
afferent cells that exhibit p75NTR-IR.  Not all bladder afferent cells express p75NTR-IR (yellow arrowheads) 
and not all cells expressing p75NTR-IR are bladder afferent cells (green arrows). G.  Triple-labeled image 
demonstrating p75NTR-IR (red) in bladder afferent cells (blue) in L6 DRG section from a rat treated 
chronically with CYP.  The DRG section was also stained for glial fibrillary acidic protein (GFAP; green).  
Bladder afferent cells exhibiting both FB and p75NTR-IR appear pinkish-purple/magenta).  (H) Summary 
histogram of the percentage of bladder afferent cells expressing p75NTR-IR in control and CYP-treated rats. 
(n=4 for each group, #, p ≤ 0.01; *, p ≤ 0.001).  Calibration bar represents 35 µm.   
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Figure 7: p75NTR mRNA in L6-S1 DRG 
CYP-induced cystitis induces a biphasic response in p75NTR mRNA in L6-S1 DRG.  For each experimental 
time period, total RNA from individual L6 or S1 DRG was reverse transcribed, and the cDNA templates 
synthesized from control and CYP-treated DRG were analyzed by real-time quantitative PCR using primers 
specific for rat p75NTR. Transcript levels are normalized to the housekeeping gene, L32 and expressed as 
relative change compared to control (100%).  n = 5 for all; *, p ≤ 0.01 versus control; **, p ≤ 0.01 versus 4 
hour treatment. 
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Table 1: Oligonucleotide primer sequences for p75NTR and the housekeeping gene, L32.  
 a: Primer positions are given as the nucleotide sequences for the Rattus norvegicus  
p75 precursor protein gene sequence with GenBank accession number NM_012610.  
b: Primer positions are given as the nucleotide sequences for the Rattus norvegicus  
L32 precursor protein gene sequence with GenBank accession number NM_013226.  
Primer 
name 
Primers sequences Location Annealing 
temp. 
p75NTR upper TGCTGCTGCTGCTGATTCTA 47U20a 65 °C 
p75NTR lower ACAAGGTCTTGCTCTGGAGGA 654L21a  
L32 upper CCTGGCGTTGGGATTGGTGA 83U20b 60 °C   
L32 lower GAAAAGCCATCGTAGAAAGA 129L20b  
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Abstract 
Previous studies demonstrated changes in urinary bladder neurotrophin content 
and upregulation of neurotrophin receptors, TrkA and the p75 neurotrophin receptor 
(p75NTR), in micturition reflex pathways after cyclophosphamide (CYP)-induced cystitis.  
p75NTR can bind NGF and modulate NGF-TrkA binding and signaling.  We examined 
p75NTR expression and the role of p75NTR in the micturition reflex in control and CYP-
treated rats. p75NTR–immunoreactivity (IR)  was present throughout the urinary bladder. 
CYP-induced cystitis (4 hour (h), 48 h, chronic) increased (p ≤ 0.05) p75NTR expression 
in whole urinary bladder as shown by western blotting.  The role of p75NTR in bladder 
function in control and CYP-treated rats was determined using conscious cystometry and 
immunoneutralization or PD90780, a compound known to specifically block NGF 
binding to p75NTR.  An anti-p75NTR monoclonal antibody or PD90780 was infused 
intravesically and cystometric parameters were evaluated. Both methods of p75NTR 
blockade significantly (p ≤ 0.05) decreased the intercontracton interval and void volume 
in control and CYP-treated rats. Intravesical infusion of PD90780 also significantly (p ≤ 
0.001) increased intravesical pressure and increased the number of number of non-
voiding contractions during the filling phase.  Control intravesical infusions of isotype 
matched IgG and vehicle were without effect.  These studies demonstrate:  (1) ubiquitous 
p75NTR expression in urinary bladder and increased expression with CYP-induced 
cystitis;  (2) p75NTR blockade at the level of the urinary bladder produces bladder 
hyperreflexia in control and CYP-treated rats. The overall activity of the urinary bladder 
reflects the balance of NGF-p75NTR and NGF-TrkA signaling. 
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Introduction 
Nerve growth factor (NGF) is important in sensory and sympathetic neuronal 
development and maintenance (Huang et al., 1999); however, many recent studies 
suggest additional role(s) for NGF in painful somatic and visceral inflammatory 
conditions (Chien et al., 2007)Friedman, 1999 #151}(Allen and Dawbarn, 2006; Chuang 
et al., 2001b; Frossard et al., 2004; Pezet and McMahon, 2006). NGF upregulation occurs 
at sites of tissue injury and inflammation (Lindholm et al., 1987; Woolf et al., 1997) and 
changes in NGF levels in urine as well as urinary bladder have been documented in 
humans with painful bladder syndrome (PBS)/interstitial cystitis (IC) and rodents with 
bladder inflammation  (Lowe et al., 1997; Oddiah et al., 1998; Okragly et al., 1999; 
Vizzard, 2000b).  A number of addition and subtraction studies have begun to 
demonstrate the role(s) of NGF in inflammatory conditions of the urinary bladder.  For 
example, intravesical infusion or intramuscular detrusor administration of exogenous 
NGF results in increased bladder activity, sensitization of bladder afferents (Chuang et 
al., 2001b; Dmitrieva and McMahon, 1996; Dmitrieva et al., 1997), increased expression 
of Fos protein in lumbosacral spinal cord in response to bladder distention and increased 
expression of neuropeptides in lumbosacral spinal cord (Zvara and Vizzard, 2007).  
Strategies to reduce NGF in micturition reflex pathways reduce or eliminate these effects 
(Dmitrieva et al., 1997; Hu et al., 2005).   
NGF signals through its specific receptor TrkA, as well as p75NTR.   TrkA is a 
tropomyosin-related receptor tyrosine kinase receptor and p75NTR belongs to the tumor 
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necrosis factor-α family of receptors (Allen and Dawbarn, 2006; Barker, 2004; Bronfman 
and Fainzilber, 2004).  p75NTR binds all neurotrophins, including brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and NT-4/5.  NGF-TrkA signaling is 
involved in some inflammatory effects of NGF (Pezet and McMahon, 2006), including 
sensitization of nociceptive afferents and the release of neuropeptides.  TrkA expression 
is increased in bladder afferent cells in lumbosacral dorsal root ganglia (DRG) with acute 
and chronic cyclophosphamide (CYP)-induced bladder inflammation (Qiao and Vizzard, 
2002).  In addition, p75NTR expression is also significantly upregulated in bladder afferent 
cells (2.4-2.8-fold) in lumbosacral DRG after CYP-induced cystitis (Klinger et al., 2008).   
The pan-neurotrophin receptor p75NTR exhibits an ubiquitous distribution, has many 
functions and multiple binding partners and ligands (Barker, 2004; Bronfman and 
Fainzilber, 2004).  In the absence of Trk expression, p75NTR is suggested to be involved 
in apoptosis and regulation of neuronal growth (Barker, 2004; Friedman and Greene, 
1999); however, in the presence of TrkA, p75NTR is suggested to function by enhancing 
Trk binding to neurotrophins (Barker, 2004; 2007; Wehrman et al., 2007).  p75NTR 
expression has previously been identified in the urinary bladder (Vaidyanathan et al., 
1998; Wakabayashi et al., 1996; Wakabayashi et al., 1995) but few studies have 
examined the role of p75NTR in bladder function or in the context of urinary bladder 
inflammation (Wakabayashi et al., 1996).  Although we do know that p75NTR expression 
is present in micturition reflex pathways in control rats and is regulated with CYP-
induced cystitis (Klinger et al., 2008), the potential role(s) of p75NTR in urinary bladder 
reflexes have not been explored.  In this study we determined:  (1) expression of p75NTR 
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in the urinary bladder with immunohistochemistry and western blot and regulation of 
p75NTR expression after CYP-induced cystitis;  (2) the effect of immunoneutralization 
with an anti- p75NTR monoclonal antibody on bladder function in female rats without 
(non-inflamed) and with bladder inflammation (48 hr CYP treatment) using conscious 
cystometry;  (3) the effect of intravesical infusion of PD90780, a compound known to 
specifically block NGF binding to p75NTR (Colquhoun et al., 2004; Hefti et al., 2006; 
Spiegel et al., 1995), in female rats without (non-inflamed) and with bladder 
inflammation (48 hr CYP treatment) using conscious cystometry.    
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Materials and Methods 
Cyclophosphamide-induced cystitis: acute, intermediate or chronic 
Chemical cystitis was induced in adult (200-225 g), female Wistar rats by CYP treatment 
(Klinger et al., 2008; Murray et al., 2004; Vizzard, 2001; Vizzard and Boyle, 1999). CYP 
was administered in one of the following ways: 1) 4 hours (h) (150 mg/kg; i.p.) prior to 
euthanasia of the animals to elicit acute bladder inflammation; 2) 48 h (150 mg/kg; i.p.) 
prior to euthanasia to examine an intermediate inflammation; or 3) administered every 
3rd day for 9 days to elicit chronic bladder inflammation (75 mg/kg; i.p.).  All injections 
of CYP were performed under isoflurane (2%) anesthesia. Control animals were gender 
matched to the experimental groups and received a corresponding volume of saline 
(0.9%) or distilled water injected intraperitoneally under isoflurane (2%) anesthesia.  
Animals were euthanized by isoflurane anesthesia (5%) plus thoracotomy at the indicated 
time points, and the urinary bladder was harvested and weighed. The University of 
Vermont Institutional Animal Care and Use Committee approved all experimental 
procedures (protocol number 06-014) involving animal use. Animal care was under the 
supervision of University of Vermont College of Medicine's Office of Animal Care in 
accordance with American Association for Accreditation of Laboratory Animal Care and 
National Institutes of Health guidelines. All efforts were made to minimize animal 
stress/distress and suffering and to use the minimum number of animals. 
 
Whole-mount bladder preparation and immunohistochemistry 
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 The urinary bladder from control (n = 5) and CYP treatment (n = 5) was dissected 
and placed in Krebs solution. The bladder was cut open along the midline and pinned to a 
Sylgard-coated dish. The bladder was incubated for 3 h at room temperature in cold 
fixative (2% paraformaldehyde + 0.2% picric acid), and the urothelium was removed as 
previously described (Zvarova et al., 2004). Urothelium and bladder musculature were 
processed separately for p75NTR-IR.  Control and CYP-treated tissues were incubated 
overnight at room temperature in rabbit anti-p75NTR antiserum (1:3000; Advanced 
Targeting Systems (ATS), San Diego, CA) in 1% goat serum and 0.1 M KPBS (0.1 M 
phosphate buffered saline (PBS) with potassium) and then washed (3 × 15 minutes) with 
0.1 M KPBS, pH 7.4.  After washing, the tissue was incubated in a species-specific 
secondary antibody (1:500; Cy3-conjugated goat anti-rabbit; Jackson Immunoresearch, 
West Grove, PA) for 2 h at room temperature, followed by washing and coverslipping 
with Citifluor (London, UK). Control tissues incubated in the absence of primary or 
secondary antibody were also processed and evaluated for specificity or background 
staining levels.  In the absence of primary antibody, no positive immunostaining was 
observed.  The specificity of the p75NTR antiserum was previously established (Klinger et 
al., 2008).  Some whole-mount preparations were stained with the pan neuronal marker, 
protein gene product 9.5 (Abcam, Cambridge, MA; 1:15) to visualize nerve fibers in the 
suburothelial plexus and to demonstrate that suburothelial nerve fibers expressed p75NTR-
IR.    
 
p75NTR localization in urinary bladder sections after intravesical p75NTR infusion  
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 Immediately after cystometric analyses, urinary bladders were harvested from rats 
that had received intravesical infusion of monoclonal antibody to p75NTR and those that 
had received intravesical infusion of protamine sulfate.  Animals were deeply 
anesthetized with isoflurane (5%) and euthanized via thoracotomy.  Bladders were 
quickly removed and postfixed in 4% paraformaldehyde overnight.  Tissues were 
cryoprotected by immersion in 30% sucrose (in 0.1 M phosphate-buffered saline) 
overnight.  Bladders were sectioned (20 µm) on a cryostat and directly mounted on gelled 
(0.5%) microscope slides.  Tissue was incubated in secondary antibody (Cy2-conjugated 
goat anti-mouse; Jackson ImmunoResearch, West Grove, PA) for two h and washed (3 
×15 minutes) at room temperature with 0.1 KPBS (pH 7.4). Slides were coverslipped 
with Citifluor (London, UK).   
Assessment of positive staining in urinary bladder 
 Staining observed in experimental tissue was compared with that observed from 
experiment-matched negative controls. Tissues exhibiting immunoreactivity that was 
greater than the background level observed in experiment-matched negative controls 
were considered positively stained.  
Imaging and Visualization of Bladder Sections 
 Tissues were examined under an Olympus fluorescence photomicroscope (Optical 
Analysis, Nashua, NH) for visualization of Cy2. Cy2 was visualized with a filter with an 
excitation range of 470-490 and an emission range from 510-530.  Images of bladder 
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sections were captured through a video camera attachment to the microscope with the 
exposure time, brightness, and contrast being held constant. 
 
Imaging and visualization of bladder whole-mounts 
 Tissue was examined and optical sections were acquired using a Zeiss LSM 510 
confocal scanning system attached to a Zeiss LSM 510 microscope using a plan Fluor 
20x or 10x objective.  An excitation wavelength of 543 nm was used for visualization of 
p75NTR.  Bladder whole-mount images were captured through a video camera attachment 
to the microscope with the exposure time, brightness, and contrast held constant. 
 
Western blotting for p75NTR expression in whole urinary bladder 
 Whole urinary bladders were homogenized separately in tissue protein extraction 
agent with protease inhibitors (T-PER; Roche, Indianapolis, IN), and aliquots were 
removed for protein assay.  Samples (23 µg) were suspended in sample buffer for 
fractionation on gels and subjected to SDS-PAGE.  Proteins were transferred to 
nitrocellulose membranes, and efficiency of transfer was evaluated. Membranes were 
blocked overnight in a solution of 5% milk, 3% bovine serum albumin in Tris-buffered 
saline with 0.1% Tween. Membranes were incubated in rabbit anti-p75NTR (1:2000; ATS) 
overnight at 4°C. Washed membranes were incubated in a species-specific secondary 
antibody (1:7000; goat anti-rabbit horseradish peroxidase) for 2 h at room temperature for 
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enhanced chemiluminescence detection (Pierce, Rockford, IL). Blots were exposed to 
Biomax film (Kodak, Rochester, NY) and developed. The intensity of each band was 
analyzed, and background intensities were subtracted using Un-Scan It software (Silk 
Scientific, Orem, UT).  Western blot analysis of erk1 and erk2 (1:2000; Cell Signaling 
Technology, Danvers, MA) in samples was used as a loading control. The specificity of 
the p75NTR antiserum was previously established (Klinger et al., 2008). In pilot studies, 
the concentration of p75NTR antiserum used for western blotting studies of urinary bladder 
was titrated.  The p75NTR antiserum concentration selected for experimentation did not 
result in saturation in control tissues and permitted changes in p75NTR expression with 
CYP treatment to be evaluated semi-quantitatively.  
  
Intravesical catheter placement 
 A lower midline abdominal incision was performed under general anesthesia with 
2-3% isoflurane using aseptic techniques.  Polyethylene tubing (PE-50, Clay Adams, 
Parsippany, NJ) with the end flared by heat was inserted into the dome of the bladder and 
secured in place with a 6-0 nylon purse-string suture (Hu et al., 2003; Studeny et al., 
2008).  The distal end of the tubing was sealed, tunneled subcutaneously, and 
externalized at the back of the neck, out of the animal’s reach.  Animals were maintained 
for 72 h after surgery to ensure complete recovery.   
 
Cystometry 
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The effects of p75NTR blockade on bladder function in control (no inflammation) 
and CYP-treated rats (48 h) were evaluated by immunoneutralization with intravesical 
infusion of anti-p75NTR monoclonal antibody (ATS; 100 µg/ml) or PD90780 (Pfizer; 10-
100 µM), known to specifically block NGF- p75NTR (Colquhoun et al., 2004; Hefti et al., 
2006; Spiegel et al., 1995) using conscious cystometry and continuous infusion of 
intravesical saline.  Intravesical instillation of an isotype-matched IgG and saline (room 
temperature, 0.9%) were used as controls.  Animals were placed conscious and 
unrestrained in recording cages with a balance and pan for urine collection and 
measurement placed below (Braas et al., 2006; Hu et al., 2005; Zvara and Vizzard, 2007). 
Intravesical pressure changes were recorded using a Small Animal Cystometry System 
(Med Associates, Inc.). Saline at room temperature was infused at a rate of 10 ml/h to 
elicit repetitive bladder contractions.  At least four reproducible micturition cycles were 
recorded after an initial stabilization period of 25 - 30 minutes.  Voided saline was 
collected to determine voided volume.  Intercontraction interval, maximal voiding 
pressure, pressure threshold for voiding and baseline resting pressure were measured 
(Maggi et al., 1986).  The number of non-voiding bladder contractions (NVCs) per 
voiding cycle during the filling phase was determined. For these studies, NVCs were 
defined as rhythmic intravesical pressure rises greater than 7 cm H2O from baseline 
pressure without a release of fluid from the urethra. Exclusion criteria Rats were removed 
from study when adverse events occurred that included: ≥ 20% reduction in body weight 
post surgery, a significant post-operative event, lethargy, pain or distress not relieved by 
our IACUC-approved regimen of post-operative analgesics or hematuria in control 
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rodents.  In the present study, no rats were excluded from the study or from analysis due 
to any of these exclusion criteria.  In addition, behavioral movements such as grooming, 
standing, walking, and defecation rendered bladder pressure recordings during these 
events unusable (Streng et al., 2006).  Experiments were conducted at similar times of the 
day to avoid the possibility that circadian variations were responsible for changes in 
bladder capacity measurements (Dorr, 1992).  Rats were euthanized at the conclusion of 
study and urinary bladder harvested as described above.  
 
Drug treatments 
The effects of p75NTR blockade on bladder function in control (no inflammation) and 
CYP-treated rats (48 h) were evaluated by immunoneutralization with intravesical 
infusion of anti-p75NTR monoclonal antibody (ATS; 100 µg/ml) or PD90780 (Pfizer; 10-
100 µM), known to specifically block NGF-p75NTR (Colquhoun et al., 2004; Hefti et al., 
2006; Spiegel et al., 1995) using conscious cystometry .  Immediately before cystometric 
analysis, rats were anesthetized (1-2% isoflurane) and bladders were manually emptied 
with the Credé maneuver.  A solution of protamine sulfate (Sigma-Aldrich, St. Louis, 
MO; 10 mg/ml in sterile saline) was then infused into the bladder (≤ 1 ml) and 
maintained (45 minutes (min)) in the bladder while the rat was anesthetized with 
isoflurane (1-2%) to prevent voiding and expulsion of bladder contents (Corrow and 
Vizzard, 2007b). Protamine sulfate is used to disrupt urothelial cell-to-cell contact and 
increase urothelial permeability (Nishiguchi et al., 2005). This concentration of 
protamine sulfate does not affect voiding frequency (Chuang et al., 2003; Fraser et al., 
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2003).  The bladder was then flushed with 0.9% sterile saline and emptied.  Rats were 
then infused (≤ 1 ml) with either anti-p75NTR  monoclonal antibody (n = 9) or with 
PD90780 (n = 24) and maintained (30 min) in the bladder while the rat was anesthetized 
(isoflurane, 1-2%) to prevent voiding and expulsion of bladder contents (Braas et al., 
2006; Corrow and Vizzard, 2007b). The concentrations and duration of PD90780 
infusion chosen for this study were based on previous experiments with PD90780 
(Allington et al., 2001; Colquhoun et al., 2004; Du et al., 2006; Spiegel et al., 1995; 
Wang et al., 2001).  The concentration anti-p75NTR monoclonal antibody used for 
intravesical infusion was based on previous studies using anti-p75NTR or anti-NGF in 
intrathecal infusion or cell culture applications (Du et al., 2006; Ito et al., 2003; Obata et 
al., 2006; Seki et al., 2002; Seki et al., 2004).   
 
Figure preparation  
 Digital images were obtained using a charge-coupled device camera (MagnaFire 
SP, Optronics; Optical Analysis, Nashua, NH) and LG-3 frame grabber attached to an 
Olympus microscope (Optical Analysis). Exposure times were held constant when 
acquiring images from control and experimental animals processed and analyzed on the 
same day. Images were imported into  
Adobe Photoshop 8.0 (Adobe Systems, San Jose, CA) where groups  
of images were assembled and labeled.  
 
Materials 
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 All standard chemicals were obtained from Sigma-Aldrich or Fisher and were 
either analytical or laboratory grade.  PD90780 was obtained through a compound 
transfer agreement with Pfizer, Inc. (Groton, CT). 
 
Statistical Analyses 
 All values represent mean ± S.E.M.  Data were compared one-way analysis of 
variance (ANOVA) or two-way ANOVA, where appropriate.  When F ratios exceed the 
critical value (p ≤ 0.05), the Dunnett’s post-hoc test was used to compare group means. 
 166
Results 
p75NTR immunoreactivity (IR) in urinary bladder  
To determine the localization of p75NTR expression in the urinary bladder, whole-
mount preparations were prepared in control (Fig. 1A-J), and 4 hour (h) (not shown) and 
chronic CYP-treated rats (not shown).  p75NTR expression was present in the urothelium 
and neuronal fibers in the urinary bladder of control rats and CYP-treated rats.  p75NTR –
IR was seen in urothelial cells (Fig. 1A, B, D), nerve fibers (Fig. 1B-J) in the 
suburothelial plexus, and in nerve fibers in the detrusor in both control and CYP-treated 
rats.  Nerve fibers adjacent to and encircling suburothelial vasculature also exhibited 
p75NTR –IR (Fig. 1C, D, H-J).  p75NTR-immunoreactive suburothelial nerve fibers and 
nerve fibers associated with the suburothelial vasculature also exhibited 
immunoreactivity for the pan neuronal marker, protein gene product (PGP9.5) (Fig. 1E-
J).  Given the widespread and overlapping nature of the p75NTR –IR in the defined 
structures, it was not possible to quantify changes in p75NTR –IR in individual structures 
with CYP-induced cystitis.  Rather, we examined regulation of p75NTR protein expression 
in whole urinary bladder using western blotting techniques. 
 
p75NTR  protein expression  in urinary bladder with CYP-induced cystitis  
p75NTR protein expression in whole urinary bladder as determined by Western 
blot analysis significantly (p ≤ 0.05) increased after 4 h (7.7-fold), 48 h (11.1-fold) or 
chronic CYP-treatment (3.3-fold) (Fig. 2A, B). 
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Effects of immunoneutralization of p75NTR on cystometry in rats with and without CYP-
induced cystitis with intravesical instillation of anti-p75 monoclonal antibody 
Control (no inflammation)  Intravesical infusion of an anti-p75NTR monoclonal antibody 
(100 µg/ml; Fig. 3B, D) increased voiding frequency, with a decreased intercontraction 
interval (ICI) (p ≤ 0.001) and decreased void volume (p ≤ 0.001) compared to control rats 
(Fig. 3A)(Fig. 4A, B) without intravesical anti-p75NTR instillation. Intravesical infusion of 
a monoclonal antibody to p75NTR did not affect baseline, micturition or threshold pressure 
or non-voiding contractions during the filling phase (Table 1).   
 
CYP treatment As previously demonstrated, CYP-treatment (48 h) decreased ICI (p ≤ 
0.001) and void volume (p ≤ 0.001; Fig. 4) and increased micturition (p ≤ 0.001) and 
threshold pressure (p ≤ 0.001; Table 1). Intravesical infusion of anti-p75NTR monoclonal 
antibody (100 µg/ml) in 48 h CYP-treated rats (Fig. 3D) resulted in an additional increase 
in voiding frequency with associated decreased ICI (p ≤ 0.001) and decreased void 
volume (p ≤ 0.005; Fig. 4A, B, Table 1).  There were no significant changes in 
micturition pressure, threshold pressure or non-voiding contractions as compared to rats 
with only 48 h CYP-treatment (Fig. 3C)(Table 1). Control experiments with intravesical 
infusion of an isotype-matched monoclonal IgG (100 µg/ml) or protamine sulfate (10 
mg/ml) showed no effects on bladder function in control or CYP-treated rats (Figs. 3, 4; 
Table 1) compared to rats without protamine sulfate or antibody infusion in control or 
CYP-treated rats. In pilot studies performed without the initial infusion of protamine 
sulfate, no changes in bladder function with subsequent intravesical infusion of the anti-
 168
p75NTR monoclonal antibody (100 µg/ml) were observed.  Therefore, all subsequent 
experiments included protamine sulfate intravesical infusion. The duration of anti-
p75NTR monoclonal antibody effects on all cystometric parameters evaluated in control 
and CYP-treated rats was 30-40 min.   
  
p75NTR immunoreactivity (IR) in urinary bladder after intravesical instillation of anti-
p75NTR monoclonal antibody 
p75NTR-IR was examined after intravesical instillation of anti-p75NTR monoclonal 
antibody by application of a species-specific secondary antibody to cryostat sections (20 
µm).  p75NTR –IR was present in urothelium and lamina propria (Fig. 5A). p75NTR –IR 
decreased in intensity with increasing distance from the bladder lumen.  Urinary bladder 
sections from rats not receiving intravesical instillation of anti-p75NTR monoclonal 
antibody exhibited no immunoreactivity above background levels (Fig. 5B).   
 
Effects of NGF-p75NTR blockade on cystometry in rats with and without CYP-induced 
cystitis with intravesical instillation of PD90780 
Control (no inflammation) rats  PD90780, a compound that specifically blocks NGF 
binding to p75NTR (Colquhoun et al., 2004; Hefti et al., 2006; Spiegel et al., 1995), was 
infused intravesically (10 µM, 25 µM, 50 µM, and 100 µM) in rats without CYP-induced 
cystitis and the effects on cystometric parameters were determined (Fig. 6A-D).  
Intravesical instillation of PD90780 decreased void volume (p ≤ 0.002) at all 
concentrations evaluated, and decreased ICI at 10 µM (p ≤ 0.05; Fig. 7) and 50 µM (p ≤ 
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0.05) (Fig. 6A, B; Fig. 7).  PD90780 instillation increased threshold pressure at 25 µM 
and 50 µM (p ≤ 0.02) and increased micturition and baseline pressure at all 
concentrations (p ≤ 0.002; Table 2) evaluated.  Effects of intravesical infusion of 
PD90780 in control rats (no inflammation) on void volume were more variable than that 
observed in CYP-treated rats (below) (data not shown); there was a disparity between 
void volume and infused volume suggestive of potential PD90780 effects on urethral 
outlet function. 
 
CYP treatment  Intravesical infusion of PD90780 in CYP-treated (48 h) rats significantly 
increased voiding frequency (Fig. 6C, D) with a decreased void volume (p ≤ 0.002; Fig. 
8B) and ICI (p ≤ 0.002; Fig. 8A) compared to rats with CYP-treatment (48 h) alone.   
PD90780 (10 µM, 50 µM, 100 µM) significantly (p ≤ 0.001) increased threshold, 
baseline and micturition pressure (Table 2).  The numbers of non-voiding contractions 
per micturition cycle during the filling phase were significantly (p ≤ 0.002) increased at 
10 µM and 50 µM PD90780 concentrations (Table 2).  The duration of PD90780 effects 
for all concentrations examined for all cystometric parameters evaluated in control and 
CYP-treated rats was 30-40 min.   
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Discussion 
We have demonstrated several novel findings with respect to the expression and 
regulation of p75NTR in urinary bladder with CYP-induced cystitis and the role of p75NTR  
in urinary bladder function in control (no inflammation) and CYP-treated rats.  p75NTR is 
expressed throughout the urinary bladder and is present in nerve fibers of the detrusor 
smooth muscle, the suburothelial nerve plexus, urothelial cells, and nerve fibers 
associated with the suburothelial bladder vasculature.  Total urinary bladder p75NTR 
expression increased after acute (4 h), intermediate (48 h) and chronic CYP-induced 
cystitis.  p75NTR blockade via immunoneutralization and PD90780, known to block NGF-
p75 NTR interactions (Colquhoun et al., 2004; Hefti et al., 2006; Spiegel et al., 1995), 
resulted in bladder hyperreflexia in control rats and further enhanced bladder 
hyperreflexia in CYP-treated (48 h) rats associated with decreased void volumes and 
intercontraction intervals (ICI) and increased number of non-voiding contractions for 
PD90780.  These studies suggest that p75NTR interactions can affect overall bladder 
function. 
 
NGF binds to two receptors, the p75NTR receptor, a member of the tumor necrosis 
factor family of receptors and TrkA, a receptor tyrosine kinase (Allen and Dawbarn, 
2006; Barker, 2007; Frossard et al., 2004). However, little information exists concerning 
the underlying interactions between neurotrophins, TrkA and p75NTR receptors in 
mediating inflammatory-induced changes in micturition pathways.  The majority of 
NGF-responsive cells express both p75NTR and TrkA (Chao and Hempstead, 1995) and 
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TrkA is exclusively expressed with p75NTR in rat DRG (Wright and Snider, 1995). NGF 
selectively binds TrkA whereas p75NTR can bind all neurotrophins with the same affinity 
(Huang et al., 1999). p75NTR also binds neurotrophin precursor molecules with high 
affinity, including proNGF (Huang et al., 1999).  The ability of NGF to bind two very 
distinct receptors and the resulting signaling via this receptor complex has puzzled 
researchers (Barker, 2007).  Much of the recent attention on p75NTR has been focused on 
its role in apoptosis and neuronal growth inhibition.  However, the original function 
attributed to p75NTR was as an accessory protein that modulates Trk receptors to regulate 
their affinity for their appropriate ligand (Barker, 2007; Chao et al., 2006).  The co-
expression of TrkA and p75NTR in heterologous cells results in high-affinity NGF binding 
sites (Barker, 2004; Verdi et al., 1994).  Thus, it has become a prevailing concept that 
p75NTR and TrkA combine to form a receptor complex that results in high-affinity NGF 
binding (Chao et al., 2006).  However, a recent study (Wehrman et al., 2007) provides 
structural and mechanistic evidence for a ligand-passing model in which NGF rapidly 
associates with p75 NTR and then is presented to TrkA (Wehrman et al., 2007). In the 
model presented, blocking NGF binding to p75NTR attenuates NGF binding to TrkA and 
subsequent TrkA activation (Wehrman et al., 2007).  It is also suggested that convergent 
signaling pathways activated by p75NTR and TrkA could underlie the complex crosstalk 
between p75NTR and TrkA (Barker, 2007; Wehrman et al., 2007). 
 
We have recently demonstrated upregulation of p75NTR in dye-labeled 
lumbosacral bladder afferents and in the superficial laminae of the dorsal horn in central 
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micturition reflex pathways after acute and chronic CYP-induced cystitis (Klinger et al., 
2008). Few studies have examined the regulation of p75NTR in rat urinary bladder after 
experimentally induced nerve regeneration or urinary bladder inflammation (Elsasser-
Beile et al., 2000; Jahed and Kawaja, 2005; Wakabayashi et al., 1998; Wakabayashi et 
al., 1996).  To our knowledge, no study has addressed the functional role of p75NTR in 
micturition reflex pathways. 
  
It is well documented that NGF is important in a number of inflammatory 
conditions including urinary bladder, colon and lung inflammation (Delafoy et al., 2006; 
Freund-Michel and Frossard, 2008; Stanzel et al., 2008; Vizzard, 2000b). The exact 
contribution of NGF to bladder function is not known but a role for NGF in bladder 
hyperreflexia and bladder overactivity has been suggested (Chuang et al., 2001b; 
Clemow et al., 1998; Dmitrieva et al., 1997; Guerios et al., 2006; Hu et al., 2005; Oddiah 
et al., 1998; Zvara and Vizzard, 2007). Experimentally induced cystitis induces bladder 
hyperreflexia and increases bladder NGF protein and transcript (Murray et al., 2004; 
Vizzard, 2000b).  In the spontaneously hypertensive rat model, increased expression of 
bladder NGF is associated with hyperactive voiding (Clemow et al., 1998). Bladder outlet 
obstruction is associated with increased expression of bladder NGF (Steers et al., 1991; 
Steers and Tuttle, 2006; Zvara et al., 2002). Intrathecal (Yoshimura et al., 2006), 
intravesical delivery of NGF (Dmitrieva et al., 1997) or adenovirus-mediated NGF 
overexpression (Lamb et al., 2004) in the bladder induces bladder hyperreflexia and 
bladder afferent cell hyperexcitability (Yoshimura et al., 2006; Yoshimura et al., 2002) in 
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control rats. NGF scavenging methods (Dmitrieva et al., 1997; Hu et al., 2005) reduce 
bladder hyperreflexia in rats with experimentally induced inflammation. Elevated levels 
of neurotrophins are detected in the urine of women with painful bladder syndrome 
(Okragly et al., 1999) (PBS)/interstitial cystitis (IC) or in the urothelium of individuals 
with neuropathic bladder (Lowe et al., 1997).  However, a recent study failed to 
demonstrate an association between increased urothelium/suburothelium NGF with 
detrusor overactivity or bladder sensation (Birder et al., 2007).  More recently, it has been 
demonstrated that urinary NGF levels are increased in overactive bladder (OAB), urinary 
incontinence and decreased in patients responding to botulinum toxin-A treatment (Liu 
and Kuo, 2008a; b).  Thus, NGF may be a potential biomarker for OAB. 
 
Neurotrophins, through interactions with Trk and/or p75NTR receptors, may 
contribute to neurochemical (Vizzard, 2000b; 2001), electrophysiological (Yoshimura et 
al., 2002) and organizational (Steers and Tuttle, 2006; Vizzard, 2000b) plasticity of 
micturition pathways after cystitis. Neurotrophin/Trk and/or p75NTR interactions could 
induce long-term changes in cells (Steers and Tuttle, 2006), including: (1) mediating 
neurotransmitter phenotype; (2) influencing dendrite size and synaptic reorganization; (3) 
increasing synaptic efficacy; and (4) controlling innervation density and target organ 
function.  Consistent with the effects of exogenous NGF on urinary bladder function, it 
has also been shown that sequestration of NGF or TrkA decreases bladder hyperreflexia 
and improves animal well being (Dmitrieva et al., 1997; Hu et al., 2005).  Systemic 
administration of REN1820, an NGF sequestering protein, decreased bladder 
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hyperreflexia associated with CYP-induced cystitis (Hu et al., 2005).  Sequestration of 
NGF with a TrkA fusion protein also reduced bladder hyperreflexia following turpentine 
oil intravesical instillation (Dmitrieva et al., 1997).  Intravenous administration of k252a, 
an inhibitor of Trk receptors, reduced referred somatic hypersensitivity of rat hindpaws 
induced by CYP-induced cystitis (Guerios et al., 2006).  Intravesical instillation of k252a 
in CYP-treated rats also reduces bladder hyperreflexia (Vizzard et al., in preparation). 
Blockade of the NGF-TrkA pathway in respiratory inflammation models with k252a 
(Mohtasham et al., 2007) or NGF blocking antibodies decreased recruitment of 
inflammatory cells and bronchial hyperresponsiveness, respectively (Frossard et al., 
2004). Immunoneutralization of p75NTR in adult rat sensory neurons inhibits upregulation 
of substance P induced by NGF application (Skoff and Adler, 2006).  Studies using 
p75NTR knock-out (KO) mice or immunoneutralization of p75NTR reduced bronchial 
hyperresponsiveness and substance P release in the airway (Farraj et al., 2006; Kerzel et 
al., 2003; Tokuoka et al., 2001).   
 
In contrast to reduced hyperresponsiveness with p75NTR blockade or absence 
(p75NTR KO) in the pulmonary system (Farraj et al., 2006; Kerzel et al., 2003; Tokuoka et 
al., 2001), the present studies demonstrate bladder hyperreflexia or enhanced 
hyperreflexia in control or CYP-treated rats following intravesical blockade of p75NTR by 
two different approaches.  Immunoneutralization of p75NTR via intravesical instillation of 
an anti-p75NTR monoclonal antibody increased urinary bladder frequency (decreased 
intercontraction interval (ICI), decreased void volume) in both control (no inflammation) 
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and CYP-treated rats whereas intravesical pressures (baseline, micturition, threshold) 
were not affected. To confirm that the observed changes in bladder function were not 
associated with non-specific actions of immunoglobulin, intravesical instillation of 
isotype-matched IgG was infused and was without effect on any cystometric parameter 
evaluated.  Intravesical infusion of PD90780, known to block NGF-p75NTR interactions 
(Colquhoun et al., 2004; Hefti et al., 2006; Spiegel et al., 1995), produced similar but also 
additional changes in the cystometric parameters evaluated.  PD90780 increased voiding 
frequency (decreased ICI, decreased void volume) in control and CYP-treated rats, but 
also altered threshold, baseline and micturition pressures; vehicle infusions were without 
effect.  This study and previous studies have demonstrated that CYP-treatment produces 
bladder hyperreflexia in addition to a number of neurochemical, electrophysiological and 
organizational changes of the micturition reflex (Hu et al., 2003; Hu et al., 2005; Vizzard, 
2000a; 2001; Vizzard and Boyle, 1999; Yoshimura and de Groat, 1999).  The 
demonstration that p75NTR blockade further increases bladder hyperreflexia shows that 
the frequency of the micturition reflex is not saturated with CYP treatment but can be 
further modulated.   
 
Intravesical infusion of PD90780 produced some differential effects between 
control (no inflammation) and CYP-treated rats in contrast to the effects produced by 
immunoneutralization of p75NTR with an anti-p75NTR monoclonal antibody that were 
similar in control and CYP-treated rats.   In control rats treated with intravesical 
instillation of PD90780, there was evidence of incomplete voiding as rats exhibited small 
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void volumes in comparison to infused volume.  This mismatch between void and infused 
volumes was not observed in CYP-treated rats infused with PD90780 or in control or 
CYP-treated rats infused with anti-p75NTR monoclonal antibody.  This mismatch between 
void volume and infused volume may suggest PD90780 effects on the urethral outlet.  
Given the ubiquitous expression of p75NTR throughout the urinary bladder demonstrated 
in the present studies and the peripheral and central nervous system in general (Friedman 
and Greene, 1999; Frossard et al., 2004; Wakabayashi et al., 1998; Wakabayashi et al., 
1996), it would not be surprising that the urethra expressed p75NTR.  Why the potential 
effects of PD90780 on the urethra are exhibited in control but not CYP-treated rats may 
be related to p75NTR and NGF expression in the urinary bladder with CYP-induced 
cystitis.  Previous and present studies demonstrated significant increases in total p75NTR 
and NGF bladder expression with CYP-induced cystitis (Hu et al., 2005; Klinger et al., 
2008; Murray et al., 2004; Vizzard, 2000b).  In control rats with less p75NTR and NGF 
expression in the urinary bladder, infusion of PD90780 may exert bladder and urethral 
effects because the drug may be more available and have broader effects and affect NGF-
p75NTR interactions at the urethra.  In contrast, with CYP-induced cystitis and increased 
p75NTR and NGF expression in the urinary bladder, effects of PD90780 infusion may be 
less available and restricted to the urinary bladder.  PD90780 effects on ICI and void 
volume in control rats were also demonstrated at the lowest concentration (10 µM) 
evaluated whereas PD90780 effects in CYP-treated rats (48 h) were observed at 25 µM 
PD90780.  Thus, differences in p75NTR and NGF expression in control versus inflamed 
urinary bladder may also underlie differences in effective doses of PD90780.  Another 
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possibility underlying differential effects of PD90780 in control and CYP-treated rats 
may be due to variable penetration of PD90780 in the inflamed urinary bladder with 
CYP-treatment.  
 
Cystometric effects of p75NTR blockade with intravesical instillation of an anti-
p75NTR monoclonal antibody may be due to blockade of other neurotrophins, in addition 
to NGF, binding to p75NTR since brain derived neurotrophic factor (BDNF), neurotrophin 
(NT)-3 and NT-4 may also bind p75NTR, are also present in urinary bladder, and 
expression of BDNF, NT-3 and NT-4 is altered by CYP-induced cystitis (Vizzard, 
2000b).  However, the PD90780 compound, which specifically blocks NGF binding to 
p75NTR (Colquhoun et al., 2004; Hefti et al., 2006; Spiegel et al., 1995), produced similar 
and broader cystometric changes.  Thus, we suggest that the observed cystometric effects 
are attributable to blockade of p75NTR-NGF interactions.  
 
These studies demonstrate widespread p75NTR expression in many cell types in the 
urinary bladder and increased total p75NTR expression in the urinary bladder with CYP-
induced cystitis.  This makes it difficult to determine the exact site(s) of action in the 
urinary bladder of the p75NTR antibody.  We do know that intravesical infusion of anti- 
p75NTR monoclonal antibody without infusion of protamine sulfate showed no 
cystometric effects.  This likely indicates a site of p75NTR action deep to the urothelium, 
since protamine sulfate is used to disrupt cell-to-cell contact of urothelial cells (Chuang et 
al., 2003; Stein et al., 1996).  Our demonstration of p75NTR –IR after intravesical infusion 
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of anti- p75NTR supports this suggestion as p75NTR –IR is present in the lamina propria.  
Potential targets include the suburothelial nerve plexus, interstitial cells of Cajal and 
myofibroblasts all distributed beneath the urothelium (Andersson and Arner, 2004) as 
well as inflammatory cell infiltrates in bladders from CYP-treated rats and nerve fibers 
innervating the detrusor smooth muscle. 
 
 p75NTR receptor blockade at the level of the urinary bladder produced changes in 
ICI, void volume, changes in threshold and micturition pressure and increases in the 
number of non-voiding contractions during the filling phase.  Changes in ICI resulting in 
changes in void volume, and changes in threshold pressure are suggestive of changes on 
the afferent limb of the micturition reflex.  Changes in micturition pressure are thought to 
be dependent on the efficiency of neurotransmission of bladder efferents (Maggi et al., 
1986).  Changes in non-voiding contractions observed with PD90780 infusions in CYP-
treated rats may have both myogenic and neurogenic components (Gillespie, 2005; 
Herrera et al., 2003; Streng et al., 2006).  For example, myogenic contractions could 
trigger afferent firing which then evokes a reflex efferent discharge that amplifies the 
myogenic contraction.  Effects of intravesical anti-p75NTR infusion were limited to ICI 
and void volume without effects on intravesical pressures suggesting that the afferent 
limb of the micturition reflex is targeted.  Greater concentrations of anti-p75NTR were not 
evaluated in the present study so it is not known if additional cystometric changes would 
have emerged suggestive of effects on the efferent limb of the micturition reflex.  In 
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contrast, effects of PD90780 on ICI, void volume and intravesical pressures suggest that 
both the afferent and efferent limbs of the micturition reflex are affected.      
 
The present experiments show that p75NTR blockade at the level of the urinary 
bladder increases voiding frequency in control rats and further increases voiding 
frequency in CYP-treated rats.  Thus, one function of p75NTR and NGF-p75NTR 
interactions in vivo may be to reduce bladder activity or to offset bladder hyperreflexia 
induced by CYP-induced cystitis. Whereas it is known that p75NTR expression can 
enhance TrkA-NGF binding in some systems (Allen and Dawbarn, 2006; Chao and 
Hempstead, 1995), it is also possible that NGF binding to p75NTR could reduce NGF-
TrkA signaling by sequestering NGF away from TrkA (Dhanoa et al., 2006; Hannila and 
Kawaja, 2005; Nykjaer et al., 2005).  The importance of p75NTR in bladder function may 
depend on the balance of NGF/TrkA and NGF/p75NTR signaling.  Although perhaps less 
clinically relevant than OAB, detrusor overactivity or bladder hyperreflexia, detrusor 
underactivity is a clinical problem that is seen most often in men although women are 
also affected (Cucchi et al., 2008).  It consists of reduced muscle contraction strength or 
velocity and often results in incomplete voiding,  post-void residual, prolonged emptying 
and reduced free uroflow (Cucchi et al., 2007; Cucchi et al., 2008).  Detrusor 
underactivity can be neurogenic, idiopathic or a result of bladder outflow obstruction 
(Cucchi et al., 2007; Murakami et al., 2008).  Whether blockade of p75NTR in this context 
would be beneficial or whether p75NTR receptors are regulated by detrusor underactivity 
awaits further study.  
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Table 1:  Effects of intravesical infusion of an anti-p75NTR monoclonal antibody on 
cystometric parameters. 
Effects of intravesical infusion of an anti-p75NTR monoclonal antibody on baseline pressure, threshold 
pressure, micturition pressure and numbers of non-voiding contractions (NVCs) per micturition cycle are 
indicated.  Threshold pressure and micturition pressure were significantly increased after 48 h CYP 
treatment.  No effects of anti-p75NTR monoclonal antibody on threshold pressure, baseline pressure or peak 
micturition pressure were observed.  The no antibody group received intravesical infusion of protamine 
sulfate (10 mg/ml), which did not differ from rats receiving intravesical infusion of protamine sulfate and 
isotype-matched IgG.  Values are means ± S.E.M.  *, p ≤ 0.001 compared to isotype-matched IgG infusion 
in control rats.  n = 4-11 rats in each group. 
 
 
 
 
 
 
 
 
 
Intravesical 
   Infusion 
 
Threshold 
Pressure 
(cm H2O) 
 
Micturition 
Pressure 
(cm H2O) 
 
Baseline 
Pressure  
(cm H2O) 
 
Non-Voiding 
Contractions 
per Micturition 
Cycle 
 
Control 
(no CYP) 
 
no antibody 
 
15.1 ± 0.9 
 
38.5 ± 1.3 
 
15.1 ± 0.9 
 
 
 
0.7 ± 0.3 
 anti-p75NTR 
monoclonal 
antibody 
 
 
14.2 ± 1.0 
 
39.5 ± 2.0 
 
15.0 ± 0.6 
 
 
 
0.8 ± 0.3 
48 h CYP  no antibody    19.3 ± 0.7*    46.7 ± 1.4*    20.0 ± 0.8* 
 
  0.2 ± 0.1* 
 anti-p75NTR 
monoclonal 
antibody 
 
 13.9 ± 1.1 44.1 ± 2.0  14.0 ± 1.0 
 
 
0.3 ± 0.1 
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Intravesical 
                 Infusion 
 
Threshold 
Pressure 
(cm H2O) 
 
Micturition 
Pressure 
(cm H2O) 
 
Baseline 
Pressure  
(cm H2O) 
 
Non-Voiding 
Contractions 
per 
Micturition 
Cycle 
no 
CYP 
PS only 15.1 ± 0.9 38.5 ± 1.3 15.1 ± 0.9 
 
0.7 ± 0.3 
 10 µM PD90780 17.0 ± 1.3    47.1 ± 3.0 *    18.4 ± 1.2 * 
 
1.9 ± 0.7 
 25 µM PD90780    20.2 ± 1.5 *    50.8 ± 1.8 *    21.5 ± 1.3 * 
 
0.8 ± 0.4 
 50 µM PD90780    19.4 ± 1.1 *    47.1 ± 2.6 *    21.5 ± 1.0 * 
 
1.6 ± 0.4 
 100 µM PD90780 19.1 ± 1.2    51.0 ± 2.1 *    21.3 ± 1.4 * 
 
1.0 ± 0.4 
48 h 
CYP 
PS only 19.3 ± 0.7 46.7 ± 1.4  20.0 ± 0.8 
 
0.2 ± 0.1 
 10 µM PD90780    25.1 ± 0.8 *    57.8 ± 2.8 *  24.3 ± 0.6* 
 
  1.1 ± 0.3 * 
 25 µM PD90780 22.1 ± 1.7 49.1 ± 3.1  21.8 ± 1.7 
 
0.3 ± 0.2 
 50 µM PD90780    25.7 ± 0.8 *    61.2 ± 2.5 *  27.7 ± 1.3* 
 
  0.6 ± 0.2 * 
 100 µM PD90780    24.0 ± 0.8 *    56.1 ± 2.6 *  24.3 ± 0.8* 
 
0.3 ± 0.1 
 
 
 
Table 2:  Effects of intravesical infusion of PD90780 on cystometric parameters. 
Effects of intravesical infusion of PD90780 on baseline pressure, threshold pressure, micturition pressure 
and non-voiding contractions (NVCs) per micturition cycle are indicated.  In control rats (no CYP 
treatment), intravesical infusion of PD90780 significantly increased micturition pressure and threshold 
pressure.  In CYP-treated rats (48 h), PD90780 infusion significantly increased threshold pressure, 
micturition pressure and NVCs.  PS, protamine sulfate (10 mg/ml).  Values are means ± S.E.M.  *, p ≤ 
0.001 compared to PS (10 mg/ml) and saline infusion in control rats. n = 4-11 rats in each group. 
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Figures 
 
Figure 1: Urinary Bladder whole-mount preparations 
p75NTR and pan-neuronal marker, protein gene product 9.5 (PGP9.5) immunoreactivity (IR) in urinary 
bladder whole-mount preparations with the urothelium/suburothelium dissected from the detrusor smooth 
muscle.  A. Confocal image of p75NTR–IR in urothelial cells.  B. Epifluorescence image of p75NTR–IR 
suburothelial nerve fibers (yellow arrows) in close proximity to p75NTR–IR urothelial cells (white arrows).  
C. p75NTR–IR in suburothelial nerve fibers (white arrows) and vasculature (yellow arrows).  D. p75NTR–
IR in vasculature (yellow arrows), nerve fibers (white arrows) and urothelial cells out of the focal plane 
(asterisks).  p75NTR-immunoreactive suburothelial fibers (arrows E, H) also expressed PGP9.5-IR (arrows 
F, I). Panels G and J show merged images of E, H and F, I, respectively.  Calibration bar represents 100 
µm. 
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Figure 2:  Western blot for p75NTR expression in whole urinary bladder 
A. Representative western blot of whole urinary bladder (23 μg) for p75NTR expression in control rats and 
those treated with cyclophosphamide (CYP) for varying duration.  Erk1 staining was used as a loading 
control.  B. Histogram of relative p75NTR band density in all groups examined normalized to Erk1 in the 
same samples.  p75NTR expression in whole urinary bladder is significantly increased with acute (4 h), 
intermediate (48 h) and chronic CYP treatment.  *, p ≤ 0.05.  n = 4 for all groups.  
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Figure 3:  Intravesical infusion of anti-p75NTR monoclonal antibody 
Intravesical infusion of anti-p75NTR monoclonal antibody in control and in CYP-treated (48 h) rats 
increased voiding frequency (decreased intercontraction interval).  Representative cystometrogram 
recordings in rats treated with (A) intravesical protamine sulfate in control rats, (B) protamine sulfate and 
anti-p75NTR monoclonal antibody (100 µg/ml) in control rats, (C) protamine sulfate in CYP-treated (48 h) 
rats, (D) protamine sulfate and anti- p75NTR monoclonal antibody (100 µg/ml) in CYP-treated (48 h) rats. 
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Figure 4: Voiding frequency and inter-contraction interval 
Intravesical infusion of anti- p75NTR monoclonal antibody (100 µg/ml) significantly increased voiding 
frequency in control and in CYP-treated (48 h) rats.  Both inter-contraction interval (A) and void volume 
(B) were significantly (p ≤ 0.001) reduced with intravesical infusion of anti-p75NTR.  n = 4-11 for all 
groups. 
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Figure 5:  p75NTR-IR in urinary bladder sections after intravesical infusion of anti-p75NTR 
p75NTR-IR in urinary bladder sections after intravesical infusion of anti-p75NTR and application of species-
specific secondary antibodies to demonstrate penetration of the antibody into the urinary bladder with 
intravesical infusion.   Epifluorescence images of (A) rat urinary bladder after intravesical infusion of anti-
p75NTR (100 µg/ml) and (B) rat urinary bladder after only intravesical infusion of protamine sulfate.  A. 
p75NTR -IR is observed in urothelium and lamina propria, with staining reduced with increasing distance 
from the bladder lumen.  B. No p75NTR-IR was observed in rat urinary bladder in the absence of intravesical 
antibody infusion.  U, urothelium; LP, lamina propria; l, lumen.  Calibration bar represents 120 µm.  
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Figure 6:  Intravesical infusion of PD90780 
Intravesical infusion of PD90780, a compound that specifically blocks NGF binding to p75NTR, results in 
decreased bladder capacity in control (no inflammation) and in 48 h CYP-treated rats.  Representative 
cystometrogram recordings in rats treated with (A) intravesical protamine sulfate in control rats, (B) 
protamine sulfate and PD90780 (100 µM) in control rats, (C) protamine sulfate in CYP-treated (48 h) rats, 
(D) protamine sulfate and PD90780 (100 µM) in CYP-treated (48 h) rats. 
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Figure 7:  Voiding frequency and inter-contraction interval in control rats 
Summary histograms of the effects of intravesical infusion of PD90780 in control rats (no CYP treatment).  
A.  Infusion of PD90780 (10, 50 µM) significantly (p ≤ 0.05) reduced inter-contraction interval.  B. Void 
volume in control rats was also significantly (p ≤ 0.05) reduced at all PD90780 concentrations evaluated 
(10 µM, 25 µM, 50 µM, 100 µM). n = 4-6 for all groups. 
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Figure 8:  Voiding frequency and inter-contraction interval in CYP-treated rats  
Summary histograms of the effects of intravesical infusion of PD90780 in CYP-treated (48 h) rats.  Rats 
were treated with CYP 48 h prior to intravesical infusion of PD90780 and analysis with conscious 
cystometry.  A.  Intravesical infusion of PD90780 (25 µM, 50µM, 100 µM) significantly (p ≤ 0.002) 
reduced inter-contraction interval in rats treated with CYP (48 h).  B. Void volume in CYP- treated (48 h) 
rats was also significantly (p ≤ 0.002) reduced at these same concentrations. n = 5-11 for all groups. 
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Chapter 5: Summary and Conclusions 
 
CYP-induced bladder inflammation is an important model that allows the study of 
the effects of acute and chronic bladder inflammation.  The results of experiments done 
in CYP-treated animals may have relevance to human conditions that involve bladder 
inflammation, including IC/PBS (Westropp and Buffington, 2002).  CYP cystitis results 
in many changes in urinary bladder reflex pathways and many are not understood.  The 
overall goal for this dissertation was to further understand and characterize the changes 
associated with bladder inflammation and specifically, the roles that both 
cyclooxygenase-2 (COX-2) and the neurotrophin receptor p75Neurotrophin receptor (NTR) play.   
 Using the CYP model of bladder inflammation, we first examined COX-2 
expression in the bladder tissues of control rats and of rats with varying duration of CYP-
induced cystitis.  By separating the detrusor from the urothelium and suburothelium and 
using Western blot analysis, we showed that COX-2 expression is significantly increased 
in both compartments, and also that COX-2 expression increased with a greater fold 
change in the urothelium/suburothelium than in the detrusor smooth muscle.  Upon 
further examination with immunostaining, COX-2 expression was indeed found to be 
upregulated in the urothelium, as well as in inflammatory infiltrates and nerve fibers in 
the suburothelial plexus with acute and chronic cystitis.  Inflammatory infiltrates were 
also present in the detrusor smooth muscle.  These results identify possible cellular 
targets for COX-2 inhibitors that have been used to attenuate bladder hyperreflexia with 
CYP in previous studies, and also identify the localization of COX-2 upregulation 
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reported previously (Hu et al., 2003; Wheeler et al., 2001).  These results suggest that 
COX-2 activation contributes to bladder inflammation in acute and chronic cystitis and, 
more specifically, may have its effect on the production of prostaglandins in urothelium, 
and nerve fibers and macrophages in the suburothelial plexus.  Prostaglandins are known 
to modulate the basal tone of the detrusor and influence detrusor contraction as well as 
target primary bladder afferents, thus influencing the micturition reflex (Angelico et al., 
2006; Maggi, 1992).  Application of prostaglandins to the detrusor stimulates the 
micturition reflex (Maggi et al., 1984).  However, the story of CYP-induced bladder 
inflammation goes beyond COX enzymes and prostaglandins; COX-2 expression can be 
stimulated in part by growth factors and inflammatory cytokines. 
 Since NGF and its receptor TrkA have been implicated in the progression of 
CYP-induced urinary bladder inflammation, the next step of this project was to explore 
the expression of the pan-neurotrophin receptor p75NTR in rat urinary bladder sensory 
neurons and spinal cord with CYP-induced cystitis.  p75NTR expression was examined 
using immunohistochemistry in lumbosacral spinal cord and DRG.  p75NTR was present in 
control and significantly increased in spinal cord dorsal horn at lumbosacral levels known 
to be involved in micturition reflexes in rats (L1-L2; L6-S1), suggesting that p75NTR 
could be involved in central processing of afferent information.  p75NTR immunoreactivity 
was also noted in control lumbosacral DRG cell bodies and staining surrounding neuronal 
cell bodies.  This staining was increased with acute, intermediate and chronic CYP 
treatment.  Upon examination with confocal microscopy, pericellular p75NTR staining did 
not co-label with GFAP, suggesting that this staining is more likely associated with the 
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neuronal cell membrane, and not of glial origin.  p75NTR mRNA expression increased 
with acute, intermediate and chronic CYP treatment in L6 DRG.  The upregulation of 
p75NTR mRNA and protein expression in whole DRG could suggest p75NTR upregulation 
in the afferents of other organs as well, including colon and urogenital structures, which 
also have afferents in lumbosacral DRG.  It is interesting to note that cross-talk can occur 
between these visceral organs, with convergence of sensory information occurring in the 
dorsal root ganglia, spinal cord and brain (Malykhina, 2007).  This cross-talk can result in 
cross-sensitization between visceral organs and may contribute to chronic pain 
experienced in both bladder, urogenital organs and colon (Malykhina, 2007).  Cross-
sensitization may be a factor in the co-morbidity of such conditions as Irritable Bowel 
Syndrome and Interstitial Cystitis/Painful Bladder Syndrome.   
A retrograde dye-tracing technique with Fastblue was used to determine p75NTR 
expression in bladder-projecting primary afferents.  Bladder-projecting afferent cells 
constitutively expressed p75NTR and expression was also significantly increased with 
acute, intermediate and chronic CYP treatment, suggesting a role for this receptor in 
normal bladder afferent signaling, and possibly in mediating the effects of bladder 
inflammation.  Overall, these results demonstrated constitutive expression of p75NTR in 
micturition reflexes and modification of this expression by bladder inflammation.  The 
functional significance of p75NTR in bladder reflexes remained to be determined. 
Upon examination of p75NTR expression in the urinary bladder, we have detected 
p75NTR immunoreactivity in urothelial cells, in nerve fibers in the suburothelial plexus, 
and in nerve fibers associated with the vasculature.  No upregulation of this staining was 
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obvious with immunohistochemical techniques because of the large amount of 
overlapping structures expressing p75NTR expression in the urinary bladder, but Western 
blot analysis of whole bladder expression of p75NTR did show a significant increase in 
p75NTR protein expression after acute, intermediate, and chronic CYP cystitis.   
Blockade of p75NTR in rat urinary bladder was achieved by intravesical infusion of 
anti-p75NTR monoclonal antibody as well as intravesical infusion of PD90780, a 
compound that specifically blocks NGF binding to p75NTR (Colquhoun et al., 2004; Hefti 
et al., 2006; Spiegel et al., 1995).  p75NTR blockade was done in both control and CYP 
(48 hour)-treated rats.  Bladder function was then studied using conscious cystometry 
with continuous intravesical infusion of saline.  Infusion with each compound 
demonstrated a significant increase in voiding frequency (decreased inter-contraction 
interval, decreased void volume) in both control and CYP-treated rats.  Changes in 
voiding frequency are suggestive of changes in the afferent limb of the micturition reflex.   
Changes in both threshold pressure and number of non-voiding contractions were seen 
with infusion of PD90780 in control and CYP-treated rats, suggestive of possible changes 
in the afferent pathway.  Increased micturition pressure was also noted, indicating an 
effect on the efficiency of the efferent branch of the micturition reflex pathway with this 
treatment.   
Based on previous results showing that blockade of Trk signaling with k252a 
attenuated the bladder hyperreflexia observed with CYP-induced cystitis, we had 
hypothesized that p75NTR blockade in the urinary bladder would also decrease bladder  
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Figure 1:  p75NTR blockade leads to increased bladder activity 
Cyclophosphamide-induced bladder inflammation results in increased NGF expression in the 
urinary bladder.  NGF signaling through TrkA results in a number of inflammatory effects, 
including the sensitization of bladder afferents.  This in turn results in increased overall bladder 
activity.  We have used anti-p75NTR monoclonal antibody and PD90780, a compound that 
specifically blocks NGF binding to p75NTR , to block NGF signaling through p75NTR .  This 
resulted in increased bladder voiding activity in both control and CYP-treated rats.  We 
hypothesize that blockade of p75NTR increases the amount of NGF available to bind TrkA, thus 
increasing NGF-TrkA signaling and increasing inflammatory effects and sensitization of bladder 
afferents.  
 
 
 
hyperreflexia with cystitis.  This hypothesis was based on data that demonstrated a role 
for p75NTR in enhancing TrkA binding NGF, thus increasing NGF-TrkA signaling, 
meaning that p75NTR and TrkA would have complementary roles (Allen and Dawbarn, 
2006).  In this model, increased NGF-TrkA signaling would result in a cascade of 
inflammatory effects, including sensitization of bladder afferents (Fig. 1) (Chuang et al., 
2001b).  The upregulation of p75NTR in bladder afferents with cystitis is more widespread 
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than the upregulation of TrkA expression after cystitis; TrkA was only upregulated in L1 
and L6 DRG, and not with all durations of CYP treatment (Qiao and Vizzard, 2002).  The 
upregulation of TrkA in bladder afferents could occur as a result of an increase in NGF 
levels in the urinary bladder with cystitis (Vizzard, 2000b), and could be evidence of 
increased NGF-TrkA signaling that contributes to the inflammatory effects and bladder 
hyperreflexia associated with cystitis.  In Chapter 3, we presented evidence that p75NTR is 
upregulated in bladder afferents with cystitis, and in Chapter 4, we showed that blockade 
of NGF-p75NTR actually increases voiding frequency in control rats and further increases 
bladder hyperreflexia in rats with CYP-induced cystitis.  This suggests that NGF-p75NTR 
signaling in the urinary bladder may actually serve to modify bladder activity in an 
opposite way to NGF-TrkA signaling, thereby reducing inflammation-related 
hyperreflexia or to maintain reflex function under control conditions as well.   p75NTR has 
long been considered as a binding partner to TrkA, with cooperation between the two 
resulting in NGF binding TrkA with greater affinity.  However, p75NTR might also bind 
NGF on its own, therefore sequestering NGF and leaving less to bind to TrkA, and 
therefore less NGF-TrkA signaling.  Furthermore, the upregulation of p75NTR in urinary 
bladder afferents seen with acute, intermediate and chronic durations of cystitis may 
serve as a compensatory mechanism of signaling, in order to attenuate inflammation-
related bladder hyperreflexia. 
Future Directions 
 This dissertation research leads to many questions for further study.  The study of 
bladder function in p75NTR –null mice is an obvious next step for further deciphering the 
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function of p75NTR in micturition reflexes.  Appendix A contains some preliminary data 
obtained for this dissertation project in p75NTR –null and in mice hemizygous for the 
p75NTR null gene.  Even with preliminary results, it seems as though these mice present a 
complex phenotype of bladder function, some with bladder hyperreflexia and others with 
urinary incontinence.  p75NTR transgenic mice have much to offer in the way of future 
research.  It would also be interesting to see the effects of over-expression of the p75NTR 
receptor, perhaps in a model of p75NTR –over-expressing mice.  Based on our current 
data, it would be hypothesized that p75NTR over-expression would increase NGF binding 
p75NTR, sequestering NGF away from TrkA.  This would then result in less NGF-TrkA 
signaling and decrease bladder activity or hyperreflexia.   
 We hypothesize that blockade of NGF- p75NTR signaling actually leads to more 
NGF available to bind TrkA, thus more NGF-TrkA signaling and bladder hyperreflexia 
(Fig. 1).  We could test this by trying a combination experiment that includes blockade of 
p75NTR as well as antagonism of TrkA.  If blockade of TrkA rescued the bladder 
hyperreflexia seen with p75NTR blockade, this would support our hypothesis and 
demonstrate that NGF signaling through TrkA is important for the increased bladder 
voiding shown with blockade of p75NTR shown in this dissertation. 
 It would also be interesting to try to determine the precise location of the action of 
the p75NTR blockade shown in this dissertation.  It would be interesting to apply a p75NTR 
–neutralizing agent exclusively to the detrusor smooth muscle, perhaps by a mini osmotic 
pump as described in Zvara and Vizzard, 2007 in order to determine the importance of 
the smooth muscle to p75NTR signaling.  Pre-treatment of experimental animals with 
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resiniferatoxin could also be used to desensitize many bladder afferent fibers.  This could 
be done before CYP treatment or before intravesical infusion of antibody or PD90780, 
and might help determine the role that afferents may play in the NGF- p75NTR signaling.   
 The present study of intravesical p75NTR blockade examined bladder function only 
after 48 hours of CYP treatment.  Previous studies involving COX-2 inhibition have 
examined bladder function after 4 and 48 hour CYP treatment (Hu et al., 2003).  It would 
be interesting, and perhaps more clinically relevant, to examine bladder function using 
cystometry after the induction of chronic bladder inflammation as well. 
This dissertation examined the importance of p75NTR signaling in the urinary 
bladder by blocking p75NTR in the urinary bladder itself.  To examine the role of p75NTR 
in the central micturition reflex processing, intrathecal application of either anti-p75NTR 
monoclonal antibody or PD90780 at the level of lumbosacral spinal cord in experimental 
rats might be used.  This could be done in control and CYP-treated rats as well. 
Finally, it is unknown what the intracellular signaling pathway(s) of NGF- p75NTR 
in the urinary bladder might be.  Further research into the fate of NGF after binding 
p75NTR in the bladder and subsequent signal transduction would be useful in 
understanding the function of p75NTR in the micturition reflex pathways.  While some 
p75NTR signaling pathways are known, such as induction of apoptosis through activation 
of the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinases (JNK), and 
induction of cell survival effects via the transcription factor NF-κB, this information may 
or may not be applicable to p75NTR signaling in the urinary bladder.  It would be 
interesting to know whether or not internalization of p75NTR after NGF signaling would 
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result in lysosomal degradation of p75NTR, or in possible recycling of the receptor at the 
cell membrane, or in downstream signaling effects. 
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Introduction 
 The pan-neurotrophin receptor p75NTR has been implicated in many cellular 
processes, including neuronal growth regulation and apoptosis (Allen and Dawbarn, 
2006).  In cells expressing TrkA, p75NTR also enhances the binding affinity of TrkA for 
NGF (Allen and Dawbarn, 2006).  p75NTR may also function to reduce NGF-TrkA 
signaling by sequestering NGF, leaving less available to bind TrkA (Coome et al., 1998; 
Dhanoa et al., 2006; Hannila et al., 2004; Nykjaer et al., 2005).  Studies in p75NTR exon 
III (p75NTRexonIII) deficient mice have shown the importance of p75NTR  in regulating 
injury-induced sprouting in rat dorsal horn and trigeminal ganglia and cerebellum 
(Dhanoa et al., 2006; Hannila and Kawaja, 2005; Scott et al., 2005).  The original 
phenotypical findings in these mice include decreased sensory innervation of the footpad 
skin, loss of heat sensitivity and the development of skin ulcers in distal extremities (Lee 
et al., 1992).  Changes were not originally seen in sympathetic innervation in sympathetic 
cervical ganglia or iris (Lee et al., 1992).   In examining  p75NTRexonIII null mice, we 
sought to (1) examine bladder function using conscious cystometry, and (2) to begin to 
characterize the expression of sympathetic, parasympathetic, and sensory innervation of 
the urinary bladder using immunohistochemistry.  This work is preliminary and 
unpublished. 
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Materials and Methods 
Genotyping 
p75NTRexonIII null mice were used in this study (Lee et al., 1992).  Adult male and female 
p75NTR -/-, p75NTR +/+, and p75NTR +/- littermates were generated using a hemizygous 
(p75NTR +/- mice) breeding strategy (Fig. 1).  To determine the genotypes of progeny, tail 
DNA samples were obtained from postnatal day 21 mice, digested with NucPrep, and 
amplified with primers for the p75NTR transgene (p75-1: 5’-
CGATGCTCCTATGGCTACTA; p75-2: 5’-CCTCGCATTCGGCGTCAGCC; and 
PGK: 5’-GGGAACTTCCTGACTAGGGG) 
Tube Implant Surgery and Cystometry 
Please refer to the Materials and Methods section of Chapter 4. 
Immunohistochemistry 
Bladder whole-mount preparations were prepared as described in Chapter 3.  Bladder 
cross sections were obtained and prepared as described in Chapter 2.  Urinary bladder 
sections and bladder whole-mount preparations were incubated overnight at room 
temperature with rabbit anti–vasoactive intestinal polypeptide (VIP) antibody (1:2000, 
Incstar, Stillwater, MN), rabbit anti-tyrosine hydroxylase (TH) antibody (1:1000, Novus 
Biologicals, Littleton, CO), or rabbit anti-calcitonin gene-related peptide (CGRP) 
antibody (1:1000, Phoenix Pharmaceuticals, Inc., St. Joseph, MO) in 1% goat serum and 
0.1 M KPBS (Phosphate Buffer Solution with potassium), and then washed (3×15 min) 
with 0.1 M KPBS, pH 7.4. Tissue was then incubated with Cy3-conjugated goat anti–
rabbit IgG (1:500; Jackson ImmunoResearch) for 2 hr at room temperature. After several 
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rinses with 0.1 M KPBS, tissues were mounted with Citifluor (Citifluor, London, UK) on 
slides and coverslipped. Control tissues incubated in the absence of primary or secondary 
antibody were also processed and evaluated for specificity or background staining levels. 
In the absence of primary antibody, no positive immunostaining was observed.   
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Results 
Cystometry in mice with the p75NTRexonIII null mutation 
 p75NTRexonIII null mice displayed a continuum of bladder function symptoms, 
ranging from bladder hyperreflexia to complete incontinence.  Incontinence involved 
subtle changes in pressure during filling and continual leaking, as evidence by the 
cystometrogram pressure tracing shown in Fig. 2B.  Bladder function was also studied in 
p75NTR +/- mice, and these mice also displayed abnormal bladder function that ranged 
from hyperreflexia to incontinence (data not shown).  Wild-type littermates had normal 
bladder function, with regular voiding events associated with a peak in bladder pressure 
followed by a decrease in bladder pressure for filling (Fig. 2A).   
TH expression in mice with the p75NTRexonIII null mutation 
 TH was used as a marker for sympathetic innervation in bladder cryostat sections 
in p75NTRexonIII null mice and in wild-type (WT) littermates (Fig. 3A, B).  TH staining 
appeared brighter and was more frequently observed in nerve fibers associated with the 
detrusor smooth muscle in null mice (A) as opposed to WT mice (B).   
VIP expression in mice with the p75NTRexonIII null mutation 
 VIP-immunoreactivity in bladder whole-mount preparations showed that VIP, a 
marker for parasympathetic neurons, is present in nerve fibers associated with the 
detrusor smooth muscle.  This staining appears to be decreased in null mice (Fig. 4B) 
compared to WT mice (Fig. 4A).  The differences in staining intensity were most obvious 
in the bladder base and urethral region. 
CGRP expression in mice with the p75NTRexonIII null mutation 
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 Immunostaining for CGRP, a marker for most sensory neurons, appeared to be 
decreased in null mice (Fig. 5B) compared to WT mice (Fig. 5A) in the lamina propria 
layer of the urinary bladder.  CGRP-immunoreactivity can also be seen in nerve fibers 
associated with the urothelium and in nerve fibers associated with the detrusor smooth 
muscle.   
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Figure 1: Genotyping of p75NTRexonIII null mice, wildtype and heterozygous p75NTRexonIII mice 
p75NTR –null mice display a band at 317 bp (homo).  Wild-type mice display a band at 
247 bp (WT).  Mice heterozygous for the null mutation show a band at both 317 and 247 
bp (het).   
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Figure 2: Cystometry in 
p75NTRexonIII null mice 
(A) Cystometrogram data 
from a wild-type (WT) 
littermate.  (B) 
p75NTRexonIII  null mice 
demonstrate a continuum 
of bladder overactivity, 
ranging from complete 
incontinence to 
pronounced hyperreflexia 
as compared to wild-type 
littermates.  Panel B 
illustrates an example of 
subtle pressure changes 
(center) not associated 
with void events.   
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Figure 3: Tyrosine hydroxylase (TH) expression in p75NTRexonIII null mice 
TH, a marker for sympathetic neurons, appears to stain more intensely and with greater 
frequency in nerve fibers in the detrusor smooth muscle of the bladder in null mice (A) as 
opposed to WT mice (B). 
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Figure 4: Vasoactive Intestinal Polypeptide (VIP) expression in p75NTRexonIII null mice 
Whole-mount preparation showing VIP staining in detrusor smooth muscle.  
Immunostaining for VIP, a marker for parasympathetic neurons, appears to be decreased 
in null mice (B) as compared to WT mice (A) in nerve fibers associated with the detrusor 
smooth muscle.  M: detrusor smooth muscle; U: urothelium.  
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Figure 5: Calcitonin gene-related peptide (CGRP) expression in p75NTRexonIII  null mice 
Immunostaining for CGRP, a marker for most sensory neurons, appears to be decreased 
in null mice (B) as compared to WT mice (A) in the lamina propria layer of the urinary 
bladder wall.  Staining can also be seen in nerve fibers associated with the urothelium and 
in nerve fibers associated with the detrusor smooth muscle.  M: detrusor smooth muscle; 
U: urothelium; LP: lamina propria. 
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Discussion 
 Mice with the p75NTRexonIII null mutation are a valuable resource for future studies 
of the functional role that p75NTR may play in micturition reflexes.  So far, these mice 
present a complex story of bladder activity, with some null mice displaying urinary 
incontinence and some with milder bladder hyperreflexia (Fig. 2B).  To determine 
whether these mice exhibit variations in urinary bladder innervation, we have used 
immunohistochemistry to begin to examine the expression of sympathetic, 
parasympathetic and sensory neurons in the urinary bladder.  Although not quantified, 
there is an indication that tyrosine hydroxylase (TH) stained with greater intensity and 
frequency in p75NTR-/- mice than in their wildtype littermates.  An increase in sympathetic 
innervation in p75NTR-/- mice has been previously reported (Hannila and Kawaja, 2005; 
Scott et al., 2005).  Vasoactive intestinal peptide (VIP) was used as a marker for 
parasympathetic innervation and this staining appeared in nerve fibers associated with the 
detrusor smooth muscle.  VIP-immunoreactivity appeared to be decreased in p75NTR-/- 
mice as compared to wildtype littermates (Fig. 4A, B).  Finally, calcitonin gene-related 
peptide (CGRP) was used as a marker for sensory neurons and this staining was present 
in small nerve fibers in detrusor smooth muscle and associated with the urothelium (Fig. 
5A, B).  Changes in sensory innervation of the footpad skin in p75NTR-/-  mice have been 
previously documented (Lee et al., 1992).   
 Our cystometry studies in p75NTRexonIII-/- mice indicate possible complex changes 
in bladder function with the p75NTRexonIII-/- phenotype.  Changes in the urethral outlet or in 
the urinary bladder could be affecting bladder function and these changes could be 
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neurogenic or myogenic.  If the change in function is due to an increase in TH expression 
(sympathetic innervation) in the urinary bladder, the experimental use of β-adrenergic 
blocking agents might remove the inhibition and normalize function. If the changes are 
due to an increase in TH expression in the urethral outlet, this could result in α-mediated 
constriction and outlet obstruction.  The experimental use of an α-adrenergic antagonist 
could relieve and normalize function.  Other future avenues for this research could 
include possible future myograph studies on muscle contractility in bladder and urethra.       
 These preliminary results also show interesting changes in autonomic and sensory 
innervation in p75NTR-/- mouse bladders.  Further study into this could consist of 
quantification of the immunostaining of TH, VIP and CGRP, as well as the use of 
western blotting or enzyme-linked immunoassays (ELISAs) to quantify the protein 
expression of parasympathetic, sympathetic or sensory neuron markers.   
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